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 The cell surface is enveloped with a myriad of carbohydrates that form complex 
matrices of oligosaccharides. Carbohydrate recognition plays crucial and varying roles 
in cellular trafficking, differentiation, and bacterial pathogenesis. Lectin microarray 
technology presents a unique platform for the high-throughput analysis of these 
structurally diverse classes of biopolymers. One significant hinderance of this 
technology has been the limitation imposed by the set of commercially available plant 
lectins used in the array. To enhance the reproducibility and scope of the lectin panel, 
our lab generated a small set of bacteria-derived recombinant lectins.  
 This dissertation describes the unique advantages that recombinant lectins have 
over traditional plant-derived lectins. The recombinant lectins are expressed with a 
common fusion tag, glutathione-S-transferase (GST), which can be used as an 
immobilization handle on glutathione (GSH)-modified substrates. Although protein 
immobilization via fusion tags in a microarray format is not novel, our work 
demonstrates that protein activity through site-specific immobilization is enhanced when 
the protein is properly oriented. Although orientation enhanced the activity of our GST-
 vii 
tagged recombinant lectins, the GSH-surface modification precluded the printing of non-
GST-tagged lectins, such as the traditional plant lectins, thus limiting the structural 
resolution of our arrays. To solve this issue, we developed a novel print technique which 
allows the one-step deposition and orientation of GST-tagged proteins in a microarray 
format. To expand our view of the glycome, we further adapt this method for the in situ 
orientation of unmodified IgG and IgM antibodies using GST-tagged antibody-binding 
proteins.  
 Another advantage of recombinant lectins is in the ease of genomic manipulation, 
wherein we could tailor the binding domain to bind a different antigen. We demonstrate 
this by producing non-binding variants of the recombinant lectins to act as negative 
controls in our microarrays. Along with the non-binding variants, we developed a lectin 
displayed on the surface of phage. In the hopes generating more novel lectins, I will 
describe our current efforts of lectin evolution using phage-displayed GafD. By 
generating novel tools in lectin microarray technology, we enhance our understanding of 
the role of carbohydrates on a global scale.   
 viii 
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Chapter 1: Introduction to current microarray technology 
1.1 Introduction 
Carbohydrates form complex, cellular matrices on the surfaces of a wide-range of species 
including mammals and pathogenic bacteria (1 - 5). Carbohydrates mediate key intracellular 
interactions (e.g., protein trafficking) and intercellular interactions (e.g., host-pathogen 
symbiosis) (Figure 1.1). It is currently estimated that ~50% of all mammalian proteins are 
glycosylated (6). Abnormal changes in the glycosylation machinery can often lead to severe 
physical defects, classes of which are genetically-linked, so called congenital disorders which 
affect the N-linked glycosylation pathway (3, 7).  
 
Figure 1.1  Cell-surface glycans as important mediators in cellular functions. Carbohydrates   
  are present at the direct interface of intercellular host-microbial interactions, and   
  also mediate protein trafficking via secreted lectins.  
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Compared to normal tissues, changes in glycosylation have also been reported under 
inflammatory stress and cancer progression (8 - 10). Unlike the more linear genome and 
proteome, carbohydrate structures can be linked in a variety of ways like the stereochemistry of 
the anomeric position, carbohydrate linkage, and overall sequence of carbohydrates (Figure 1.2). 
Even with a simple disaccharide, one can envision a possible 8 different structural isomers, thus 
highlighting the combinatorial diversity of carbohydrates. In terms of types of glycans, there are 
three main classes of mammalian glycoconjugates, N-linked, Ser/Thr-linked, and lipid-linked 
oligosaccharides (Figure 1.1). Based on the collective knowledge of known glycan structures, it 
has been recently estimated that there are around 7000 different glycan-binding features in the 
mammalian glycome (11).  
Due to the staggering complexities of cellular glycosylation, a practical and general 
method to analyze these carbohydrates in a high-throughput manner was greatly needed. To 
address this issue, protein microarrays utilizing carbohydrate-binding proteins (CBPs) were 
developed. This technology is analogous to DNA microarray technology, in which 
oligonucleotides are printed in a microscale format. For lectin microarrays, a set of lectins, non-
enzymatic CBPs, is arrayed in a nanoscale format, and then tested for activity against 
fluorescently-labeled glycoproteins or other carbohydrate-containing samples (12 - 14). The 
resultant glycopatterns can be further analyzed to reveal discrete carbohydrate epitopes present in 
the sample. To overcome inherent pitfalls of native plant lectins, recombinant lectins were 
created to give our lectin microarrays a distinct advantage over current technologies. Prior to 
microarray technology, carbohydrate analysis was low-throughput and labor intensive. Methods 
included whole cell agglutination and mass spectrometry, which required additional purification 
of the glycan or glycoprotein of interest (15 - 17). 
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Figure 1.2 The ten major building blocks of the mammalian glycome. These monosaccharides are  
  glucose (Glc), galactose (Gal), mannose (Man), fucose (Fuc), N-Acetylglucosamine  
  (GlcNAc), N-Acetylgalactosamine (GalNAc), xylose (Xyl), glucuronic acid (GlcA),  
  iduronic acid (IdA), and N-Acetylneuraminic acid, or sialic acid (Sia). Symbols used by  
  the Consortium for Functional Glycomics are shown below glycans.  
 
 This dissertation focuses on the development of protein microarray technology, 
specifically, creating new techniques and platforms on which to evolve protein microarrays. The 
first part of this thesis describes the production of an affinity tag-based method for orienting 
recombinant lectins. The technique of orienting proteins based on a particular activity tag is not a 
novel concept, yet no other protein microarray format has been able to address two key issues in 
site-specific protein orientation. The first issue is that most oriented microarray formats are 
restricted to the specific affinity tag of interest. This need for a particular affinity handle excludes 
the printing of non-tagged or differently-tagged proteins, thus limiting the scope of the protein 
microarray. And second, despite the numerous efforts in protein orientation in microarray 
technology, not one describes how orientation affects protein activity against a target protein or 
glycan.  The second part of my thesis describes my efforts to modify our protein orientation 
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strategy to a more simple and systematic method by performing a one-step deposition and 
orientation of the GST-tagged recombinant lectins. I then demonstrate that this one-pot method 
can be applied to more complex protein mixtures in order to orient antibodies in situ. In applying 
this technique, I have created a method to expand the current lectin microarray with antibodies, 
an often under-applied class of CBPs, for direct glycomic profiling. The third section of this 
dissertation describes the development of binding variants of the current set of recombinant 
lectins. Due to the ease of genomic manipulation of recombinant proteins, I generated a set of 
non-binding mutants of the lectins to act as controls in microarray technology. In a concerted 
effort of generating novel lectins, I will also describe my current efforts in the directed evolution 
of GafD, a β-GlcNAc-binding lectin derived from Escherichia coli. Under the direction of 
Professor Jonathon Lai (Albert Einstein College of Medicine), I created constructs to produce 
GafD on the surface of phage, which I show to be a stable, displayed protein capable of binding 
to a known antigen. I generated a library of GafD variants, yet I had very little luck in selecting 
for any full-length protein. Although I had little luck with my GafD library in my selections, this 
does not mean that phage-display technology will not work, but a couple of different suggestions 
on how to move forward will be discussed. In conclusion, the majority of this dissertation will 
focus on the inherent advantages of recombinant lectins over traditional, natural plant lectins 
which are normally used in glycomic analysis.  
 In the following sections of this chapter, I will discuss the development of protein 
microarray technology, and then I will specifically discuss the origins and evolution of the lectin 
microarray platform. I will then conclude this section by discussing the current issues in 
manufacturing protein microarrays, and I will introduce our approaches to solving these 
problems. 
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1.2  Protein Microarray technology 
1.2.1 Development of protein microarrays 
 In the pursuit of the high-throughput analysis of complex samples, protein microarray 
technology was first developed as a protein-based adaptation of gene microarrays. The seminal 
work by MacBeath and Schreiber showed that protein microarrays could be used to analyze 
protein-protein interactions, kinase substrates, and protein-small molecule interactions (18). In 
addition, the pair printed a single protein, FKBP12-rapamycin binding protein (FRP), in the 
presence of over 10,000 spots of a different protein. When probed with fluorescently-labeled 
FKBP12, the only interaction observed was the FRB-FKBP12 complex (18). This work 
highlighted that not only can arrayed proteins maintain their function, but it also shows that a 
vast array of proteins can be miniaturized on a small scale (Figure 1.3). Another textbook case in 
protein microarray technology was the global analysis of protein-protein interactions of the yeast 
proteome (19). The group cloned 5800 yeast proteins and arrayed them on functionalized glass 
slides. After probing with calmodulin and phospholipids, the group identified novel binding 
motifs for both epitopes (19). This work highlights the importance that high-throughput analysis 
of protein-protein interactions which can help identify proteins of unknown functions. The 
authors also demonstrate the use of site-specific immobilization technique which allows uniform 
deposition of the entire proteome. All of the proteins were expressed as fusions with a 
hexahistidine (His6)-tag and printed on a Nickel
2+
-nitriloacetic acid (Ni
2+
-NTA) modified slide 
surface. This was a good idea, but the group never demonstrated that protein immobilization 
affects binding activity.  
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Figure 1.3 Overview of protein microarray technology. Proteins, such as antibodies or lectins, are  
  immobilized either covalently or non-covalently on a microscopy-sized slide. The  
  number of proteins to be arrayed is determined by both the number of subarrays and spot  
  size. 
 
 
1.2.2 Lectin microarrays for glycomic analysis 
 To address the issue of global carbohydrate analysis, our lab developed lectin microarray 
technology, which is the direct immobilization of plant-derived lectins onto a solid support 
(Figure 1.4). In this technique, fluorescently-labeled glycoconjugates are hybridized to an array 
of lectins with defined specificities (20). Our lab‟s initial work focused on the discernment of 
glycopatterns from a couple of different purified glycoproteins (13). In this work, Pilobello et al. 
immobilized 9 well-characterized lectins onto amine-reactive microscope slides. After probing 
with labeled substrates, the glyocpatterns observed from the lectin array matched to the known 
glycan epitopes of each respective glycoprotein (13). 
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Figure 1.4 Schematic of a lectin microarray experiment. Fluorescently-labeled samples are   
  incubated with a pre-fabricated lectin microarray. After an incubation time, the arrays are 
  washed and scanned at the appropriate wavelength. Known lectin acitivities indicate  
  which glycans are present in the biological sample. 
 
 Our group also demonstrated that a lectin microarray could monitor changes in bacterial 
glycosylation over time (21, 22). In this case, Hsu et al. also demonstrated the ability of the lectin 
microarray to distinguish between pathogenic and non-pathogenic bacteria, which differ in the 
synthesis of the surface lipopolysaccharide (21).  Furthermore, in more recent work, 
Krishnamoorthy et al. examined the biogenesis of the HIV-1 virion (23). In theory, HIV-1 
replicates by viral budding from the cell surface, which can incorporate host glycoproteins into 
the secreted microvesicles. Using a two-color labeling scheme (24), they demonstrated that the 
HIV-1 virions and microvesicles share a common glycomic signature that is dependent on the 
cell line from which they were derived (23). Given the previous difficulties in generating a 
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vaccine against HIV-1, using lectins microarrays highlights these difficulties by analyzing whole 
cell glycosylation.  
 Subsequent to our initial work on lectin microarrays, another group, the Hirabayashi 
laboratory, published a similar platform. Although our two systems are similar overall, the 
Hirabayashi platform has two distinct differences in their technology: their choice of slide 
chemistry and the scanning technology (14). First, although we initially used epoxy slides to 
immobilize lectins, we switched to N-hydroxysuccinimide (NHS)-activated slides (Nexterion H). 
These slides are specially designed to both lower overall background signals and maintain 
protein structure (25, 26). The Hirabayashi lab still uses epoxide-derivatized surfaces, which are 
relatively inexpensive, but lack efficient protein immobilization and low background 
fluorescence (13). Second, our arrays are processed using conventional and widely used DNA 
array scanners, whereas the Hirabayashi arrays are processed using more expensive evanescent 
wave scanners (27). However, their system is unique since they can detect weaker lectin-glycan 
interactions, leading to a more sensitive platform (27). Despite the differences, their lab 
demonstrated the differences in glycosylation between non-differentiated and differentiated stem 
cells using a lectin microarray (28). They also showed that the lectin microarray platform can 
distinguish proteoglycans from healthy and malignant tissues, leading to the discovery of new 
glycan-biomarkers (29).  
 Current lectin-based microarray technology has enabled the analysis and discovery of 
new glycoprotein biomarkers and the rapid profiling of cell-surface carbohydrates. With the 
limited number of plant lectins commercially available, with respect to possible carbohydrate 
structures, our lab began to search for new lectins with unique binding motifs (30 - 34). In both 
lectin microarray formats, plant lectins have been the sole class of CBPs used, but there are two 
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major disadvantages to using only plant lectins in an array. First, since the lectins are naturally 
derived, they often have lot-to-lot variances, further complicating analysis. Second, the majority 
of commercially available plant lectins are glycosylated. When probed with complex mixtures 
that contain CBPs, such as bacteria, this increases the occurrence of false-positive signals on the 
array. In response to these limitations, our lab looked toward lectins derived from bacteria (35). 
Recombinant proteins have an advantage due to the expression and purification of protein 
without post-translational modifications, allowing for strict quality control. Furthermore, the 
inclusion of fusion tags can standardize the purification of multiple proteins of varying glycan 
specificities. Given that bacteria express lectins to mediate host-pathogen interactions, microbial 
genomes are a rich source of CBPs. Hsu et al. cloned out seven lectins derived from a variety of 
bacterial sources (Table 1.1). The lectins were optimized for expression and purified via the 
glutathione-S-transferase (GST) affinity tag with glutathione (GSH)-sepharose (Figure 1.5). 
When probed against a glycan microarray developed by the Gildersleeve group (36, 37), the 
lectins retained their known binding preferences (35). The recombinant lectins were then 
immobilized on NHS-activated slides, and probed for activity against glycoproteins and renal 
and melanoma tumor cell lines from the NCI-60 cell line panel. The resultant glycopatterns were 
dependent on the probe being tested, and gave distinct glycopatterns. Additionally, the inclusion 
of a mutant of GafD, GafD-m, confirmed that any binding of wild-type GafD to the sample was 
carbohydrate-based (35). Prior to this work, recombinant lectins have not been utilized in lectin 
microarrays, and this work highlighted the potential benefits of recombinant lectins over 
naturally-purified lectins. 
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Lectin
 
Source Binding Specificity 
GafD
 
F17 fimbrae (Escherichia coli) β-GlcNAc 
PA-IL
 
Non-fimbrae (Pseudomonas aeruginosa) Galactose 
PA-IIL
 
Non-fimbrae(Pseudomonas aeruginosa) Fucose/Mannose 
PapGII
 
P-pili (Escherichia coli) GbO4 
PapGIII
 
P-pili (Escherichia coli) GbO5 
RS-IIL
 
Non-fimbrae (Ralstonia solanacearum) Mannose/Fucose 
GafD-m F17 fimbrae (Escherichia coli) ~80% reduction in binding 
Table 1.1  List of recombinant lectins. This list was genearated by Hsu et al. (35) 
 
 
 
 
Figure 1.5 Schematic of a standardized method to producing recombinant lectins. Desired lectin  
  gene is PCR amplified and cloned into pET41 vector. The lectin is then expressed and  
  purified via the GST-tag. Characterization of glycan-binding activity can be assessed by  
  the detection of multiple fusion tags. Once assayed, the lectin can be incorporated into the 
  lectin microarray, expanding the current set of lectin.  
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1.2.3 Issues in current microarray fabrication 
 Like all new technologies, improvements in protein microarray technology are necessary 
toward widespread implementation. In the production of these arrays, the most important factor 
is the deposition and the activity of the immobilized protein. One commonly used deposition 
method is the immobilization via side chain lysine amines and amine-reactive functional groups 
(38). However, regardless of the slide surface, most protein microarrays result in immobilization 
through random deposition onto the slide. Unfortunately, these techniques can deposit a protein 
in which the functional domain is not oriented toward the protein-sample interface, resulting in 
diminished activity. This issue prompted the development of various protein immobilization 
techniques based on known and specific biological interactions, such as biotin-avidin and GST-
GSH (39). For example, Chen et al. describe an immobilization technique where a boronic acid 
modified slide binds to the oligosaccharide present on an Fc-tagged lectin (40). And since the 
group modifies the entire slide with the boronic acid, only Fc-tagged proteins can be printed on 
their array. Although technically unique, the method suffers from the same complicated process 
and protein exclusivity that every other site-specific immobilization technique does.  We 
believed that we could use the GST domain to immobilize the recombinant lectins on a GSH-
modified surface. With our initial success of immobilizing these lectins on a slide treated with 
GSH, we realized that a GSH-surface would greatly restrict the number of CBPs we could print 
to the recombinant lectins. By restricting the type of protein to be deposited, we restrict the 
number of oligosaccharides observed. We wanted to include the non-GST-tagged plant lectins 
while orienting our GST-tagged recombinant lectins, so we created a dual-surface array. This 
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platform would maintain the NHS-activated surface for the plant lectins and then a GSH-
modified surface for the recombinant lectins (41). 
 In addition to our dual-surface array format, we created a protein orientation method 
which would site-specifically immobilize our recombinant lectins in a one-step technique (42). 
By supplementing the print buffer with an excess amount of GSH, we can out-compete the lysine 
side chains for available NHS-activated esters, thereby generating a localized GSH-modified 
surface that can then orient the recombinant lectins in situ. Once we simplified our original 
orientation technique, we next wanted to expand the technology to other types of CBPs. 
Carbohydrate-binding antibodies are an often under-utilized CBP in glycomic analysis. In 
particular, lectin microarrays do not include this class of CBPs, but antibodies can be a good 
supplement due to their higher specificities compared to lectin-glycan interactions. Antibody 
microarrays are typically printed onto nitrocellulose-coated slides, but these slides are not 
compatible with our lectin microarrays. We wondered whether it was possible to not only 
include antibodies in our array but also orient the proteins by supplementing the print buffer with 
GSH and a GST-tagged antibody binding protein. We were successful in orienting these 
antibodies in situ, thereby creating the first protein microarray with two classes of proteins.  
 Another issue in lectin microarray technology is the lack of negative controls. In DNA 
microarrays, in a given array set it is common to have an array that contains a non-binding gene 
for a specific data pool (43).  When the array is hybridized with labeled probes, the non-binding 
gene should not display fluorescence across multiple arrays. In the case of lectin microarrays, the 
only technique to determine whether or not a lectin-sample interaction is carbohydrate-based is 
by performing inhibition experiments (13).  With the use of recombinant lectins, we can quickly 
generate binding mutants due to the ease of genetic manipulation. By printing non-binding 
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variants along with the wild-type lectins, we can easily determine whether an observed lectin 
binding event is carbohydrate-based. We also show that we can switch the binding preferences of 
the orthologous lectins PA-IIL and RS-IIL by a single point mutation. In the pursuit generating 
novel lectins, the Hirabayashi lab attempted to evolve the Ricin B chain lectin from a galactose-
binding lectin to a sialic acid-binding protein (44). The Ricin B variant that they generate does 
not lose all galactose-binding activity, and as such, they merely modified the activity to bind 
more epitopes. With our single point mutant of RS-IIL (A22S), we perform a similar switch in 
binding preference without having to create a whole new evolution system. However, in order to 
expand the proteins on our array to increase our view of the glycome, we wanted to create an 
evolution-based method to generate novel lectins. We chose to evolve GafD from a β-GlcNAc-
binder to a β-GalNAc-binding lectin, a relatively simple C4 epimer. With the aid and guidance of 
Professor Jonathan Lai (Albert Einstein College of Medicine) we were able to produce GafD 
lectin on the surface of phage as a pIII fusion protein. Although we generated a library of phage 
clones with 10
9
 codon diversity, we were unable to find any definitive enrichment against our 
target glycan. Fortunately, not all selection conditions were tested meaning that future work 
could select for a decent binding lectin from the library I generated.  
 With these advances in lectin microarray technology, we hope to have a broader impact 
in the protein microarray field. The orientation and then in situ orientation of our recombinant 
lectins solves two major issues in protein arrays: orientation, to enhance lectin sensitivity, and 
protein diversity. We also demonstrate that non-binding variants of the recombinant lectins can 
act as efficient controls in the lectin microarray. Also, to generate novel lectins to incorporate 
into our array, we produce phage-displayed lectins in order to select against new binding 
proteins. 
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Chapter 2: Orientation of recombinant lectins in a microarray format 
 
2.1 Introduction 
 A primary concern in protein microarray technology is the activity of the deposited 
protein. The majority of proteins are deposited onto a reactive surface, with random orientation, 
which can affect the activity of the printed sample. One way to enhance the activity of 
immobilized samples on a microarray is via protein orientation. The orientation of tagged-
proteins onto orthogonally-modified surfaces has the potential of increasing the activity of 
deposited substrates, enhancing the detection capabilities of a microarray. We demonstrate the 
effectiveness of protein orientation using our GST-tagged recombinant lectins. By creating a 
dual-surface array, we are able to incorporate non-tagged proteins along with our GST-tagged 
lectins in the same array, allowing for the first time the direct comparison of oriented versus non-
oriented proteins. We show that orientation via the GST-domain enhances the activity of the 
deposited protein.  
2.1.1 Common protein deposition methods 
 Protein deposition onto microarray surfaces can be divided into two categories: covalent 
and non-covalent coupling chemistries. For non-covalent attachment, the protein is typically 
adsorbed into the support. For example, most antibody arrays are printed onto nitrocellulose-
modified glass slides (1). Nitrocellulose slides are used mainly because of their high adsorption 
properties, resulting in a greater concentration of deposited protein (2). Unfortunately, the typical 
nitrocellulose slide auto-fluoresces, increasing the background binding of the sample which can 
disrupt the analysis of a given sample. Due to this flaw, there are several manufacturers of 
specially-coated slides to decrease auto-fluorescence (2, 3). Another non-covalent deposition 
technique requires the use of amine-coated slide surfaces which attract negatively-charged ions. 
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The use of these slides is typically reserved for DNA microarrays, where the phosphate 
backbone is an ideal ionic partner to the positively-charged amines, but some groups have used 
these slides to deposit proteins (4, 5). These non-covalent methods of attachment are good for 
general use in microarray technology, but the deposition is non-covalent and the orientation of 
the protein is not controlled (6). 
 The covalent attachment of proteins on a solid support is typically performed through the 
terminal amines on side chain lysines or the sulfhydryl groups on cysteine residues (Figure 2.1). 
For amine-based coupling chemistry, typical slide surfaces are composed of N-
hydroxysuccinimide- (NHS)-activated esters (7 - 9), aldehydes (7, 10, 11), and epoxides (7, 10, 
12). Of these three groups, the least used is the aldehyde, which forms a Schiff base with the 
deposited protein. In our lab‟s seminal work in lectin microarray technology, Pilobello et al. 
printed lectins on both aldehyde- and epoxide-modified surfaces and found that the aldehyde 
slide gave overall higher activity (10). Since that time, we have stopped using aldehyde slides, 
but work by other groups show that these slides are still commonly used (11). In terms of lectin 
microarray technology, epoxide-derivatized surfaces are the slide surface of choice for the 
Hirabayashi lab, and their associated company GP Biosciences (12).  In our hands, the epoxide-
coated slides gave significant background fluorescence, however the Hirabayashi slides are 
designed to probe for lectin-glycan interactions in the solution phase using evanescent wave 
technology (13). This technology requires expensive equipment in lieu of a traditional 
microarray scanner. Epoxy slides are stable under various pH buffers, humidity, and can react 
with various functional groups, although the primary reactive group is the free amine of lysine 
(7).  
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Figure 2.1 Common covalent protein immobilization strategies. The two most common covalent  
  coupling techniques are through amine- and sulfhydryl-functional groups on the   
  deposited protein. Amines from side chain lysine groups can react with NHS-activated  
  esters, aldehydes, and epoxide functional groups. Sulfhydryl-reactive functional groups  
  include maleimide, vinyl sulfones, and various disulfide functional groups. 
 
 However, aside from poor background fluorescence, epoxide slides have slow reactivity 
and, consequently, each protein can be deposited differently depending on incubation times (14). 
As a result, the Mahal lab has been using NHS-activated slides purchased from Schott North 
America (Nexterion H), technology originally developed by the Grainger laboratory (15, 16). 
These slides are specially developed with NHS-activated esters embedded into a polyethylene 
glycol (PEG) matrix, creating a 3D polymer coating which can maintain the structural integrity 
of the deposited protein (15). The PEG layer is a highly hydrophilic layer which results in very 
low background binding from a given sample (16). Given the work of our lab wherein our lectin 
microarrays are probed for activity against complex glycan mixtures such as cellular micellae, 
whole bacteria, and viral particles, the low background properties of the Nexterion H slide have 
proven useful in post-hybridization analysis.  
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 Covalent attachment of proteins via cysteine residues occurs through selective sulfur-
reactive chemistry (Figure 2.1). For example, the most prominently used coupling molecule is 
maleimide, which serves as an effective Michael acceptor (17 - 19). Another substrate used in 
sulfhydryl-based protein coupling is the Michael addition into vinyl sulfone (20). In accordance 
with the low background of PEG-surfaces, several groups have created hybrid vinyl sulfone/PEG 
slide surfaces which lower overall background fluorescence (21). When the protein is deposited 
in a buffer below pH 9, these sulfur-reactive functional groups are highly selective for cysteine 
residues (20). This slide coupling method is very selective, yet the availability of solvent-
exposed cysteine residues varies from protein to protein, if there are any at all. Although the 
covalent or non-covalent attachment of proteins to a slide surface is a simple and cost-effective 
immobilization technique, there is little control on the orientation of the protein acitve site or 
binding domain, resulting in aberrant activity.  
2.1.2 Protein immobilization through affinity tags 
 Although initially used to facilitate protein production, affinity tags can also be used to 
track proteins in more complex systems. In the post-genomic era, the high-throughput expression 
of affinity-tagged systems has become increasingly important in analyzing protein-protein and 
protein-ligand interactions (22). Several groups have attempted to immobilize proteins via 
affinity tags, presumably orienting the protein in a more favorable fashion (7). However, no 
group has ever shown that these immobilization techniques improve activity by comparing the 
same protein randomly immobilized onto a different slide surface, a point addressed in our work. 
The three most common affinity tags used for site-specific immobilization in protein microarray 
systems are streptavidin-biotin (23 - 27), hexahistidine (His6)- Ni
2+
-NTA (28 - 32), and GST-
GSH (33 - 36) interactions (Figure 2.2). 
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Figure 2.2 Common protein immobilization methods using fusion tags. These    
  interactions include streptavidin-avidin, His6-Ni
2+
-NTA, and GST-GSH activities. For  
  streptavidin-biotin interactions, it is believed that one monomer of the streptavidin  
  temtramer is inactive due to inaccessibility on the biotin-binding domain. Therefore, a  
  single streptavidin protein can bind up to three biotinylated proteins. For His6-Ni
2+
-NTA  
  interactions, a single molecule of Ni
2+
-NTA can bind two histidine residues. On the other  
  hand, the GST-GSH interaction forms in a 1:1 molar ratio. 
 
 These interactions have been so widely used that these specialized slide surfaces are 
commercially available. Streptavidin-biotin interactions for use in protein microarray 
fabrications have become increasingly widespread due to the well-established, and very high 
affinity interaction between streptavidin and biotin (Kd ~ 10
13
) (37). This interaction is heavily 
used in biotechnology and several groups have generated microarray surfaces capable of 
immobilizing biotinylated biomolecules. Peluso et al. describe the site-specific immobilization of 
antibodies onto a streptavidin coated slide (25). Their slide surfaces were fabricated with biotin-
capped poly-L-lysine, a common molecule used in grafting, and the biotin-capped slide was 
treated with streptavidin, which is a tetrameric protein. And like most streptavidin-biotin 
microarray systems, the group modified antibodies with a biotin conjugate. The group mildly 
oxidized the glycans present on the Fc domain; the resulting aldehyde groups were condensed 
with biotin-hydrazide and applied to the straptavidin-coated slide (25). Another group generated 
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a system to biotinylate recombinant maltose-binding protein (MBP) in vitro using an intein-
mediated biotinylation scheme and immobilized the substrate onto a streptavidin-coated array 
(38). Although these two groups use an exogenous biotinylation scheme, the use of in vivo 
biotinylation expression systems have the potential to easily generate oriented protein 
microarrays on streptavidin substrates.  
 Hexahistidine (His6) fusion tags are one of the most widely used fusion tags available. 
When Zhu et al. performed the yeast proteome microarray experiment, the ORFs were cloned 
into vectors containing N-terminal His6-tags, and were printed onto nickel
2+
-nitriloacetic acid 
(Ni
2+
-NTA)-modified slides (31). The His6-Ni
2+
-NTA complex has relatively mild affinity (µM) 
compared to other fusion systems used and is labile under strenuous conditions (7). As a 
consequence, protein immobilization using the standard His6-tag and Ni
2+
-NTA may be 
insufficient to obtain substantial deposited protein (39). Given the poor binding affinity of this 
interaction, several groups have been developing methods to enrich the binding affinity in this 
system (32). For instance, the Piehler group has been experimenting with a synthesized multi-
valent NTA ligand that could provide tighter binding to a His6-tag (40). It is a commonly known 
fact the two histidine side chains interact with one Ni
2+
-NTA complex. The group developed bi- 
and tri-dentate NTA ligands to bind stronger to His6-tagged proteins. Adapting this method, the 
same group synthesized a biotinylated tri-dentate NTA ligand, which is able to both complex 
His6-tagged proteins and immobilize the proteins on a streptavidin-modified slide (26). In an 
analogous method, two other groups have created multi-His-tagged vectors. In one example, 
Khan et al. cloned two N-terminal His6-tags separated by a spacer of 11 amino acids capable of 
orienting a GFP protein on a microarray slide (32). In another study, Fischer et al. created a 
similar double His-tagged protein with His6- and His10-tags. In this study, the authors perform 
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surface plasmon resonance (SPR) studies on protein immobilization on a Ni
2+
-NTA surface and 
demonstrated the labile nature of the His6-Ni
2+
-NTA interaction. Although the His10-tag by itself 
greatly improved binding, the double tagged protein maintained a stable complex, with no visible 
elution from the slide observed (buffer not containing imidazole) (39).  Again, these techniques 
are promising in the development of oriented protein microarrays, but they fail to demonstrate 
any improvement in activity upon protein orientation.  
 The third most widely used fusion tag for protein immobilization is glutathione-S-
transferase (GST), which shows moderate binding activity (µM) to the tri-peptide glutathione 
(GSH) (41). One of the first applications of site-specific immobilizations of GST-tagged proteins 
was the deposition of GST-calmodulin onto a GSH-treated gold surface (33). The group also 
showed that the GSH-GST interaction was labile and could be eluted off with excess GSH. 
Although a simple technique, the robust method showed that GSH could be immobilized onto a 
solid support which could then capture a GST-tagged protein (33). Two other techniques of 
GST-specific protein immobilization used a modified version of a GSH-gold sulfhydryl 
interaction. One group modified a gold surface with a maleimide-thiol molecule. Once reacted, 
GSH is added and forms the Michael product, and can then be used to immobilize GST-tagged 
proteins (36). The second group synthesized a dithiol head group and conjugated GSH to it, 
followed by conjugation to a gold surface. Although unique, the method is not practical given the 
synthesis of the GSH molecule (3 steps, 6.5% yield) (42). In terms of protein microarray 
fabrication, the work presented by Kawahashi et al. is the most direct use of profiling protein 
binding from GST-tagged proteins on a GSH-derivatized surface (35). The group grafted a slide 
with GSH- poly-L-lysine, and then printed a cadre of GST-tagged proteins that were synthesized 
in vitro and then the resultant arrays were probed for protein-protein interactions with 
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fluorescently-labeled conjugates (35). These previous approaches to immobilizing GST-tagged 
proteins on a GSH-modified surface are novel in their own right, but suffer from the same issues 
of other endeavors in tag-specific protein orientation. Specifically, the various groups do not 
show that the site-specific immobilization of GST-tagged proteins positively affects the activity 
of the printed protein. Moreover, the affinity tag immobilization methods described above do not 
allow for the deposition of non-tagged proteins onto the same slide surface, which drastically 
limits the diversity of proteins present on a microarray. 
2.1.3 Fabrication of a GSH-surface to create an oriented recombinant lectin microarray 
 Prior to fabricating the arrays, we observed two significant pitfalls of current microarray 
fabrications for protein orientation. First, all microarray formats for protein orientation are for a 
single type of fusion tag. For example, only His6-tagged proteins are printed on a Ni
2+
-NTA 
surface and GST-tagged proteins are printed only on a GSH-modified surface. By limiting the set 
of proteins one can print in a microarray, you decrease the observable profile of protein-protein 
or protein-ligand interactions. Second, of all the work published on oriented protein microarrays, 
not one actually addresses the question of how the orientation of a protein will affect its affinity 
or binding activity. All but one study simply assumes that the fusion-tagged protein will be 
favorably immobilized upon deposition. The one study that attempts to address this question 
prints two different proteins, GST-tagged and non-tagged, on separate slide surfaces, GSH and 
non-GSH, respectively (42). However, without directly comparing the deposition of the same 
protein on both surfaces, the group fails to address this important issue in protein microarray 
technology. Since the GST-GSH interaction has been used in immobilizing GST-tagged proteins, 
we wanted to directly determine the effect of protein orientation using our unique set of GST-
tagged recombinant lectins (43). 
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 Our recombinant lectins are cloned into the pET41 vector (Novagen), a vector that 
contains three different affinity tags (Figure 2.3A). Starting at the N-terminus, the vector 
expresses a GST domain, followed by a His6 epitope, then an S·tag peptide, followed by the 
multiple cloning site (MCS). As a result, all of our lectins are located at the C-terminus. 
Fortunately, the binding domains of our current set of lectins are not located at the N-terminus 
meaning that the affinity tags shouldn‟t interfere with glycan-binding (43). This vector also 
contains a thrombin protease site located between the His6- and S·tag domains (Figure 2.3B). 
This feature allows us to cleave the lectin from the GST domain wherein we could assess the 
effects of the GST-tag on protein orientation and subsequent activity. 
 
Figure 2.3 Fusion-tag system of the pET41b vector. A) Linear arrangement of the fusion tags and  
  the multiple-cloning site (MCS) of the pET41 vector (Novagen). From the N-terminus, a  
  GST-tag is followed by the hexahistidine tag (His6), followed by an S·tag domain,  
  followed by the MCS. In between the His6- and S·tag sites is a thrombin protease  
  domain. An optional C-terminal His6-tag is available, but in our lectin constructs, we  
  engineer in a stop codon (TAA) at the end of the MCS. B) Schematic of a thrombin- 
  protease treatment of a GST-tagged lectin. Upon immobilization to gluthatione (GSH)- 
  sepharose, the lectin is cleaved from the GST- and His6- domains by thrombin. Capture  
  of the thrombin protease then yields purified lectin with an N-terminal S·tag. 
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 Our traditional lectin microarrays were printed on NHS-activated slides, Nexterion H 
(Schott North America), on which the activated esters react with side chain lysine groups 
forming covalent amide bonds, thus immobilizing the lectin to the surface (Figure 2.4A) (9). We 
wondered whether GSH, which contains a free amine, could react with the NHS-esters and form 
a GSH monolayer (Figure 2.4B). Our initial experiments were geared toward optimizing both the 
concentration of GSH and buffer composition. We believed that the effectiveness of GSH 
immobilization is directly dependent on the amount of the small molecule and the pH of the 
coupling buffer. 
 
 
Figure 2.4 Recombinant lectin orientation strategy. A) The standard NHS-activated    
  slides are typically used without further modifications. Printing on the NHS-activated  
  surface results in the random deposition of protein on the surface, perhaps blocking the  
  carbohydrate-binding domain. B) The NHS-activated esters could be reacted with a  
  glutathione (GSH) solution creating a uniform GSH-layer. Then GST-tagged lectins are  
  printed and oriented on the GSH surface (53). 
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We also wanted to print non-GST-tagged plant lectins in the same array in order to expand the 
range of glycomic markers we can observe. To accomplish this, we decided to divide the arrays 
in two with a hydrophobic solution using a PAP pen (Beckman Coulter). One half of the array 
would remain unmodified, maintaining the NHS-surface, and the second half would be reacted 
with an optimized GSH-solution creating a GSH-surface (Figure 2.5). With this setup, we 
believed we could print non-tagged lectins on the top half of the array, and then we could 
directly compare protein deposition and activity by printing the recombinant GST-tagged lectins 
on both surfaces. 
 
 
Figure 2.5 Schematic of the dual-surface array. The top half of the array would be left alone while  
  the bottom half of the slide would be reacted with GSH. This would allow the printing of  
  both plant and recombinant lectins on the NHS-activated surface in conjunction with the  
  printing, and hence orientation of our GST-tagged lectins on the bottom half (53). 
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2.2  Results and discussion 
2.2.1 Optimization of GSH-immobilization on a solid support 
 In order to create a dual-surface slide for the direct comparison of oriented and non-
oriented lectins, we needed to determine the optimal GSH immobilization conditions. In this 
work, we did not directly measure GSH deposition as a function of concentration, although we 
developed one technique for this which will be discussed in Chapter 3. However, we indirectly 
measured GSH deposition as a function of the binding activity of the deposited protein. For our 
initial studies, we printed RS-IIL, a GST-tagged mannose-binding lectin derived from the 
bacterium Ralstonia solanacearum (44), and probed for activity against Cy5-labeled chicken egg 
ovalbumin (OVA-Cy5), a known hybrid mannose-containing glycoprotein (45). Activity of the 
immobilized RS-IIL was measured as signal to noise ratio (Absolute fluorescence/background 
fluorescence, S/N) (Figure 2.6). The coupling of GSH to an NHS-activated ester is an amide-
forming reaction, therefore, we reasoned that pH would play an important factor. The primary 
amine of the tripeptide is the most likely nucleophile. The amide coupling reaction should occur 
more favorably in a higher pH, in which the primary amine (pKa ~ 9) would not be protonated. 
Therefore, we tested three common buffers: phosphate buffered saline (PBS, pH 7.4), sodium 
borate (pH 8.3), and sodium bicarbonate (pH 9.4) containing varying amounts of GSH (200, 100, 
50, 25, 12.5, 6.25, and 3.125 mM). RS-IIL was printed at varying concentrations (24, 12, 6, 3, 
and 1.4 µM) on the GSH-derivatized surface and probed with 600 nM OVA-Cy5. In theory, the 
GST-GSH binding activity should orient the RS-IIL carbohydrate-binding domain away from the 
slide surface, making it more accessible to the incoming glycoprotein. Sodium bicarbonate gave 
us the highest overall binding (Figure 2.6A, paired t-test: bicarbonate vs. PBS, p = 0.0004, 
bicarbonate vs borate, p = 0.0152). 
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Figure 2.6 Optimization of GSH-deposition. A) Distribution of binding for varying amounts of RS- 
  IIL to OVA-Cy5 with respect to the three different buffers used in the print. Individual  
  arrays were incubated with GSH (200, 100, 50, 25, 12.5, 6.25, 3.125 mM) in either PBS  
  (pH 7.4), sodium borate (pH 8.3), or sodium bicarbonate (pH 9.4) buffers. After   
  processing, RS-IIL was printed on each  array (24, 12, 6, 3, and 1.4 µM) and probed with  
  600 nM OVA-Cy5. B) Distribution of binding for varying amounts of RS-IIL to OVA- 
  Cy5 with respect to different GSH concentrations in sodium bicarbonate buffer. .  
  Individual arrays were incubated with GSH (200, 100, 50, 25, 12.5, 6.25, 3.125 mM) in  
  sodium bicarbonate (pH 9.3) buffer. After processing, RS-IIL was printed in each array  
  (24, 12, 6, 3, and 1.4 µM) and probed with 600 nM OVA-Cy5. Each box plot represents  
  the distribution of binding (S/N) across the different conditions tested. The interquartile  
  range (box) represents the distribution of ~50% of all signals and was used to compare  
  the optimal GSH coupling conditions. Data presented is representative of 3 slides. The  
  optimized buffer conditions were 50 mM GSH in sodium bicarbonate buffer. 
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 For the optimization of GSH concentration, we chose concentrations that centered around 
the optimized blocking solution recommended by the slide manufacturer, Schott North America. 
In general after protein printing, the entire slide must be incubated in a solution of 50 mM 
ethanolamine in sodium borate buffer to react with the remaining NHS-activated esters, thereby 
inactivating the slide surface. Failure to inactivate the slide results in significant background 
fluorescence from the primary and/or secondary reactions with fluorescently-labeled probes. 
Therefore, we surmised that 50 mM GSH would be a good start to test coupling conditions. 
Comparing the distribution of binding with respect to GSH concentration in all three buffers, we 
observe that 50 mM GSH is the optimal concentration of GSH (Figure 2.6B). From these initial 
experiments, we determined that 50 mM GSH in sodium bicarbonate buffer yielded the best 
activity of our lectin-glycoprotein system. 
2.2.2 Activity of oriented versus non-oriented GST-tagged lectins 
 To assess the effects of orientation on glycan-binding activity, we printed the GST-
tagged recombinant lectins on both GSH-modified surfaces (oriented) and on NHS-activated 
surfaces (non-oriented). Immobilized lectins GafD, a terminal β-GlcNAc-binding lectin derived 
from E. coli (46), and RS-IIL were probed for binding activity against varying concentrations of 
OVA-Cy5 (Figure 2.7). When randomly immobilized onto the NHS-activated surface, non-
oriented GafD displayed low levels of glycan-binding. At the highest concentration on OVA-
Cy5 (2 µM), observed binding to GafD was very close to our cut-off of a true positive signal 
(S/N = 5). When oriented on the GSH-modified surface, GafD displayed a remarkable increase 
in activity (S/N ≈70) against OVA-Cy5 (2 µM), a 17-fold increase in activity compared to the 
non-oriented GafD (Figure 2.7A and B). 
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Figure 2.7 Activity of oriented recombinant lectins GafD and RS-IIL against OVA-Cy5. A)   
  Comparison of GafD (10 µM) and RS-IIL (12 µM) binding against decreasing amounts  
  of OVA-Cy5, coupled in either in a random (- GSH, NHS-mediated) or oriented (+ GSH, 
  GSH-mediated) manner. Lectins shown are printed in the same array on the same slide.  
  B) Graphical representation of data shown in A) for GafD as a function of signal to noise. 
  C) Graphical representation of data shown in A) for RS-IIL as a function of signal to  
  noise. All data shown are representative of triplicate slides, and error bars are standard  
  deviations from the median signal to noise (53). 
 
 
 Similar results were obtained when comparing oriented versus non-oriented RS-IIL 
probed against OVA-Cy5. At the highest concentration of OVA-Cy5 tested (2 µM), oriented RS-
IIL displayed a 5-fold increase in binding activity compared to the randomly deposited RS-IIL. 
Herein, we define activity as an increase in observed fluorescence for a particular glycoprotein. 
Overall, oriented RS-IIL displayed a ~3-fold increase in activity compared to non-oriented RS-
IIL over the other concentrations of glycoprotein (Figure 2.7A and C).  
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Figure 2.8 Activity of oriented and non-oriented RS-IIL and PA-IIL lectins against Cy5-labeled  
  RNase B (RNase B-Cy5). A) RS-IIL (24 µM) printed on NHS-activated surface (non- 
  oriented) and GSH-modified surface (oriented). B) PA-IIL (12 µM) printed on NHS- 
  activated surface (non-oriented) and GSH-modified surface (oriented). Error bars  
  represent the standard deviation. Data is representative of 3 replicate slides.  
 
 
 We also tested the activity against Cy5-labeled RNase B (RNase B-Cy5), a glycoprotein 
containing an N-linked high mannose site (51). As expected, the mannose-binding lectins RS-IIL 
and PA-IIL, a lectin derived from Pseudomonas aeruginosa (47), displayed the highest activities 
with this glycoprotein. With respect to RS-IIL, very little differences exist between the activities 
of oriented versus non-oriented lectin at higher concentrations of RNase B-Cy5 (Figure 2.8A). 
At high concentrations of RNase B-Cy5 (2 µM), there is no observable difference in activity 
between non-oriented and oriented RS-IIL. However, when observing binding at low levels of 
glycoprotein, a clear pattern emerges showing that oriented RS-IIL shows higher binding 
sensitivity than randomly deposited RS-IIL. Variations in the level of enhancement of activity of 
the deposited lectins are expected due to differences in the presentation of the carbohydrate-
binding domains, which can skew the apparent binding activity of the adhesin. We believe that 
lectin orientation through GST-GSH activity results in a more accessible lectin domain. Also, the 
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sensitivity of detection for the RS-IIL-RNase B-Cy5 interaction was lowered from 3.2 nM to 
0.64 nM, a 5-fold increase in detection limits (Figure 2.8A). Although traditionally a fucose-
binding lectin, PA-IIL does bind well to high-mannose structures (48). The activity of oriented 
versus non-oriented PA-IIL is ~2-fold over multiple concentrations of RNase B-Cy5 (Figure 
2.8B). Compared to the increases in activity observed for GafD and RS-IIL with their respective 
ligands, PA-IIL displays only a moderate increase in activity upon orientation. Again, the 
relative differences in activity between the lectins are dependent on the presentation of the 
glycan epitope.  
 Overall, we observed increases in activity for the rest of the recombinant lectins against 
either or both of the Cy5-labeled glycoproteins (Figure 2.9).  For example, in the case a PA-IL, a 
α-galactose-binding lectin also derived from Pseudomonas aeruginosa (49), did not show an 
increase in activity when oriented against OVA-Cy5, but it did show a moderate increase with 
RNase B-Cy5 upon lectin orientation. Interestingly, the PapG lectins (II and III), which are 
lectins derived from E. coli that bind to the galactosylated/GalNAcylated globoside lipids (50), 
showed an increase in activity upon orientation when probed against the two glycoproteins 
(Figure 2.9A). In the case of these three lectins, it is not surprising to observe an increase in 
activity against OVA-Cy5, given that the predominant epitope is a hybrid N-linked glycan, 
possibly containing terminal galactose residues (45). When it comes to RNase B, it is very 
surprising to see these lectins, along with GafD, displaying an increase in activity against this 
high-mannose ligand upon orientation (Figure 2.9B). This glycan-binding activity may be due to 
contamination of other glycoproteins, or with the ortholog RNase C, a hybrid N-linked-
containing protein (51). Since all of our lectins showed enhanced activity upon orientation, we 
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needed to determine whether this increase in activity is due to orientation, and not simply 
because of increased protein deposition. 
 
 
Figure 2.9 Orientation does not affect lectin specificity. All oriented (GSH, black bars) recombinant  
  lectins displayed increases in activity compared to non-oriented lectins (NHS, white bars) 
  against OVA-Cy5 and RNase B-Cy3. A) Graphical representation of signal to noise  
  (S/N) data on dual-surface array probed  with OVA-Cy5 (400 nM). B) Graphical   
  representation of S/N data on dual-surface array probed with RNase B-Cy3 (400 nM).  
  GST-tagged lectins (GafD, PA-IL, PA-IIL, PapGII, RS-IIL, GafD-m) were printed at 0.5  
  mg/mL (~9-12 μM, dependent on the lectin). Average S/N from a single array is shown.  
  Our standard threshold for positive signals (S/N = 5) is represented by a red bar.   
  Enhancement of all positive signals was  observed on the array. Error bars represent the  
  standard deviation for 3 spots. Data is representative of 3 replicate arrays. 
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2.2.3 Determination of lectin deposition upon orientation 
 One possible reason for the observed increase of activity upon orientation is increased 
deposition of GST-tagged lectin on the GSH-modified surface. To test this, we labeled GafD 
with Cy5-NHS and deposited the protein on the two surfaces. We observed a 40% decrease of 
GafD-Cy5 (Figure 2.10A and B) when printed onto the GSH-modified surface compared to 
random deposition on the NHS-activated surface. Also, we performed a secondary detection 
experiment by probing with phycoerythrin-conjugated α-S·tag antibody (α-S·tag-PE). Through 
observing the Cy3 channel, we can indirectly detect the amount of GafD-Cy5 printed on the 
slide. When printed onto the GSH-modified surface, we observed a ~4.5-fold increase in α-S·tag-
PE binding to GafD (Figure 2.10C and D). In the pET-41 vector, the S·tag domain is nearer to 
the C-terminus of the protein (Figure 2.3A), and given the results of the direct labeling 
experiment, we concluded that upon orientation via the N-terminal GST tag, the S·tag domain is 
also more accessible, hence the increase in detection observed in the Cy3 channel.  
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Figure 2.10 Evidence for recombinant lectin orientation. A) Direct detection of GafD-Cy5 (10 µM)  
  printed on the NHS-activated surface (- GSH) and GSH-modified surface (+ GSH). B)  
  Graphical representation of data shown in A). C) Indirect detection of GafD-Cy5 (10  
  µM) printed on the NHS-activated surface (- GSH) and GSH-modified surface (+ GSH)  
  and detection with α-S·tag-PE. D) Graphical representation of data shown in C).   
  Signals are average between two subarrays with 3 spots per array shown. Error   
  bars represent the standard deviation. 
 
 
 To confirm that orientation of GafD requires the GST-tag, we cleaved the GST-domain 
with thrombin protease (see Figure 2.3B), and purified the Cy5-labeled, thrombin-cleaved GafD 
(tc-GafD-Cy5, ~ 25 kDa) (Figure 2.11A). We printed tc-GafD-Cy5 on both the NHS-activated 
surface and on the GSH-treated surface. Significant protein deposition was observed on the 
NHS-activated surface, however, only background levels of protein were seen on the GSH-
modified surface (Figure 2.11B and C). This experiment validated that the GST-GSH interaction 
is crucial for protein binding and orientation on the GSH-treated surface.  
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Figure 2.11 Deposition of tc-GafD-Cy5 on the dual-surface array. A) Full-length    
  GafD (~50 kDa) was isolated from a cultured cell pellet (Lane 1) using GSH-sepharose.  
  Immobilized protein was then labeled with Cy5-NHS, then cleaved with thrombin,  
  washed (Lane 2), thus releasing tc-GafD-Cy5 (~23 kDa, lane 3 is supernatant containing  
  free lectin). B) tc-GafD-Cy5 was printed on the NHS-activated and GSH-treated surfaces. 
  C) Graphical representation of data shown in B). Data is representative of 3 arrays. Error  
  bars represent the standard deviation. 
 
 
 
2.2.4 Creation of the dual-surface array 
 To directly compare binding activity of our recombinant lectins, we needed to 
manufacture a dual-surface array capable of random protein coupling via NHS-esters and 
orientation through GSH-GST activity (Figure 2.12). Considering that plant lectins are the most 
widely used proteins in glycomic analysis, we also wanted to include these naturally-purified, 
non-GST-tagged lectins. On the NHS-activated surface (blue outline), we printed 21 naturally-
purified plant lectins along with the seven recombinant lectins (with serial dilutions) (See 
Appendix Table 1 for print list). On the GSH-modified surface (yellow outline), we only printed 
the GST-tagged recombinant lectins. The dual-surface arrays were then probed with 400 nM 
OVA-Cy5 (Figure 2.12). As shown below, the glycopattern observed after incubation with the 
array are in agreement with known glycans present on the glycoprotein (45). As expected, we 
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observed activity against mannose-binding lectins (ConA, RS-IIL, and PA-IIL) and β-GlcNAc-
binding lectins (DSA, GS-II, WGA, and GafD). 
 
Figure 2.12 Fabrication of a dual-surface array. Subarrays were generated were subdivided by a  
  hydrophobic solution. A single sub-divided array was probed with 400 nM OVA-Cy5.  
  NHS-activated surface outlined by a blue line, and the GSH-modified surface is outlined  
  in yellow (53). 
 
 
2.3 Conclusions 
 The creation of a dual-surface array allowed us to have randomly deposited, non-GST-
tagged plant lectins printed on an NHS-activated surface in the same array as oriented GST-
tagged lectins printed on a GSH-modified surface (53).  Although we developed this method to 
be of general use in protein microarray technology, we discovered three main issues with this 
array platform. First, the production of the dual-surface arrays is very tedious and very prone to 
human error. Indeed, one minor slip of movement while subdividing the array can completely 
distort a single subarray and possibly disrupt the printing process. The second issue is the 
requirement of a GST-tag on the protein deposited. Without subdividing the slide, non-GST-
tagged proteins cannot be printed on the GSH-surface. For decades, native, non-tagged, plant 
lectins have been used to analyze glycosylated substrates (9, 10, 12, 54). Lectin microarrays take 
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advantage of the well-defined set of commercially available lectins. Ideally, these plant lectins 
would be replaced by recombinant substitutes due to issues mentioned earlier in Chapter 1, 
however, that is currently not feasible. The requirement for only GST-tagged recombinant lectins 
on a GSH-modified surface limits the depth of analysis to glycopatterns obtained with only a 
strict set of recombinant lectins. The third issue is that when probing the GSH-modified surface 
with complex mixtures, such as cellular micellae (9), we observed very high background signal. 
The coating of the Nexterion H slides was created to maximize protein repulsion, which then 
dispels non-specific binding interactions, effectively lowering the background levels of 
fluorescence (16). However, when we probed our GSH-modified surface with membrane 
preparations from some tumor cell lines, we observed significant background fluorescence 
(Figure 2.13). This is most likely due to the fundamental change of the hydrophobicity and 
surface charge of the Nexterion H slide. 
 
Figure 2.13 GSH disrupts the anti-adhesive coating of the Nexterion H slide. A) Array probed with  
  Cy5-labeled 10 µg of ACHN membrane preps hybridized with a recombinant lectin  
  microarray deposited on an NHS-activated surface. B) Array probed with Cy5-labeled 10 
  µg of ACHN membrane preps hybridized with a recombinant lectin microarray oriented  
  on a GSH-modified surface.  
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GSH is a small, zwitterionic peptide, but when immobilized through the primary amine, the C-
terminal carboxyl group provides a negatively-charged surface, capable of forming ionic 
interactions with positively-charged samples. Because of these varying limitations, we wanted to 
develop a method wherein we could preserve the anti-adhesive coating of the Nexterion H slide 
while taking advantage of the GST-based protein orientation.  
 Another issue pertains to the construct that we clone our recombinant lectins into.  The 
pET41 vector contains the N-terminal GST tag, and as yet, no other company or group to our 
knowledge has created a C-terminal GST vector. It is possible that a GST tag on the C-terminus 
may allow better access to the carbohydrate-binding domain. Also, if one encounters expression 
difficulties due to truncated products co-purifying on a GSH-column, a C-terminal GST-tag 
would allow the purification of full length GST-tagged proteins. To this end, I modified the 
pET45b vector, and subcloned in a GST-tag at the C-terminus by replacing the S·tag (Figure 
2.14). Future experiments in the lab will have to be conducted to prove the utility of this new 
vector. 
 
 
 
Figure 2.14 Construction of a C-terminal GST-fusion vector, pPS. The S·tag was cut out of the  
  pET45b vector, and a GST construct was ligated into the cut vector yielding pPS. 
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2.4 Materials and methods 
2.4.1 Optimization of glutathione immobilization 
 Optimization of GSH treatment conditions: N-hydroxysuccinimide activated slides 
(Nexterion slide H, Schott North America) were mounted in a 24-subarray frame (Arrayit 
Corporation) and buffer or glutathione mix (100 µL) was added to each well. Three buffers were 
tested: phosphate-buffered saline (PBS, 100 mM sodium phosphate, 150 mM sodium chloride, 
pH 7.4), sodium borate (50 mM, pH 8.3), and sodium bicarbonate buffer (100 mM, pH 9.4). 
Different concentrations of glutathione were prepared in these buffers at the following 
concentrations: 200, 100, 50, 25, 12.5, 6.25, and 3.13 mM. The remaining subarrays were 
incubated with buffer to act as a control. Slides were incubated with the solutions for 1 h, 
removed from the frames, and dried on a slide spinner. The slides were washed three times with 
PBS-T (PBS + 0.005% Tween 20) and once with PBS. Slides were then blocked with 
ethanolamine (50 mM) in sodium borate buffer for one hour. Slides were then washed and dried 
as described above, and used for printing. RS-IIL was printed at various concentrations (24, 12, 
6, 3, and 1.4 µM) as previously described (53). Briefly, lectins were diluted in print buffer (1 
mM CaCl2, 1 mM MgCl2, 1 mM of the appropriate monosaccharide (see Appendix Table 1), 0.5 
mg/mL BSA, in PBS). The lectin solutions were loaded into a 384-well plate, and the glass slides 
were printed by using a Spotbot personal microarrayer with SMP3 pins (TeleChem International 
Inc., Sunnyvale, CA, USA). Three spots per lectin were printed. During the printing, the arrayer 
was kept between 50–60% humidity and 8°C. Upon completion of the array print, slides were 
incubated for 2 h, and then blocked and washed as described above. Slides were then placed into 
the 24-subarray frames and incubated with chicken egg ovalbumin (600 nM, Sigma) 
fluorescently labeled with Cy5 (Cy5–NHS ester, GE Life Sciences) in PBS-T++ (PBS, 0.005% 
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Tween 20, 1 mM CaCl2, 1 mM MgCl2) for 2 h at room temperature. Upon completion, the slides 
were washed and dried as described above and scanned on a Genepix 4100 A slide scanner 
(Molecular Devices). Genepix Pro 5.1 software (Molecular Devices) was used for extraction of 
the data. Microsoft Excel and Graphpad Prism 4.0 software were used for statistical analysis and 
to generate graphs and tables. For data analysis, lectin binding was defined as the signal to noise 
ratio (S/N): median fluorescence intensity of the sample at 635 nm/median fluorescence intensity 
of the local background at 635 nm. The average and standard deviation of the S/N for the three 
replicate spots were reported. 
2.4.2 Creation of the dual-surface lectin microarray 
 To create distinct chambers in a single subarray, a 16-well FAST frame hybridization 
chamber (Whatman) was coated with a hydrophobic solution from a Super PAP Pen (Beckman-
Coulter). The coated FAST frame was then used to stamp the N-hydroxysuccinimide activated 
slides (Nexterion slide H) to create 16 individual subarrays. Each subarray was then further 
chambered by physically drawing a barrier (~2/3 the length of the subarray) using the 
hydrophobic solution. To print two distinct lectin panels into a single subarray, the subgrid 
dimensions and the lateral and vertical offsets must be adjusted accordingly (Figure 2.15).  
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Figure 2.15 Dual-surface lectin microarray layout. 
 
 Currently, the maximum numbers of probes with three replicate spots per probe that can 
be printed in the top and bottom chambers are 70 and 49, respectively (Note: these settings are 
optimized for the Spotbot Personal Microarrayer and the software provided by Arrayit to print 
multiple subarrays onto glass slides. Additional optimization would be needed to adapt this 
configuration to other systems). The full panel of both recombinant and plant lectins (see 
Appendix A Table 1) was printed onto the top half of each subarray by using the printing 
procedure described above. Prior to printing, the bottom half of each subarray was incubated 
with 10 µL of the GSH buffer (50 mM GSH, pH 9.4) and allowed to incubate during the printing 
procedure. Upon completion of the printing, the slides were incubated for ~2 h to ensure that the 
coupling process was complete. Please note, total incubations times of longer than 5 h (print 
time+incubation) can lead to evaporation of the GSH solution. The slides were washed three 
times with PBS-T and then once with PBS. Slides were then blocked with 50 mM ethanolamine 
in sodium borate buffer (pH 8.5) for 1 h at room temperature. Slides were washed and dried as 
described above and were then ready for printing the second panel of lectins (lectins 1–49, see 
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Appendix A Table 1) in the bottom subarray. Upon completion of the second print, the slides 
were incubated for ~2 h at room temperature, washed, and dried as described above. Slides were 
then placed into the 16-well FAST frame hybridization chamber. Each subarray was incubated 
OVA–Cy5 or RNaseB–Cy5 (New England Biolabs) in PBST++ at varying concentrations for 2 h 
at room temperature. Upon completion, slides were gently washed and dried, as described 
previously. Slides were then scanned on a Genepix 4100 A slide scanner, and data was extracted 
and analyzed as described above. 
2.4.3 Cy5-labeling, thrombin treating, and deposition of GafD on a dual-surface array   
 A single cell pellet, grown from a 1 L culture, was resuspended and lysed as previously 
described (8). The lysate was split into three fractions and loaded onto GSH-sepharose (GE 
Healthcare, 20μL of beads per mL of lysate). After incubation at room temperature (30 min) the 
beads were pelleted and washed 3 x with 100 mM NaHCO3 buffer (pH 9.3). The beads were then 
reacted with 5 μL of 15 μM NHS-Cy5 for 1 hr at room temperature to label the protein. After 
labeling, GST-GafD-Cy5 was either eluted from the beads using 10 mM GSH in 50 mM  
Tris*HCl (pH 8.0) or washed 3x with PBS and subjected to thrombin treatment (5 U, 1 hr, RT) 
to release tc-GafD-Cy5. Thrombin cleaved GafD was treated with 100 μL of benzamidine beads 
(GE Healthcare) to remove thrombin. The released labeled proteins were then dialysed against 
PBS, flash frozen and stored at -80 °C until use on the microarrays. 
2.4.4 Cloning of pPS 
 The GST domain was PCR amplified from the pET41b vector containing GafD in the 
multiple cloning site with the appropriate restriction sites: XhoI Forward: 5‟ – GAT ATA CAT 
CTC GAG ATG TCC CCT ATA CTA GGT TAT TGG – 3‟; PacI Reverse: 5‟ – CCA TCC 
GAT TAA TTA ATT TTG GAG GAT GGT CGC CAC CAC C – 3‟. PCR reactions were 
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performed with the Hot Start DNA Polymerase (New England Biolabs (NEB), #F120S) and 
reactions were tailored to product specifications. The PCR product and pET45b DNA were 
treated with both XhoI (NEB, #R0146) and PacI (NEB, #R0547) in buffer 4 (NEB). After PCR 
purification (Qiagen, #28104), the products were mixed and ligated with T4 DNA ligase (NEB, 
#M0202) and incubated overnight at room temperature. After another PCR purification, the 
eluant was transformed into electrocompetent NovaBlue Gigasingles (Novagen, #71227), grown, 
and purified DNA was isolated using the Qiaprep Mini Kit (Qiagen, #27106), and sequenced. 
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Chapter 3: In situ orientation of GST-tagged lectins for glycomic analysis 
 
3.1 Introduction  
 A major issue in protein microarray technology is the activity of the deposited protein. In 
some studies, groups demonstrated that as few as 5 – 20% of deposited protein samples show 
proper activity (1 - 3). As discussed in Chapter 2, the orientation of proteins via affinity tags can 
greatly enhance the binding sensitivity of a given microarray (4). In our original orientation 
work, we subdivided arrays on a microarray slide to generate dual-surface arrays. Although this 
methodology did allow both oriented and non-oriented proteins to be printed on the same array, 
it was technically challenging and impractical for use with complex samples such as membrane-
bound glycans (5). We wondered whether we could simplify this two-step process into a single 
protein deposition and orientation step. We rationalized that supplementation of the print buffer 
with an excess of GSH in a slightly basic buffer might be able to outcompete protein 
immobilization through side chain lysines, allowing for a one pot in situ orientation scheme 
(Figure 3.1). 
 
Figure 3.1 Schematic of the in situ orientation method. When printed under standard conditions, we  
  obtain randomly deposited protein, thus affecting the activity of the immobilized protein.  
  If we supplemented the print solution with an excess of GSH, we might be able to create  
  a GSH-surface in situ which would organize GST-tagged proteins upon the GSH- 
  scaffold (16). 
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 We theorized the kinetics of the immobilization would favor the small molecule GSH 
over the protein, a large biomolecule. GSH is smaller, in excess, and contains a free terminal 
amine (pKa ~ 8), thus it might outcompete the more bulky protein containing protonated lysine 
groups (pKa ~ 10). If this were the case, when the protein solution is deposited onto the slide 
surface, the GSH would react first with the slide, creating a GSH-modified surface in situ which 
would organize the GST-tagged lectins upon it (Figure 3.1). To our knowledge, a microarray 
fabrication method for simultaneous slide derivatization and protein deposition has not been 
reported. Herein, we describe this new print methodology. 
3.2  Results and Discussion 
3.2.1 Optimization of print conditions for in situ orientation of GST-tagged lectins 
 For our initial experiments of in situ protein orientation, we chose to probe two lectins, 
GafD and RS-IIL, against Cy5-labeled chicken egg ovalbumin (OVA-Cy5), and just RS-IIL 
against Cy3-labeled RNase B (RNase B-Cy3). Based on our previous results in protein 
orientation, we tested both sodium borate (pH 8.5) and sodium bicarbonate (pH 9.3) buffers, as 
pH plays an important role in the amide coupling reaction between GSH and the NHS-activated 
slide. Once again, we analyzed overall lectin binding as the distribution of activities between the 
two lectins with respect to both buffer composition and amount of GSH additive (Figure 3.2). 
 We printed both GafD (20 µM) and RS-IIL (24 µM) in sodium borate and sodium 
bicarbonate buffers and in both buffers, a range of concentrations of GSH was tested (100, 50, 
25, 10, and 0 mM). In Figure 3.2A, we plot the observed activity of GafD and RS-IIL against 
various concentrations of OVA-Cy5 with respect to each printing buffer containing all GSH 
concentrations. Again, just as in Chapter 2, we define activity as an increase in observed  
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Figure 3.2 Optimization of GSH deposition for in situ orientation of GST-tagged lectins. Box and  
  whisker plots representing the distribution of binding between two GST-tagged lectins  
  GafD and RS-IIL, and two glycoproteins OVA-Cy5 and RNase B-Cy3. A)   
  Distribution of binding of the two lectins against OVA-Cy5 in varying concentrations of  
  GSH (100, 50, 25, 10, and 0 mM) with respect to the two print buffers sodium borate (pH 
  8.5) and sodium bicarbonate (pH 9.3). B) Distribution of binding of RS-IIL against  
  RNase B-Cy3 with varying concentrations of GSH (100, 50, 25, 10, and 0 mM) with  
  respect to the two print buffers sodium borate and sodium bicarbonate. C) Distribution of  
  binding of the two lectins against OVA-Cy5 in both buffers with respect to GSH   
  concentration. D) Distribution of binding of RS-IIL against RNase B-Cy3 in both buffers  
  with respect to GSH concentration. From all the data collected, the optimized print buffer 
  was found to be 100 mM GSH in sodium borate buffer (pH 8.5). Each box plot represents 
  the distribution of binding in absolute fluorescence. The interquartile range (boxed)  
  represents the distribution of 50% of the total binding signals and was used to compare  
  between the different printing conditions (16). 
 
fluorescence for a particular glycoprotein. In Figure 3.2B, we probed RS-IIL (24 µM) against 
RNase B-Cy3 using the same GSH concentrations as in A). In both conditions, the sodium borate 
buffer was found to be statistically better and different from the sodium bicarbonate values (p < 
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0.001). We initially believed that 50 mM GSH would be the optimal orientation concentration 
based on our previous work (4). When we analyzed the same data set to determine an optimal 
GSH concentration, the activities of GafD and RS-IIL against OVA-Cy5 at 100 and 50 mM GSH 
concentrations are very similar (p = 0.7) (Figure 3.2C). On the other hand, as shown in Figure 
3.2D, the difference between the activities of RS-IIL against RNase B differ a significant amount 
between 100 and 50 mM GSH (p < 0.001). Upon closer examination of the data, we separated 
GafD and RS-IIL binding to OVA-Cy5 and noticed considerable differences. The difference 
between the 100 and 50 mM GSH concentrations for RS-IIL was statistically significant (p = 
0.025), although for GafD they were not (p = 0.96).  Thus we concluded that the optimal buffer 
for general GST-lectin activity was 50 mM sodium borate (pH 8.5) with 100 mM GSH. 
However, with the subtle differences in lectin binding activity between the two GSH 
concentrations for GafD, it may be possible that other proteins would require different buffer 
compositions. For the work presented in this chapter, our in situ orientation buffer (GSH-B, 50 
mM sodium borate, pH 8.5, with 100 mM GSH, supplemented with 0.5 mg/mL BSA, final pH 
4.2) was optimal for lectin activity compared to our standard print conditions (PB, 10 mM 
sodium phosphate, 15 mM sodium chloride, pH 7.4, supplemented with 0.5 mg/mL BSA). 
 This optimized buffer contains twice as much GSH as our buffer optimization for the 
production of our dual-surface arrays (4). We directly compared all three protein immobilization 
conditions to determine the effectiveness of both orientation methods compared to random 
deposition printing (Figure 3.3). RS-IIL (24 µM) was printed in GSH-B, PB, and then on a GSH-
modified surface, and probed for activity against varying concentrations of OVA-Cy5  
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Figure 3.3 Comparison of the lectin orientation conditions between the in situ oriented and lectin  
  oriented on GSH-surface. RS-IIL (24 µM) was printed in GSH-B (in situ oriented) and  
  PB (non-oriented) on an NHS-activated surface. We also printed RS-IIL on a GSH- 
  modified surface, and both slides were treated with varying concentrations of OVA-Cy5  
  (10, 5, 2.5, 1.25, 0.63, 0.31, and 0.16 µM). A) Activities of in situ oriented RS-IIL  
  (closed circles), non-oriented RS-IIL (open circles), and RS-IIL oriented on a GSH- 
  surface (tan circles) were plotted against the OVA-Cy5 concentration. B) Scatchard plots  
  of RS-IIL binding to OVA-Cy5. Observed dissociation constants (Kd‟s) were similar in  
  each deposition method. In situ oriented RS-IIL showed the greatest activity. Data is  
  representative of triplicate arrays. Error bars indicate the standard deviation from the  
  mean value (16).  
 
(Figure 3.3). A direct comparison of the orientation methods revealed ~2-fold increase in activity 
in favor of in situ oriented RS-IIL over RS-IIL oriented on a pre-modified GSH-surface (Figure 
3.3A). For further analysis, the data was plotted in the form of a Scatchard plot and the binding 
affinities were analyzed using linear regression to obtain apparent dissociation constants (Kd) 
(Figure 3.3B). The observed Kd‟s were similar to each other: (In situ oriented Kd = 2.05 ± 0.33 
µM, non-oriented Kd = 3.59 ± 0.39 µM, and RS-IIL oriented on GSH-surface, Kd = 2.63 ± 0.47 
µM); and were in the typical range of binding activities for RS-IIL (6). The exact reason for the 
increase in activity between the two orientation methods is unknown, but the differences may 
arise from the different fabrication processes.  
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3.2.2 Activity of in situ oriented GST-tagged lectins 
 To demonstrate the effectiveness of in situ orientation, we printed GafD and RS-IIL in 
both GSH-B and PB and probed for activity against fluorescently-labeled glycoproteins, OVA-
Cy5 and RNase B-Cy3, respectively.  
 
 
 
Figure 3.4 In situ orientation of recombinant lectins. A) Comparison of the activity of RS-IIL  
  (24 µM) against varying concentrations of Cy3-labeled RNase B (RNase B-Cy3) printed  
  in either GSH-B or PB. Data is representative of triplicate arrays. B) Graphical   
  representation of data shown in A). C) Comparison of activity of GafD (10 µM) against  
  varying concentrations of OVA-Cy5 printed in either GSH-B or PB. Data is   
  representative of triplicate arrays. D) Graphical representation of data shown in C). Error  
  bars indicate the standard deviation of the mean (16). 
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Both lectins displayed increased activity upon orientation. Moreover, improved spot morphology 
was observed for both lectins (Figure 3.4A and C). Under our standard print conditions, RS-IIL, 
the mannose-binding lectin, could detect RNase B-Cy3, a glycoprotein with a single high-
mannose epitope (7), down to 16 nM. However, when oriented, we could detect the same 
glycoprotein down to the high picomolar range (640 pM), an increase of 25-fold in detection 
limits (Figure 3.4A and B). When GafD, the β-GlcNAc-binding lectin, was oriented in situ, an 9-
fold increase in activity was observed against OVA-Cy5 versus the non-oriented lectin (Figure 
3.4C and D). We also probed in situ oriented RS-IIL against OVA-Cy5 and observed a similar 
increase in activity against the mannose-containing glycoprotein. At the highest concentration of 
OVA-Cy5 tested (2 µM), we observed an ~8-fold increase in activity of in situ oriented RS-IIL 
over non-oriented RS-IIL (Figure 3.5). We also tested the effects of in situ orientation of PA-IIL, 
the fucose- and high-mannose binding lectin, against RNase B-Cy3. Consistent with our previous 
work (4), orientation increases glycan-binding activity is increased ~2-fold over several 
concentrations (Figure 3.6). 
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Figure 3.5 In situ orientation and activity of RS-IIL. A) RS-IIL (24 μM) was printed in either  
  GSH-B (in situ oriented) or PB (non-oriented) and hybridized with Cy5-labeled   
  ovalbumin (OVA-Cy5). B) Graphical representation indicates that the largest difference  
  in activity is ~8-fold in favor of the oriented RS-IIL. The enhanced spot    
  morphology of the oriented lectin is also clearly visible. Error bars indicate the standard  
  deviation from the mean value. Data is representative of triplicate arrays (16). 
 
 
Figure 3.6 In situ orientation of PA-IIL. A) PA-IIL (24 μM) printed in either GSH-B (in situ  
  oriented) or PB (non-oriented) and hybridized with varying concentrations of Cy3- 
  labeled RNase B (RNase B-Cy3). Graphical representation of the data in B) indicates that 
  binding of RNase B by PA-IIL shows modest improvement in activity (~1.5 – 2x) when  
  oriented. Error bars indicate the standard deviation from the mean value. (b) Array data  
  showing PA-IIL binding to RNase B. Data is representative of triplicate arrays (16). 
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Figure 3.7 Competition of carbohydrate-binding of in situ oriented GafD and RS-IIL against OVA- 
  Cy5 (10 µM).  GafD (20 µM, black bar) displayed significant binding, yet when inhibited 
  with 100 mM N-acetylglucosamine (GlcNAc, white bar), glycan-binding activity is  
  diminished to background levels of binding.  RS-IIL (24 µM, dark blue bar) showed  
  significant binding, but when inhibited with 100 mM mannose (light blue bar), glycan- 
  binding activity was decreased to background levels of binding. 
 
 In our original orientation work, we printed the same lectin-containing buffer on two 
different surfaces (4). In this work, we are dramatically altering the print buffer, therefore we 
wanted to determine that the lectin binding activity is not being affected by the excess GSH. In 
our previous work, we observed significant levels of background fluorescence on the GSH-
modified surface. We wanted to know whether the signals observed after hybridization were 
carbohydrate-specific, and not due to the effects of a GSH monolayer. To test this, we printed 
GafD and RS-IIL in GSH-B and in PB, and then probed for activity against OVA-Cy5 in the 
absence or presence of inhibiting monosaccharide (Figure 3.7). Since GafD is a β-GlcNAc-
binding lectin, we inhibited the carbohydrate interaction with 100 mM GlcNAc, and with RS-
IIL, we inhibited the interaction with 100 mM mannose. The inhibition of GafD resulted in the 
loss of 93% of the fluorescence signal and the inhibition of RS-IIL resulted in a 95% decrease of 
fluorescence (Figure 3.7).  
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3.2.3 Testing the nature of the in situ orientation technique 
 To obtain a better understanding of both the limits and the mechanisms of in situ 
orientation, we performed several non-carbohydrate-based experiments. First, we fluorescently 
labeled BSA, a common additive in protein microarrays, with a maleimide-Alexa Fluor 647 
conjugate and then printed in sodium borate buffer (3.5 µM Alexa Fluor 647 BSA in 50 mM 
sodium borate buffer, pH 8.5) with varying concentrations of GSH (Figure 3.8). To probe for 
deposition of GSH, we took advantage of the cysteine residue of the peptide and incubated the 
array with maleimide-PEG2-biotin (250 µM), followed by incubation with Cy3-labeled 
streptavidin (streptavidin-Cy3, 50µg/mL). In the Cy3 channel, we observed deposition of the 
peptide at the lowest concentration tested (1 mM GSH, 180 A.U. (fluorescence) versus 0 mM 
GSH, 100 A.U.). Most notably, GSH deposition increases with GSH concentration, effectively 
out-competing the labeled BSA at higher concentrations (Figure 3.8). Given that our lectins are 
typically printed at ~20 µM, at the highest concentration, containing ~7 µM BSA and that both 
proteins contain ~30 lysines per protein, then we estimate that each lectin solution contains an 
~800 µM concentration of lysine residues. At the 100 mM GSH concentration, we anticipate a 
molar excess of over 100-fold of GSH to lysine residues in our in situ orientation buffer. We 
cannot say with certainty the density of NHS-activated esters per spot volume, but the original 
slide developers concluded that 50 mM of a small amine was sufficient at deactivating the NHS-
esters (8). In fact, the manual accompanying the Nexterion H slides suggests that, after protein 
printing, the slide should be blocked with 50 mM ethanolamine in sodium borate buffer (pH 8.5) 
(9). Therefore, we believe that at the 100 mM GSH concentration we can sufficiently react with 
all NHS-activated esters to form a GSH-modified surface in situ, thereby orienting GST-tagged 
proteins and repelling non-GST-tagged proteins. 
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Figure 3.8 Competition of GSH and BSA for NHS-activated surface. Printing of Alexa Fluor 647- 
  conjugated BSA (BSA-AF, 3.8 µM) in sodium borate buffer (pH 8.5) with varying  
  amounts of GSH. A) Array data of BSA-AF printed in buffer containing GSH. The array  
  was probed 250 µM maleimide-PEG2-biotin, followed by 50 µg/mL of streptavidin-Cy3.  
  Deposition of BSA-AF is observed in the Cy5 channel, and GSH deposition levels are  
  observed in the Cy3 channel. An overlay of the spots is shown as a ratio (Cy5/Cy3). B)  
  Graphical representation of data shown in A). Data is shown on a log4 scale to aid in  
  visualization (16). 
 
 
 Given the increased activity of our GST-tagged lectins, we needed to determine whether 
the increased activity is simply due to increased levels of protein deposition. We printed Cy5-
labeled GafD (GafD-Cy5) in both GSH-B and PB, and examined protein deposition and 
orientation by direct observation and indirect detection using the PE-conjugated α-S·tag antibody 
(α-S·tag-PE) (Figure 3.9). In our previous orientation method, we observed a ~40% decrease in 
deposition upon immobilization on the GSH-modified surface (4). When we printed GafD-Cy5 
under these new set of conditions, we observed a 30% decrease in deposition of GafD-Cy5 when 
in situ oriented (Figures 3.9A and B). We also observed an increase in the indirect detection with 
α-S·tag-PE when GafD was oriented in situ (Figure 3.9C and D). These results are consistent 
with our previous findings on protein orientation as discussed in Chapter 2.  
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Figure 3.9 Comparison of the deposition and orientation of GafD-Cy5. A) GafD-Cy5 (10 µM) was  
  printed in either GSH-B or PB. Array data is shown and representative of three separate  
  arrays. B) Graphical representation of data shown in A). C) Indirect detection of GafD- 
  Cy5 printed in GSH-B or PB and detected with α-S·tag-PE (1 µg/mL). Array data is  
  shown and representative of three separate arrays. D) Graphical representation of  
  data shown in C). The arrays spots shown are the same printed samples, just   
  observed in two different emission channels. Error bars indicate the standard   
  deviation from the mean value, and data is representative of triplicate arrays. 
 
 To quantify these results in terms of non-labeled GafD and the corresponding binding 
activity, we made a few assumptions in our calculation. First, all of the GafD immobilized and 
oriented in GSH-B binds to the glycoprotein. Second, the relative differences in activity of 
oriented versus non-oriented protein can be estimated from the differences in fluorescence signal 
from binding to OVA-Cy5. And third, the concentration of non-labeled and oriented GafD is also 
30% lower than non-oriented GafD. Taking in these assumptions, we discover that only 8% of 
the non-oriented protein binds to the same glycoprotein (Calculation: (relative deposition/relative 
activity)*100%). 
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 To demonstrate the necessity of the GST-domain for in situ orientation, we printed Cy5-
labeled thrombin-cleaved GafD (tc-GafD-Cy5) (4) in both GSH-B and PB (Figure 3.10). When 
observing direct deposition in the Cy5 channel, we noticed a ~73% reduction of deposited tc-
GafD-Cy5 when the protein was printed in GSH-B versus PB (Figures 3.10A and B). When we 
probed for the S·tag domain using α-S·tag-PE, we also observed a concomitant ~73% reduction 
in indirect detection of the deposited protein (Figures 3.10C and D). The equal reduction in both 
deposition and detection of an activity tag highlights that the necessity of a GST-tag for the in 
situ orientation.  
 
Figure 3.10 Comparison of the deposition and orientation of tc-GafD-Cy5. A) tc-GafD-Cy5 (10 µM)  
  was printed in either GSH-B or PB. Array data is shown and representative of three  
  separate arrays. B) Graphical representation of data shown in A). C) Indirect detection of  
  tc-GafD-Cy5 printed in GSH-B or PB and detected with α-S·tag-PE (1 µg/mL). Array  
  data is shown and representative of three separate arrays. D) Graphical    
  representation of data shown in C). The arrays spots shown are the same printed   
  samples, just observed in two different emission channels. Error bars indicate the  
  standard deviation from the mean value, and data is representative of triplicate   
  arrays. 
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 The GST-GSH interaction is known to be a labile interaction in the presence of excess 
GSH, so we expected a facile elution of oriented GafD-Cy5 from the slide.  However, when we 
attempted to remove deposited GafD-Cy5 using an excess of 1 M GSH, we observed moderate 
deposition prior to treatment with 1 M GSH, and saturating fluorescence after GSH treatment. 
Unfortunately, the Cy5 dye is very sensitive to reducing conditions (10), so the results were not 
interpretable. We also analyzed this phenomenon is solution, and observed an increase of 
fluorescence with respect to increasing GSH concentration. As an alternative, we incubated the 
array under denaturing conditions of 6 M urea for 1 hr. We would expect that the GST-GSH 
interaction would be disrupted upon denaturation of the GST domain, and a comparison of a 
before and after treatment of urea showed a 50% loss in GafD-Cy5 deposition (Figure 3.11). In 
contrast, GafD-Cy5 that was randomly immobilized onto the NHS-activated surface displayed no 
decrease in fluorescence upon treatment with urea (Figure 3.11). Our observation indicates that 
at least 50% of our in situ oriented protein is non-covalently bound to our GSH surface. 
However, half of all protein was still present after the denaturing conditions.  
 
Figure 3.11 The effects of denaturation of in situ oriented and randomly immobilized GafD-Cy5  .  
  GafD-Cy5 (10 µM) was printed in both GSH-B and PB, scanned (before urea), and then  
  treated with 6 M urea, and re-scanned at the same conditions (after urea). Error bars  
  indicate the standard deviation from the mean value. Data is representative of duplicate  
  arrays (16). 
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 There may be several possible reasons for this result. First, it is plausible that the GSH 
binding domain of GST is buried within the Nexterion H surface, which may protect it from 
denaturation by urea. When in a dry state, the NHS-PEG surface of the slide is ~10 nm thick. 
When hydrated, the surface expands to between 50 – 100 nm, thus allowing adsorption of the 
sample into the slide (8). Considering that proteins, in general, are well within a ~100 nm 
diameter, the GSH binding domain could be buried within the Nexterion H slide, protecting the 
protein and also making the binding interaction difficult to compete out. Another possible reason 
may be that the remaining GafD is covalently bound to the surface. In this instance, the GSH 
may still initially form a GSH monolayer, yet some NHS-esters still remain, thus leaving those 
remaining amine-reactive functional groups available for lysine conjugation. In both cases, we 
expect an initial formation of a GSH monolayer. 
 When testing the pH of the final solution of GSH-B, we observed some intriguing results. 
First, as expected, the 50 mM sodium borate buffer alone and with additives Tween 20 (0.001%) 
or BSA (0.5 mg/mL) had very similar pH values (8.58, 8.57, and 8.54, respectively). However, 
with the addition of 100 mM GSH, we lower the pH down to 4.22, creating a more acidic 
environment than previously expected. To determine whether the final pH of the buffer is 
important for in situ orientation, we printed GafD (10 µM) in both the standard buffer, GSH-B 
pH 4.2, and in a buffered solution, GSH-B pH 8.5, against Cy3-labeled GlcNAc-BSA (GlcNAc-
BSA-Cy3, Figure 3.12). In fact, when observing the activity over multiple concentrations of 
GafD (40, 20, 10, 5, and 2.5 µM) and multiple concentrations of GlcNAc-BSA-Cy3 (2000, 400, 
80, 16, 3.2, 0.64, 0.128, and 0.256 nM), the activity of in situ oriented GSH-B pH 4.2 is 
statistically different than GSH-B pH 8.5 (p < 0.001). Although the amines in solution are most 
likely protonated at this low pH, the mechanism of immobilization and orientation should remain  
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Figure 3.12 Comparison of activity between GafD printed in two different GSH-Bs. GafD was  
  printed in the original print buffer GSH-B has a pH of 4.2 (closed circles), a   
  modified GSH-B was buffered to pH 8.5 (red circles), and our standard PB was   
  maintained at pH 7.4 (open circles). 
 
the same, since the relative pKa‟s are still the same, meaning the GSH molecule will still 
outcompete the the lysines on GST-tagged GafD. Also, since we observed enhanced spot 
morphology with our in situ orientation method, ie no “coffee cup effect” (11), the excess GSH 
competes with the protein for interactions with the air-water interface resulting in more uniform 
protein deposition. 
3.3 Conclusions 
 Herein we present a new method for the orientation of recombinant, GST-fusion proteins 
in situ on a solid support. By taking advantage of the difference in reaction kinetics between our 
proteins and GSH for amide bond formation with an NHS-ester, we have created a one-pot 
method for the fabrication of a localized GSH scaffold and the organization of GST-tagged 
proteins upon it. After some optimization, we found that we could supplement our print buffer 
with GSH, which could modify the NHS-activated slide surface in situ that could then orient our 
GST-tagged lectins. We observed increased activity to a similar extent of our lectins printed on 
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our dual-surface array, and we showed that we are indeed orienting our lectins in situ. Our 
method maintains the native slide chemistry of the NHS-activated slide, allowing us to maintain 
the diversity of lectins afforded to us from the naturally derived proteins, crucial to the utility of 
our arrays in glycomic analysis. In this study, we only analyzed orientation by using reduced 
glutathione, however, since GST can still bind to oxidized GSH (GSSG) (12), it may be possible 
to use this ligand as well. Although we apply our orientation strategy to GST-tagged 
recombinant lectins, there is little to suggest that this method cannot be widely applied to other 
GST-tagged proteins or even, with some modification, to other protein tag systems. Indeed, it 
may be possible to orient the other two most widely used activity tags, biotin- and His6-tags. For 
biotinylated substrates, we might be able to synthesize a GST-streptavidin fusion protein. When 
printed in GSH-B and with a biotin-tagged protein, the GSH could orient the GST-streptavidin, 
which would then orient a biotinylated protein. As for the His6-tag, it may be possible to orient a 
His6-tagged protein using a Ni
2+
-NTA mixture. Indeed, current efforts in the group indicate that 
we could orient a multi-His-tagged (13) lectin with a Ni
2+
-NTA-containing buffer. Lectin 
microarray technology is shifting toward the implementation of more recombinant lectins. Aside 
from our work, another group has attempted to integrate recombinant lectins into their format 
(14). Integrating new recombinant lectins with common fusion tags requires the corresponding 
development of newer orientation methods.  
3.4 Materials and methods 
3.4.1 General microarray fabrication 
 Recombinant lectins were expressed and purified as described previously (15) GafD-Cy5 
was expressed, purified, and labeled as previously described (4)
   
Unless otherwise noted, all 
microarrays were printed via the following protocol: Lectins were diluted in either GSH-B (50 
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mM sodium borate buffer, pH 8.5, containing 100 mM GSH) or PB (phosphate buffered saline 
(PBS), 10 mM sodium phosphate, 15 mM sodium chloride). For lectin printing, both print 
buffers contain 1 mM CaCl2, 1 mM MgCl2, and 1 mM of appropriate monosaccharide (Appendix 
A Table 2), and 0.5 mg/mL BSA. Prepared samples were loaded into a 384-well microplate 
(Whatman, Piscataway, NJ), and loaded into the SpotBot2 Personal Microarrayer (ArrayIt, 
Sunnyvale, CA). Printing programs were created with the MMF Spocle Program. Samples were 
printed onto Nexterion H slides (Schott North America, Elmsford, NY) with an SMP3 pin 
(ArrayIt, #SMP3). During the print, the slides were kept at 8 °C with internal humidity 
maintained at ~50% throughout the print process. After printing, the slides were allowed to warm 
to room temperature for 2 hr, while maintaining humidity at ~50%. After 2 hr, the slides were 
then placed in a coplin jar and blocked with 50 mM ethanolamine in 50 mM sodium borate 
buffer (pH 8.5) for 1 hr, at room temperature with mild shaking. After one hour, the slides were 
washed with PBS with 0.05% Tween (0.05% PBS-T, 3 x 3 min) and once with PBS. The slides 
were dried using a slide spinner (Labnet Intl., Edison, NJ), and then fastened in a 24-well 
hybridization chamber (ArrayIt). Fluorescently labeled samples were diluted into 0.005% PBS-
T, and 100 µL were added to each subarray and samples were incubated for 2 hr at room 
temperature with gentle shaking. For visualization with α-S·tag-PE antibody, the buffer was 
changed to 0.005% PBS-T with 1% BSA. After 2 hr, samples were aspirated and washed with 
0.005% PBS-T (0.005% Tween 20 in PBS, 3 x 3 min) and once with PBS. The slides were dried 
as before and loaded into the Genepix 4100A slide scanner (Molecular Devices, Union City, 
CA). Data was extracted with GenePixPro 5.0 (Molecular Devices) and analyzed and graphed 
using Microsoft Office Excel 2007. 
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 For the buffer optimization, we printed GafD (20 µM) and RS-IIL (24 µM) versus two 
OVA-Cy5 and RNase B-Cy3. The lectins were printed in either 50 mM sodium borate buffer 
(pH 8.5) or 100 mM sodium bicarbonate (pH 9.3) supplemented with various concentrations of 
GSH (100, 50, 25, 10, and 0 mM). After immobilization and blocking, the slides arrays were 
incubated with varying amounts of OVA-Cy5 and RNase B-Cy3 (10, 5, 2.5, 1.25, 0.625, and 
0.313 µM). The box and whisker plots were generated using Microsoft Excel 2007.  
3.4.2 Labeling and printing of BSA-AF 647 
 Alexa Fluor® 647 C2-maleimide (667 µM, dissolved in PBS, Invitrogen #A20347) was 
added to BSA (10 mg/mL, ~150 µM) in PBS and incubated at room temperature for 1 hr with 
gentle shaking. After 1 hr, the sample was dialyzed against PBS for 12 hr, and the final 
concentration was determined by DC Assay (Bio Rad #500-0112). BSA-AF (3.8 µM) was 
dissolved in 50 mM sodium borate buffer (pH 8.5) with varying amounts of GSH (200, 100, 50, 
10, 5, 1, and 0 mM) and printed as described above. After blocking, washing, and drying the 
slide, 100 µL of 250 µM Maleimide-PEG2-Biotin (Thermo Fisher Scientific, #21901), in 0.005% 
PBS-T was added to the array and incubated at room temperature for 1 hr. After 1 hr, the slide 
was washed with 0.005% PBS-T (3 x 3 min) and once with PBS, and dried. 100 µL of 50 µg/mL 
of Cy3-labeled streptavidin (Invitrogen, #43-4315) was then added to each well and incubated 
for 1 hr at room temperature. After 1 hr, slides were then washed, dried, and scanned as 
previously described. 
3.4.3 Urea treatment of immobilized lectins 
 GST-GafD was printed in 50 mM sodium borate (pH 8.5) containing 100 mM GSH 
(GSH-B) on Nexterion H slides as described above. After printing, the slides were allowed to 
incubate for two hours, equilibrating to room temperature. The slides were then blocked with 50 
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mM ethanolamine in 50 mM sodium borate buffer (pH 8.5) for 1 hr, then washed with 0.05% 
PBS-T (3 x 3 min) and once with PBS. The slides were dried and fastened to a 24-well 
hybridization chamber (ArrayIt). Arrays were then either treated to 100 µL of 6 M urea in PBS 
or 0.005% PBS-T, and were incubated for 1 hr at room temp. After 1 hr, the slides were washed 
with 200 µL of 0.005% PBS-T (3 x 3 min), then were treated with either 10 µM Cy5-labeled 
ovalbumin (OVA-Cy5) or α-S·tag antibody PE-conjugated in 0.005% PBS-T or 0.005% PBS-T 
with 1% BSA, respectively. The slides were then washed with 0.005% PBS-T (3 x 3 min) and 
once with PBS. The slides were dried, scanned, and analyzed as described above. 
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Chapter 4: In situ orientation of non-tagged IgG and IgM antibodies 
 
4.1 Introduction 
 Despite the widespread use of lectin microarrays, the majority of protein microarrays 
produced today employ antibodies as the antigen-binding proteins (1 - 5). Antibodies, which 
typically bind in the nM to pM Kd range (3), are ideal supplements to the lectin microarray for 
glycomic profiling. Antibody microarrays are typically printed onto highly adsorptive surfaces, 
such as nitrocellulose slides, which can often give high background fluorescence (6). Previous 
work in the Mahal lab indicated that a small set of antibodies printed on the Nexterion H slides 
gave poor activity. This may be a result of using an inactive antibody or, since protein 
immobilization can result in aggregation or blocked antigen-binding sites, greatly diminished 
activity (3). With the successful oriention of GST-tagged lectins in situ, we wondered whether 
we could apply this technique to the immobilization of antibody-binding proteins that would then 
orient the antibodies in situ. 
 The most prevalent and commercially-available carbohydrate-binding antibodies are IgG 
and IgM antibodies (Figure 4.1). The IgG class of antibodies is the most abundant in the body 
(~75%) (7), and is subdivided further into four subclasses (IgG1, IgG2, IgG3, and IgG4), which 
vary structurally in the composition of the Fc domains (8). With respect to the IgM antibodies, 
IgG antibodies are monomeric in nature, meaning they comprise two antigen-binding domains 
(FAb) tethered to a single constant domain (Fc) (9). In contrast, IgM antibodies are pentameric 
when secreted, comprising of five antibody monomers with a total of ten antigen-binding 
domains (10). The monomers are all connected through the Fc domains via disulfide bridges to a 
central peptide, called the J chain (11).  
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Figure 4.1 Representations of the IgG and IgM class of antibodies. The most abundant class  
  of antibodies, IgG, are monomeric antibodies with two antigen binding domains   
  located at the tip of the variable regions of heavy and light chains (VH and VL).   
  Secreted IgM antibodies are pentameric antibodies which contain 10 antigen   
  binding domains, connected at the end of the individual Fc domains by a J chain   
  peptide. 
 
 Protein A (SpA) and protein G (SpG) are well-characterized antibody-binding proteins 
secreted by the bacterial families Staphylococcus and Streptococcus, respectively (12,13). Both 
antibody-binding proteins bind to the Fc domains, but SpG can also bind to the constant regions 
of the Fab to a minimal degree (14). Groups that have reported on the orientation of IgG 
antibodies using SpG, simply assume that the Fc domain is bound and not the Fab due to the 
differences in activity. The first two groups that attempted antibody orientation directly 
immobilized SpA to activated slide, such as epoxy- or aldehyde-modified surfaces (15 - 17). 
Wang et al. demonstrated the immobilization of SpA on a gold nanoparticle surface in a flow-
reaction chamber to use in an antibody-antigen binding system (15). Matson et al. describe a 
method to orient antibody microarrays using a print-over-print method, which requires two 
separate print procedures (16). One widely-cited work on protein orientation regards the 
orientation of Fc-fused dectin-1 (18). Chen et al. tested three orientation methods, two of which 
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used SpG and boronate esters, to bind to the N-glycans present on the Fc domain of the 
antibodies. The authors end up not using SpG, but it highlights the need for a general method for 
antibody orientation in a microarray format (18). A major issue with these methods is that not 
one discusses any potential benefits of the immobilization technique of the SpA/G. It seems 
obvious that improved antibody orientation can be achieved with an oriented SpA/G. To address 
this issue, another group, whose work is discussed in the Chapter 2, synthesized a GSH-
containing small molecule which they coated onto a gold surface. GST-tagged SpG derivatives 
were then printed onto the modified slide and binding activities to IgG antibodies were assessed 
(19). Although a good example for the need of oriented SpG, the synthesis of the small molecule 
is not practical. Furthermore, since entire slide chemistries are specialized to a specific protein, 
there is a loss of diversity in the potential of arrayed proteins, which severely limits the 
application of this method.  
 Since we could orient single GST-tagged protein in situ, we wondered whether we could 
print GST-tagged SpA or SpG with an IgG antibody in our GSH-containing buffer. 
Unfortunately, only about half of all commercially-available carbohydrate-binding antibodies are 
IgG, the rest are IgM antibodies. Given the pentavalent nature of IgM antibodies, we 
hypothesized that the Fc domains would be inaccessible for binding by the traditional antibody-
binding proteins SpA and SpG. For this reason, we generated a GST-tagged version of Protein L 
(PpL), an antibody-binding protein derived from Peptostreptococcus magnus, which binds the 
constant region of κ light chain (20). Although available as a resin for the purification of 
antibodies (Pierce, Rockford, IL), PpL has never been used to orient IgM antibodies nor in 
protein microarray fabrications. When PpL and an IgM antibody are printed in GSH-B, the GSH  
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Figure 4.2 Schematic for the in situ orientation of IgM antibodies using GST-PpL. When the  
  solution is printed, the GSH reacts first with the slide surface, forming the initial   
  GSH-monolayer. Then the GST-tagged antibody binding protein GST-PpL is   
  oriented onto the GSH-surface, which tethers the IgM protein in an oriented   
  manner. IgG antibodies are printed in the same way except for the use of GST-  
  tagged SpA and SpG. 
 
 
forms a small monolayer which would orient the GST-PpL fusion protein, which in turn would 
orient the antibody via the κ light chains (Figure 4.2). For IgG antibodies, the orientation scheme 
is identical except that the GST-tagged versions of SpA and SpG orient the antibody via the Fc 
domain. We are currently exploring this method and the possible applications in generating a 
diverse library of CBPs for glycomic analysis. 
4.2 Results and Discussion 
4.2.1 In situ orientation of IgG antibodies 
 In order to orient IgG antibodies using the GSH-based orientation scheme, I cloned the 
antibody-binding fragments of Protein A and G from either commercially available genomic 
DNA (SpA) or from synthesized DNA (SpG, See Appendix B for gene), and ligated the 
fragments into the pET41 Ek/LIC kit (Novagen). After transformation and expression, the 
antibody-binding proteins were purified via the GST-domains (Figure 4.3). 
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Figure 4.3 Purified GST-tagged antibody-binding proteins SpA, and SpG. Proteins were   
  expressed in BL21 DE3 cells and purified via GSH-sepharose columns.  A) 10% SDS- 
  PAGE gel analysis of SpA, B) SpG, and Both GST-tagged SpA and SpG proteins are ~  
  44 kD in size. 
 
 
 After purification of GST-tagged SpA and SpG, our initial work focused on optimizing 
the antibody to SpA/G ratio using the in situ orientation method. To do this, we developed a two-
color orientation experiment with orthogonally labeled antibodies. SpA (125 µg/mL) would 
dissolved in GSH-B (see Chapter 3) and mixed with varying concentrations of Cy5-labeled goat 
α-mouse IgG. The immobilized antibody would be probed for activity against a Cy3-labeled 
mouse IgG antibody (Figure 4.4).  To compare to the affect of orientation on the activity of 
deposited antibody, we printed the Cy5-labeled antibody in our standard print buffer (PB, see 
Chapter 3). With this method, we will be able to directly compare the amount of deposited 
antibody versus the resultant activity under in situ orientation conditions and print conditions that 
result in the random immobilization of the antibody. 
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Figure 4.4 Experimental design of a dual color antibody orientation format. Cy5-labeled Goat α- 
  mouse IgG antibody is printed with GST-SpA in GSH-B. Deposition of the protein  
  solution results in the in situ derivitization of the NHS-activated surface. Upon this GSH- 
  layer, the GST-tagged SpA is oriented, which then binds to the Fc domain of the IgG  
  antibody. The oriented Cy5-labeled antibody can then more effectively bind to a Cy3- 
  labeled mouse IgG. 
 
 
 To control for binding of the secondary antibody to the oriented GST-SpA, we analyzed 
the binding of various concentrations of Cy5-labeled goat α-mouse IgG versus a single 
concentration of GST-SpA (125 µg/mL). At the concentrations tested, we observed that at about 
a 1:1 molar ratio of antibody:GST-SpA, we observe a saturation of binding (500 µg/mL antibody 
: 125 µg/mL GST-SpA) (Figure 4.5). At this concentration, when directly compared to Cy5-
labeled antibody printed in PB, the oriented antibody displayed ~13-fold decrease in overall 
antibody deposition (Figure 4.6A and B). To compare the activity of the oriented antibody, we 
probed the arrays with Cy3-labeled mouse IgG antibody (50 µg, α-actin). Given the substantial 
amount of randomly immobilized antibody compared to in situ oriented antibody, we were 
surprised to observe an increase of 7-fold more activity for the oriented antibody (Figure 4.6A 
and B).  
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Figure 4.5 Determination of the saturation of the antibody-binding sites of SpA against varying  
  concentrations of Cy5-labeled IgG. In this buffer composition (GSH-B/GST-SpA), at a  
  1:1 molar concentration of antibody and GST-SpA, we observe a saturation of binding  
  (500 µg/mL antibody:125 µg/mL GST-SpA). 
 
 
 
 
Figure 4.6 Deposition and activity of in situ oriented Cy5-labeled Goat α-mouse. A) Visualization of 
  the direct deposition (Cy5 channel) and the activity of deposited antibody (Cy3 channel).  
  A ratiometric picture is shown to aid in visualization. B) Graphical representation of the  
  data shown in A). Cy5 channel graphs shows direct deposition of the antibody, and the  
  Cy3 channel shows the activity of the deposited protein against Cy3-conjugated mouse  
  IgG (50 µg). Data is representative of triplicate arrays. 
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 As a corollary, we tested another Cy3-labeled mouse IgG to see how the oriented 
antibody bound to other target antibodies. After printing our in situ oriented and non-oriented 
antibodies, we probed with 50 µg of mouse α-β-tubulin (Figure 4.7). Through observing the Cy3 
channel, we found that the oriented antibody showed ~10-fold more binding activity than when 
the antibody was randomly deposited onto the slide surface. When comparing the activity of 
deposited goat α-mouse IgG-Cy5 against α-actin-Cy3, we observe a 91-fold increase in activity 
((relative decrease in deposition) x (relative increase in activity)). When comparing the activity 
of deposited goat α-mouse IgG-Cy5 against α-β-tubulin-Cy3, we observed a 130-fold increase of 
oriented antibody activity over non-oriented antibody.  
 
 
Figure 4.7 Deposition and activity of in situ oriented Cy5-labeled Goat α-mouse. A) Visualization of 
  the direct deposition (Cy5 channel) and the activity of deposited antibody (Cy3 channel).  
  A ratiometric picture is shown to aid in visualization. B) Graphical representation of the  
  data shown in A). Cy5 channel graphs shows direct deposition of the antibody, and the  
  Cy3 channel shows the activity of the deposited protein against Cy3-conjugated mouse  
  IgG (50 µg, α-β-tubulin). Data is representative of triplicate arrays. 
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 With this dual-color antibody orientation experiment, we demonstrated that we could 
orient the antibodies in situ. Our next objective was to apply this technique to the orientation of 
carbohydrate-binding antibodies to implement in our lectin microarrays. We chose two 
antibodies 7LE and 2-25LE which are Lewis A and Lewis B antigen binders, respectively. 
Moreover, their respective neoglycoproteins are also commercially available and can be easily 
converted into Cy-labeled glycoconjugates. In accordance with our optimized SpA/G (125 
µg/mL) to antibody (500 µg/mL) ratios, we printed these mixtures and compared the affect of 
orientation by printing the antibody alone in PB.  With the two antibodies tested, SpG performed 
the best, giving a higher median of total signals. This is not all too surprising given that these 
antibody-binding proteins are known to bind differently to the various classes of IgG antibodies 
(21). To combat the differences in the activity of antibody-binding proteins for different IgG 
subclasses, a hybrid Protein A/G could be cloned since it has been shown that it binds to all 
classes of IgG antibodies (22). After labeling the BSA conjugates with Cy3-NHS, the antibody 
arrays were probed with varying concentrations of Cy3-labeled Lewis A-BSA (Lewis A-Cy3, 
Figure 4.8) and Cy3-labeled Lewis B-BSA (Lewis B-Cy3, Figure 4.9). Testing the Lewis A-
specific antibody 7LE, we observed a dramatic increase in the detection limits of the deposited 
antibody. Upon in situ orientation (GSH-B/GST-SpG), 7LE bound to Lewis A-Cy3 down to the 
64 pM concentration, whereas the non-oriented 7LE (PB) could detect the same glycoprotein 
down to the 40 nM concentration, a remarkable increase of 625-fold in the detection limits in 
favor of the oriented antibody (Figure 4.8). However, the same increase in the detection limits 
was not observed with the Lewis B-specific antibody 2-25LE, in fact, the limit was not lowered 
at all (Figure 4.9). Assuming that the Cy5-labeled antibody is deposited in the same manner as 
these two carbohydrate-binding antibodies, we are seeing a greater increase of activity upon in  
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Figure 4.8 In situ orientation of Lewis A antibody 7LE. A)  Array data showing the advantages of in 
  situ oriented 7LE (GSH-B/GST-SpG) against non-oriented antibody (PB). Oriented  
  antibody can detect down to the 64 pM concentration of glycoprotein compared to 40 nM 
  with non-oriented 7LE, an increase of 625-fold in detection limits. B) Graphical   
  representation of data shown in A). Data is representative of triplicate arrays and error  
  bars represent the standard deviations from the mean. 
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Figure 4.9 In situ orientation of Lewis B antibody 2-25LE. A)  Array data showing the advantages  
  of in situ oriented 2-25LE (GSH-B/GST-SpG) against non-oriented antibody (PB). The  
  detection limits of the antibody is not lowered, yet the non-oriented antibody shows  
  saturation of binding at higher concentrations whereas in situ oriented 2-25LE does not.   
  B) Graphical representation of data shown in A). Data is representative of triplicate  
  arrays and error bars represent the standard deviations from the mean. 
 
 
situ orientation. Nonetheless, when observing the higher concentrations of Lewis B-Cy3, the 
amounts of bound ligand are higher with the in situ oriented antibody.  This increase may be a 
result of saturation of the binding sites of the non-oriented 2-25LE (PB). In contrast, the binding 
sites of in situ oriented 2-25LE (GSH-B/GST-SpG) are not yet saturated, arguing for a general 
increase in activity against higher amounts of Lewis B-Cy3. Although we observed an increase 
in activity of these two antibodies, we wanted to determine if their specificity profiles changed as 
a result of orientation. I printed the two antibodies, 7LE and 2-25LE, both in an oriented and 
non-oriented manner along with the recombinant lectin PA-IIL, a fucose- and high-mannose-
binding lectin (23). This lectin performed well as a positive control against the fucosylated Lewis 
antigens, but when the array was probed with RNase B-Cy3, the high-mannose containing 
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glycoprotein, the antibodies displayed very low activity, even when oriented (Figure 4.10). On 
the other hand, PA-IIL bound well to RNase B-Cy3, arguing that the oriented antibodies show 
increased activity against their respective glycans, while maintaining their specificity profiles. 
 
 
Figure 4.10 Orientation does not affect antibody activity. Activity of oriented antibodies, 7LE and 2- 
  25LE, and PA-IIL against RNase B-Cy3. A) Activities of oriented and non-oriented 7LE  
  and oriented PA-IIL against varying concentrations of RNase B-Cy3. B) Activities of  
  oriented and non-oriented 2-25LE and oriented PA-IIL against varying concentrations of  
  RNase B-Cy3. Data is representative of triplicate arrays and error bars represent the  
  standard deviations from the mean. 
 
 
4.2.2 In situ orientation of IgM antibodies 
 To orient IgM antibodies, I cloned the antibody-binding fragments of Protein L from a 
synthesized gene (PpL, See Appendix B for gene), and ligated the fragments into the pET41 
Ek/LIC kit (Novagen). After transformation and expression, the antibody-binding proteins were 
purified via the GST-domains (Figure 4.11). To highlight the need for a novel antibody-binding 
protein for the orientation of IgM antibodies, we oriented all three proteins, SpA, SpG, and PpL, 
in situ and probed for IgM binding against Alexa Fluor 488 conjugated IgM isotype control 
(IgM-488, Figure 4.12A). When the antibody-binding proteins were probed with 2 µg of IgM-
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488, we observed dramatic differences in antibody-binding activity (Figure 4.12B). This 
difference in antibody binding is not a great surprise if one considers the structure of this class of 
antibodies. When secreted from hybridoma cell lines, the IgM antibody is a multivalent antibody 
consisting of 5 individual IgG antibodies tethered together via the individual Fc domains to a 
central peptide called the J chain (10). When in the pentavalent structure, the Fc domains are 
buried underneath the exposed antigen-binding domains; therefore proteins which bind to Fc 
domains may not efficiently bind to IgM antibodies (Figure 4.12B). However, one report does 
mention the development of an assay that uses protein G in the detection of IgM antibodies (24). 
This was the only report I could find suggesting that SpG could be used in the orientation of IgM 
antibodies. Based on all of the reported binding activities, I would only expect PpL to bind IgM 
light chain fragments more easily, thereby orienting the IgM antibody and the remaining antigen-
binding domains. Taking advantage of this structural feature will allow us to include in situ 
oriented IgM antibodies in our microarray prints. 
 
 
 
Figure 4.11 Purified GST-tagged antibody-binding protein PpL. Protein was expressed in BL21 DE3 
  cells and purified via GSH-sepharose columns.  A) 10% SDS-PAGE gel analysis of PpL.  
  GST-PpL has a molecular weight ~75 kDa. 
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Figure 4.12 Antibody capture assay of immobilized antibody-binding proteins to IgM-488. A)  
  Schematic of oriented GST-PpL capturing IgM-488 from solution. B) Data and graphical  
  representation of the antibody-binding proteins activity for IgM-488. 
 
 
  
 Using our standard in situ orientation print buffer, we printed the Sialyl Lewis A-binding 
IgM antibody CA19-9 with PpL in GSH-B. As a comparison, we also printed CA19-9 in PB. 
The activity of the deposited antibodies was tested against varying concentrations of Cy3-labeled 
Sialyl Lewis A-BSA neoglycoprotein (Sialyl Lewis A-Cy3). The difference in activity of CA19-
9 was mildly improved upon antibody orientation (Figure 4.13). The in situ oriented antibody 
showed a 5-fold increase in the detection limits of the deposited antibody. Although not as a 
significant increase like our other antibody 7LE, the oriented antibody showed consistent 
increases in activity, whereas the non-oriented antibody showed no significant increases in 
activity over every concentration of Sialyl Lewis A-Cy3 tested (Figure 4.13B). As a technical 
note, we observed improved spot morphology when the antibody was printed in situ, a common 
characteristic of proteins printed in this buffer (Figure 4.13A).  
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Figure 4.13 In situ orientation of CA19-9 (250 µg/mL). A) In situ oriented CA19-9 (GSH-B) was  
  compared to non-oriented CA19-9 by probing with varying concentrations of Sialyl  
  Lewis A-Cy3. Improved spot morphology was observed for all samples printed in GSH- 
  B. B) Graphical representation of data shown in A). Data is representative of triplicate  
  arrays and error bars represent the standard deviations from the mean. 
 
 Although CA19-9 worked moderately well for in situ orientation, three other antibodies 
that I tested did not perform as expected. Z5H-2 and CLCP-19B, both blood group B-binding 
antibodies, and 4C9, a Lewis X-binding antibody, displayed activity in an ELISA format, yet 
when printed with PpL in GSH-B, no activity was observed. With the high amount of GSH in 
our print solution, it may be that GSH reduction of disulfide bonds is fragmenting the IgM 
antibody resulting in lessened activity. It has been well documented that low concentrations (<1 
mM) of dithiothreitol (DTT) is enough to fragment the antibody (25,26). In preparation and 
during the print process, the print solutions are incubated for at least 1 hour prior to deposition. 
To test the effects of GSH and DTT on antibody activity, I performed ELISA assays with 
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separate pre-treated mixtures of Z5H-2 and 4C9 with varying concentrations of GSH or DTT 
(Figure 4.14). For Z5H-2, the IC50 for GSH is ~ 20 mM, whereas for DTT the IC50 is ~1 mM 
(Figure 4.14A). For 4C9, the IC50 for GSH is ~30 mM, whereas DTT remains stronger with an 
IC50 of ~2.3 mM (Figure 4.14B). DTT was the more reactive molecule as expected, but most 
notably there was no visible activity at 100 mM GSH, the concentration present in GSH-B. The 
fact that CA19-9 antibody shows modest improvement in activity might actually be improved if 
the level of GSH was reduced. 
 
 
Figure 4.14 Inhibition of IgM activity by disulfide reduction using GSH and DTT. A) Effects of GSH 
  and DTT on the activity of Z5H-2 against blood group B neoglycoprotein. DTT (IC50 ~1  
  mM) affects the antibody binding activity better than GSH (IC50 ~20 mM).  B) Effects of  
  GSH and DTT on the activity of 4C9 against Lewis X neoglycoprotein. DTT (IC50 ~2.3  
  mM) affects the antibody binding activity better than GSH (IC50 ~30 mM). Both   
  antibodies are inhibited at the highest concentration of GSH tested, which is present in  
  the in situ orientation buffer. 
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4.3 Conclusions 
 With the success of our in situ orientation of our GST-tagged lectins, we wanted to 
expand this technology to include oriented antibodies by creating a new technique in microarray 
technology. By printing a mixture of an IgG antibody and GST-tagged antibody-binding protein, 
such as SpA or SpG, we demonstrate that it is possible to orient antibodies in situ, thus 
preserving overall slide chemistry for the inclusion of non-GST-tagged proteins. We wanted to 
also include IgM antibodies considering this isotype constitutes ~50% of the commercially-
available carbohydrate-binding antibodies. SpA and SpG are not efficient at binding to secreted 
IgM antibodies, so we created a GST-tagged version of PpL which was able to orient CA19-9 in 
situ. Unfortunately, only 1 of 4 antibodies tested for the in situ orientation of IgM antibodies 
showed any activity upon deposition onto the slide surface. After further experiments, we believe 
that this loss of activity can be attributed to the high concentration of GSH in the print buffer. 
The disulfide bridges holding the IgM antibody seem to be very reactive toward this high 
concentration of reducing agent. This does not seem to be the case in IgG antibodies, but further 
work will be needed to elucidate the effects of GSH on this class of antibodies. As an alternative, 
current work in the Mahal lab is looking into expanding the in situ orientation idea to multi-His-
tagged (27) proteins using an excess of Ni
2+
-NTA ligand in the print buffer. It may be possible to 
use multi-His-tagged antibody-binding proteins to orient the reducing-agent susceptible 
antibodies. 
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4.4 Materials and Methods 
4.4.1 Cloning, expression, and purification of GST-tagged SpA, SpG, and PpL 
 Protein A (SpA) was cloned from Staphylacoccus aureus subsp. aureus, strain Mu3 
(ATCC #700698D-5). Protein G (SpG) was cloned from a synthetic gene that was codon 
optimized for Escherichia coli (see Appendix B).  Protein L was cloned from a synthetic gene 
that was codon optimized for E. coli expression (see Appendix B). Protein A primers; Forward: 
5‟ GAC GAC GAC AAG ATG GCT GAT AAC AAT TTC AAC AAA GAA CAA CAA AAT 
GC 3‟, Reverse: 5‟ GAG GAG AAG CCC GGT TTA AGC ATC GTT TAG CTT TTT AGC 3‟. 
Protein G primers; Forward: 5‟ GAC GAC GAC AAG ATG ACG TAT AAA CTG ATC CTG 
3‟, Reverse: 5‟ GAG GAG AAG CCC GGT CTA TTC CGT CAC GGT GAA TG 3‟. Protein L 
primers; Forward: 5‟ GAC GAC GAC AAG ATG AAA GAG GAA ACC CCG 3„, Reverse: 
5„GAG GAG AAG CCC GGT TTA ACC GGC GAA ACG AAT G 3„. PCR reactions were 
performed with the Hot Start DNA Polymerase (New England Biolabs, #F120S) and reactions 
were tailored to product specifications. PCR products were treated and ligated into the pET-41 
Ek/LIC kit (Novagen, #71017-3) according to the manufacturer‟s directions. DNA was then 
transformed into electrocompetent NovaBlue Gigasingles (Novagen, #71227), grown, and 
purified DNA was obtained using the Qiaprep Mini Kit (Qiagen, #27106), and sequenced. 
Positive sequences were transformed into electrocompetent BL21(DE3) cells, and grown on LB-
Agar supplemented with kanamycin (30 µg/mL). Colonies were picked for overnight growth in 
LB, and were then inoculated into 900 mL of LB supplemented with kanamycin (30 µg/mL). 
Cultures were grown to an OD600 0.7 – 1.0, then induced with 0.2 mM IPTG and grown for 3 hr 
at 37°C, shaking at 250 rpm. Cells were pelleted (3000 x g, 15 min) and resuspended in 40 mL 
of lysis buffer (PBS + 0.2% Triton-X10) with protease inhibitor mix. Lysozyme (~1 mg/mL) was 
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added and mixed on ice for 30 min. DNase I (New England Biolabs #M0303, ~5 units/mL of 
lysate) was added and mixed for 10 min on ice. Mixture was then centrifuged at 30,000 x g for 
30 min. The supernatant was then loaded onto a 1 mL GSH-sepharose column (GE Healthcare, # 
17-0756-01), washed with 10 mL of PBS, and eluted with 10 mM GSH in 50 mM Tris, pH 8.0, 
and collecting 1 mL fractions. Purification was analyzed by SDS-PAGE (Figure 4.3 and 4.11), 
and fractions containing sample were pooled and dialyzed against PBS. Aliquots were prepared 
and snap frozen in liquid N2 and stored at -80°C until needed.  
4.4.2 In situ oriented antibody microarray 
 For the oriented antibody array using the IgG antibodies, the antibodies and GST-SpA or 
-SpG were printed in ~1.1 : 1 molar ratio  (0.5 mg/ mL Ab: 0.125 mg/mL GST-SpA/SpG) in 
GSH-B. For standard printing, antibodies were printed in PBS.  For dual color antibody printing, 
Cy5-labeled Goat α-Mouse IgG antibody (0.5 mg/mL, Abcam #ab6563) and GST-SpA (0.125 
mg/mL) were diluted in GSH-B or PB. Samples were printed as described above, and the array 
was hybridized for 2 hr with either Cy3-labeled Mouse IgG α-Actin (2 µg/mL in 0.005% PBS-T, 
Abcam #ab11004) or Cy3-labeled Mouse IgG α-β-Tubulin (2 µg/mL in 0.005% PBS-T, Abcam 
#ab11309).  For the analysis of the carbohydrate-binding antibodies, Lewis A-specific antibody 
(0.5 mg/mL, 7LE, Abcam #ab3967) or Lewis B-specific antibody (0.5 mg/mL, 2-25LE, Abcam 
#ab3968) and GST-SpG (0.125 mg/mL) were dissolved in GSH-B or PB. Samples were printed 
as described above, and were hybridized in 0.005% PBS-T with either Cy3-labeled LNFP II-
BSA (Lewis A neoglycoprotein, Dextra, UK #NGP0501) or Cy3-labeled LNDFHI-BSA (Lewis 
B neoglycoprotein, Dextra #NGP0601). The neoglycoproteins were labeled with Cy3-NHS (GE 
Healthcare, #PA13104) prior to hybridization.  
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 For the orientation of CA19-9, the antibody (0.25 mg/mL, Abcam #ab3982) and GST-
PpL (0.125 mg/mL) were diluted in GSH-B, or CA19-9 was printed alone in PB. Samples were 
printed as described above, and the array was hybridized for 2 hr with varying concentrations of 
Cy3-labeled Sialyl Lewis A-BSA conjugate (2000, 400, 80, 16, 3.2, 0.64, 0.128, and 0.0256 nM) 
diluted into 0.005% PBS-T. The neoglycoproteins were labeled with Cy3-NHS (GE Healthcare, 
#PA13104) prior to hybridization. 
4.4.3 ELISA activity assays 
 Enzyme-linked immunosorbent assays (ELISAs) were performed as previously described 
(28) with specific adaptations for the detection of antibodies. Briefly, 100 µL of blood group B-
BSA (Dextra UK), for Z5H-2 and CLCP-19B, and Lewis X-BSA (Dextra UK), for 4C9, was 
dissolved in PBS (5 ng/µL) and added to 96-well microtiter plates (Grenier Bio-one, #655061, 
Monroe, NC).  Following incubation (overnight at 4°C), the plates were washed five times with 
0.05% PBST (PBS and 0.05% Tween 20). Wells were then blocked with PBS containing 5% 
BSA for 1 h at RT and again washed five times with 0.05% PBST. Upon drying, 50 µL of Z5H-2 
(1:5000), CLCP-19B (1:2500), and 4C9 (1:5000) in 1% BSA in 0.05% PBST were added to 
separate wells and incubated for 1 hr. For the inhibition experiments, antibody mixtures were 
pre-incubated for 1 hr with varying amounts of GSH or DTT, and then the samples added to the 
wells and incubated for 1 hr. In all experiments, wells containing buffer alone were used to 
measure the background (noise) of the plate. After the incubation times, wells were washed five 
times with 0.05% PBST and lectin binding was detected with anti-mu chain-horseradish 
peroxidase (HRP) conjugated antibody (50 µL, 1 : 1000 in 0.05% PBST, 1 h, RT, Novus 
Biologicals No. NB600-393, Littleton, CO). Wells were then washed 5 times with PBST and 
HRP activity was detected using o-phenylenediamine dihydrochloride (OPD Pierce No. 34 005, 
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Rockford, IL). In brief, OPD solution (100 mL, 0.4 mg/mL in 0.1 M phosphate/citrate, pH 5.0 
containing 0.004% H2O2) was added to each well. After 30 min, the enzymatic reaction was 
stopped by the addition of 50 mL of 2.5 M H2SO4. The absorbance at 492 nm was read using a 
Synergy HT microplate reader (BIO-TEK, Winooski, VT). A reference wavelength of 620 nm 
was subtracted from these values to account for non-specific absorbance. For data analysis, the 
antibody binding activity was defined as the signal to noise (S/N): absorbance of samples divided 
by the average background absorbance values. To determine inhibition of reducing agents, 
percent of control (% control) was calculated: (the absorbance of the sample in the presence of 
inhibitor/absorbance of uninhibited sample)/100. Microsoft Excel 2007 software was used for 
statistical analysis, curve fitting, and to generate graphs and tables. 
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Chapter 5: Designed lectin variants as tools in microarray technology 
 
5.1 Introduction 
 Within our set of recombinant lectins, we have two classes of bacterial lectins (Figure 
5.1): fimbrial and tetrameric, soluble adhesins. The fimbrial adhesins include GafD (1), PapGII 
(2) and PapGIII (3), and FimH (4), although in our lab we have yet to obtain FimH lectin that 
binds to mannosylated conjugates, a continuing issue to be resolved in the group. Fimbrial pilin 
structures are produced in Gram-negative bacteria, and in this case arise from certain strains of 
Escherichia coli (5). In the examples cited above, the carbohydrate- binding proteins are located 
at the terminus of the pilin domain, and in E. coli, there are typically over 200 fimbrial domains 
on the cell surface (6). Although structurally similar, the fimbrial lectins bind a diverse set of 
glycans, arguing for divergent evolution from a common scaffold (7). GafD is a terminal β-
GlcNAc-binding lectin derived from E. coli strains isolated from bovine intestine (1). PapGII 
and III are two alleles that have high sequence homology, but which are found in species-
dependent uropathogenic bacteria (8). PapGII-containing E. coli strains effectively infect human 
and mouse tissues and PapGIII cannot, andyet PapGIII-containing strains can infect canine tissue 
(2-3). These differences are based on the biosynthesis of their corresponding glycolipids. The 
PapG adhesion family bind to the globoside glycan family; PapGII binds to globotetratose 
(GbO4, GalNAcβ1-3Galα1-4Galβ1-4Glc-Cer) and PapGIII binds to globopentaose (GbO5, 
GalNAcα1-3GalNAcβ1-3Galα1-4Galβ1-4Glc-Cer) (8). The other known allele of this family, 
PapGI, was not developed prior to this work, but I will show that it too can be cloned, expressed 
and retain its known binding activity for globotriose (GbO3, 3Galα1-4Galβ1-4Glc-Cer). 
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Figure 5.1 Examples of the structures of two types of recombinant lectins. GafD (PDB 1OIO), a  
  pilin adhesin, lies at the tip of a column of pilin proteins. The structure of these pilin  
  adhesins adopts a β-barrel jelly roll fold and has been compared to the fold of   
  immunoglobulin-type folds. PA-IL (PDB: 2VXJ) is a tetrameric, soluble adhesion which  
  is secreted by Pseudomonas aureuginosa to mediate bacterial interactions. Crystal  
  structures were isolated with their corresponding carbohydrates. 
 
 
 The second type of bacterial lectins is the Ca
2+
-dependent, tetrameric, soluble adhesins. 
The opportunistic human pathogen Psuedomonas aeruginosa secretes two bacterial lectins, PA-
IL and PA-IIL (also called LecA and LecB) (9). PA-IL is a galactophilic lectin with specificity 
for terminal α-galactose residues (10). PA-IIL is primarily a fucose-binding lectin that has the 
ability to bind mannose epitopes, but to a lower degree (11). The production of these lectins is 
regulated through quorum sensing (12), and as such, has been linked to biofilm formation. In a 
related species, the plant pathogen Ralstonia solanacerum produces two lectins as well, RS-IL 
and RS-IIL, both lectins being orthologous to the PA-IIL lectin (13). RS-IL is a fucose-binding 
lectin, and RS-IIL is mainly a mannose-binding lectin, but does show some binding to 
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fucosylated epitopes to a lower degree (13). The lectins are homologous, i.e. RS-IIL and PA-IIL 
share a common binding motif in the carbohydrate-binding domain. Interestingly, the binding 
domains of these lectins differ in a single amino acid which can shift binding preferences from 
fucose to mannose, or vice versa (14). The first section of this chapter will focus on the lectins 
mentioned above and the creation of simple binding mutants that can act as negative controls on 
a given lectin microarray. The second half of this chapter will focus on my efforts to evolve of 
one of these lectins, GafD. 
5.2 Results and Discussion 
5.2.1 Controls in protein microarray technology 
 As discussed earlier in this dissertation, recombinant lectins have several advantages over 
the more commonly used native plant lectins (15). One advantage lies in the ease of genetic 
manipulation, wherein we could mutate the binding domain to bind a different antigen. In 
previous work developed by the lab, Hsu et al. generated a subset of GST-tagged lectins (15) 
which I used to orient on a solid support (Chapters 2 and 3). Among these lectins was a mutant 
of GafD (GafD-m), a single point mutation in the binding site (D88L) that showed an ~80% 
reduction in binding to GlcNAc (16). In the original work on the mutant, how the activity was 
assessed was not described. Nonetheless when subcloned into the pET41 vector, GafD-m 
displayed no significant binding to glycoproteins, although inhibitable activity was observed 
when tested against membrane-bound glycans (data not shown) (15). This binding mutant was 
useful in determining real versus non-specific interactions; therefore we wondered whether we 
could generate a binding mutant for each recombinant lectin. Non-binding mutants of the lectins 
would act as negative controls for recombinant lectins that show binding activity in a microarray.  
108 
 
 Given the volume of data collected in microarray technology, controls are a crucial aspect 
of this technique. In gene microarrays, negative controls, which are specific for a set of 
experiments, provide background binding data which the positive signals can be compared 
against (17). In lectin microarray technology, such negative control lectins do not exist. The 
specificity of lectin-carbohydrate interactions are determined by the disruption of lectin activity 
with inhibiting monosaccharides. This method is imprecise because most lectins bind to di- and 
trisaccharides, thus inhibitions with monosaccharides are not very effective with strong 
interactions. Furthermore, inhibitions require the use of multiple arrays, both limiting the number 
of samples tested and increasing the amount of sample used. Production of GafD-m opened up 
the possibility of a more precise set of negative controls in the form of a matched pair of non-
binding mutants and wild-type recombinant lectins. 
5.2.2 Non-binding mutants of the pilin adhesins GafD, PapGI, II, and III 
 As discussed earlier, GafD is a fimbrial protein which binds to terminal β-linked N-
acetylglucosamine (β-GlcNAc) epitopes (18).  In earlier work, we demonstrated that the GafD 
adhesin can be expressed as a GST-fusion protein and still bind to GlcNAc-containing residues 
on a glycan microarray (15). In this work, we also showed that a binding mutant (GafD-m, GafD 
D88L) shows less binding to the same glycan epitopes when compared at identical 
concentrations (15). The creation of this GafD variant provides a significant control for lectin 
microarrays. However, the effectiveness of this mutant was reported to reduce binding activity 
by 80% (16). When probed against samples containing high amounts of terminal GlcNAc 
epitopes, residual activity can arise since binding is reduced and not absent. This issue prompted 
us to design another GafD variant based on a solved crystal structure with β-GlcNAc nestled in 
the binding domain (16). We generated several variants of GafD by mutating residues in and 
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around the glycan-binding domain to alanine (Figure 5.3A). The Trp109 residue is common in 
other pilin adhesins FimH and PapG (7), and aromatic side chains are known to create key 
hydrophobic binding contacts in other plant lectins (19). Cys110 is not directly involved in the 
binding domain, yet forms a stable, internal disulfide bridge which may influence the shape of 
the binding pocket. The hydroxyl residue of Thr117 makes formative hydrogen bonding contacts 
with the N-acetyl group at the C2 position of the glycan (16). Because of this interaction, we 
generated a double mutant (D88L + T117A) which we hoped would solve issues of any residual 
binding from GafD D88L.   
 To screen many samples at once, we developed a glycoprotein microarray, the inverse of 
a lectin microarray, capable of detecting the binding of our recombinant lectins to known glycan 
epitopes (Figure 5.2). A variety of glycoproteins and neoglycoproteins were purchased, diluted 
to 0.5 mg/mL in phosphate buffered saline and printed onto NHS-activated slides (Table 5.1). 
The glycoprotein microarray was developed by another member of the lab, Linlin Wang, and 
was originally developed to screen new carbohydrate-binding proteins of unknown specificity. 
However, in the development process, the original recombinant lectins were used to test the 
effectiveness of the array and since the method proved to be robust, we decided to test our 
binding variants in concert with the wild type recombinant lectins. In brief, the recombinant 
lectins were diluted into 0.005% PBS-Tween with 1% BSA and hybridized to the array. After 
washing away unbound lectin, the bound lectins were detected using an Alexa Fluor 488-
conjugated α-GST antibody (α-GST-488). The data shown in the following sections is shown as 
a heat map, where we took the log2 of the background subtracted values and applied a color 
scheme to the values. In our standard lectin microarrays, we typically use a fluorescence value of 
110 
 
1000 arbitrary units (A.U.) and above to determine a positive signal, and used the value of 9.97 
as a cutoff point for activity (Log21000 = 9.97).  
 
 
 
 
Figure 5.2 Schematic of glycoprotein microarray. The glycoproteins are immobilized onto an NHS- 
  activated surface. The GST-tagged lectins are the incubated with the array and are  
  washed away. Lectin-binding interactions were then probed with alexa fluor 488-  
  conjugated  α-GST antibody. 
 
 
 
 
 
 
 
111 
 
 
Glycan Description Abbreviation Supplier 
α1-Acid Glycoprotein from bovine plasma 99% AGP Sigma  
Asialofetuin from fetal calf serum Type I ASF Sigma  
Bovine submaxillary Mucin BSM Worthington 
Fetuin from fetal calf serum Fet Sigma  
Ovalbumin Ova Worthington 
Ovomucoid, Trypsin Inhbitor Ovo Worthington 
Ribonuclease B from bovine pancreas RNase B Sigma  
Thyroglobulin from bovine thyroid Thy Sigma  
Transferrin human TrF Sigma  
2'Fucosyllactose-BSA(2'FL-BSA) (3 atom spacer) 2‟FL DextraUK 
3'-Sialyl Lewisx-BSA(14 atom spacer) SLe
x
 DextraUK 
3'-Sialyl-3-fucosyllactose-BSA(3 atom spacer) SFLac DextraUK 
3'-Sialyl-N-acetyllactosamine-BSA(14 atom spacer) SLacNAc DextraUK 
6'Sialyllactose-APD-HSA SLac Glycotech 
Acetylgalactosamine-BSA (14 atom spacer) GalNAc DextraUK 
β1-4-Galactosyl-Galactose-BSA(3 atom spacer) Galb1-4Gal DextraUK 
Blood group A-BSA (6 atom spacer) BGA DextraUK 
Blood group B-BSA (6 atom spacer) BGB DextraUK 
D-Galactose-BSA (14 atom spacer) Gal DextraUK 
D-Mannose-BSA (14 atom spacer) Man DextraUK 
Gala1-3Galb1-4Glc-HSA(3 atom spacer) iGbO3 DextraUK 
Gala1-3Galb1-4GlcNAc-BSA(14 atom spacer) α-Gal DextraUK 
Gala1-3Gal-BSA(14 atom spacer) Gala1-3Gal DextraUK 
Globotriose-HSA (3 atom spacer) GbO3 DextraUK 
Lacto-N-fucopentaose II-BSA(LNFP II-BSA) (3 atom 
spacer) 
Le
a
 DextraUK 
Lewisx-BSA(3 atom spacer) Le
x 
DextraUK 
L-Fucose-BSA (14 atom spacer) Fuc DextraUK 
LNF I-APD-HSA Le
d
 Glycotech 
LNF III-APD-HSA Le
x
 Glycotech 
N-Acetylglucosamine-BSA (14 atom spacer) GlcNAc DextraUK 
N-Acetyllactosamine-BSA(14 atom spacer) LacNAc DextraUK 
Sialyl-LNF V-APD-HSA SLNFV Glycotech 
Table 5.1: List of glycoproteins and neoglycoproteins printed in glycan microarray. 
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Figure 5.3 Mutational analysis of GafD lectin. A) Visualization of the crystal structure of GafD with 
  GlcNAc in the binding site is shown the left. B) Heat map representation of GafD wt and  
  variant binding to GlcNAc-BSA. Of all the mutants, the double mutant D88L + T117  
  showed the lowest overall activity.  
 
 As expected, wild-type GafD (GafD WT) bound to GlcNAc-BSA on our glycoprotein 
microarray (19,140 A. U.) (Figure 5.3B). Contrary to our previous work with GafD, the lectin 
showed no significant binding to chicken egg ovalbumin possibly due to the use of a different lot 
of glycoprotein, which can vary in glycosylation. Our GafD C110A variant displayed an 85% 
reduction in binding to GlcNAc-BSA when compared to GafD WT, arguing that the cysteine 
residue provides some structural integrity of the binding domain (Figure 5.3B). It is unclear 
whether the disulfide bridge is necessary given that when exposed to high amounts of GSH, the 
GafD lectins is still active. The GafD W109A variant activity was reduced to 86% of the WT 
binding to GlcNAc-BSA, illustrating the importance of hydrophobic pockets in glycan-binding 
interactions. By far, the best non-binding mutants were GafD D88L, GafD T117A, and GafD 
D88L + T117A. With respect to GlcNAc-BSA, activity for all three variants was reduced to 
~500 A.U. (~98% reduction in binding). We are currently examining the activities of these 
variants against more complex carbohydrate samples. 
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 PapG alleles class I-III are associated with infections of the urinary tract (20). The PapG 
adhesins recognize Galα1-4Gal core of the globoside lipids. In previous work, we demonstrated 
that PapGII and PapGIII are expressed and bind to their respective ligands in a recombinant 
format (15). To further study the globoside class of glycolipids, we added PapGI to our panel of 
recombinant lectins by cloning it from Escherichia coli strain J96 (gift from Prof. Rodney 
Welch, Univ. Mad.-Wisc.) (21). It has been shown that the three alleles have differing 
specificities to the globosides. PapGI binds to the trisaccharide GbO3 (Pk antigen), PapGII binds 
to the tetrasaccharide GbO4, and PapGIII binds to GbO5 (Forssman antigen) (8). A sequence 
alignment of the three adhesins and a crystal structure of PapGII with GbO4, revealed the critical  
 
Figure 5.4 Mutational analyses of the PapG lectins. A) Visualization of the crystal structure of  
  PapGII with GbO4. Residues with contact with the ligand are shown in blue and the  
  W109 residue is highlighted in red. B) Heat map representation of the binding of wt  
  PapG lectin, with inhibitions, compared to the tryptophan mutants. 
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residues for glycan-binding (Figure 5.4A). Based on previous work on the crystallization and 
mutational analysis of PapGII, Waksman and colleagues show that a point mutant W107A 
reduced the agglutination of human erythrocytes, yet could still expressed as well as wild-type 
PapGII (8). This tryptophan residue forms hydrophobic interactions with the lactose core of the 
globoceramides and is conserved in all three alleles. 
 Based on this work, we made the W to A mutation in all three adhesins (PapGI W105A, 
PapGII W107A, and PapGIII W107A) and assayed their activities compared to the wild-type 
proteins (Figure 5.4B). As expected, PapGI bound to only to GbO3 (16,225 A.U.) and iGbO3 to 
a minor extent (1,544.5 A.U.). Inhibition with 100 mM lactose reduced the binding by 89% and 
75%, respectively against both glycoproteins (Figure 5.4B). On the other hand, PapGI W105A 
reduced binding to both glycoproteins by 99.6% and 93%, respectively. PapGII WT behaved in a 
similar manner, but bound both GbO3 and GbO4 the same (21,851 and 22,036 A.U., 
respectively). Inhibition with lactose again reduced activity by 86% and 88%, respectively 
(Figure 5.4B). Again, the W107A mutant of PapGII showed less activity when compared to the 
inhibition experiments (99% and 96% reduction in binding, respectively). In previous work on a 
different glycoprotein array, PapGIII bound several galactosylated ligands and glycoproteins 
such as ovalbumin and thyroglobulin (15). Surprisingly, PapGIII did not bind to anything on our 
glycoprotein array, so we could not assay the effect of mutants.  
5.2.3  Non-binding mutants of the soluble lectins PA-IL, PA-IIL, and RS-IIL 
 The calcium-dependent, galactophilic lectin PA-IL derived from the Pseudomonas 
aueruginosa has been widely characterized by our lab and others (10, 11, 15, 22, 23). From the 
initial glycan array screen, PA-IL had a broad preference for terminal α-galactose residues. 
However, the lectin bound tighter to Galα1-4Gal residues preferentially over Galα1-2/3Gal, and 
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other α-galactose epitopes with varying internal glycans (23). A crystal structure of PA-IL with a 
bound ligand isoglobotriose (iGbO3, Galα1-3Galβ1-4Glc) was solved by Imberty and colleagues 
highlighting key residues in glycan-binding (23) (Figure 5.5A). The binding pocket of PA-IL 
contains hydrophilic and charged residues that bind the Ca
2+
 ion and the terminal galactose 
epitope. Residues D100 and N107 bind to both the glycan and the coordinated metal, hence, we 
mutated both residues to Ala, thereby maintaining structural integrity but losing the electrostatic 
interactions. Wild-type PA-IL bound well to the galactose-containing glycoproteins GbO3 
(64,890 A.U.), α-Gal trisaccharide (64,945A.U.) and Gal (22,520 A.U.), and unexpectedly bound 
to the GalNAc neoglycoprotein (21,010 A.U.) (Figure 5.5B).  Recently, the Gildersleeve group 
demonstrated the effects of glycan density and multivalency of carbohydrate-presenting carrier 
proteins (ie BSA) (24).  
 
Figure 5.5 Mutational analysis of PA-IL. A) Visualization of the crystal structure of  PA-IL with  
  bound GbO3. Close-up of the interactions of N107 and D100 with the terminal α- 
  galactose and Ca
2+
 ion. B) Heat map representation comparing wt PA-IL and PA-IL  
  N107A.  
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Using our GST-tagged PA-IL, the Gildersleeve group demonstrated that lectin binding to 
GalNAc-presenting carrier proteins can vary based on the density of the glycans, therefore 
altering the effective concentration of the presented glycan, resulting in ligand binding (24). 
Although we observe this phenomenon, PA-IL still displays insignificant binding to β-galactose 
epitopes (LacNAc, Le
a
, and Le
x
) and others. When PA-IL D100A and PA-IL N107A were 
hybridized to our array, we observed significantly reduced activity (~98%), with PA-IL N107A 
displaying the lowest median signal from all glycoproteins (226 A.U. for PA-IL D100A versus 
108 A.U. for PA-IL N107A). Henceforth, we used PA-IL N107A as our negative control for PA-
IL. 
 Pseudomonas aeruginosa and Ralstonia solanacearum produce lectins, PA-IIL and RS-
IIL, respectively, with similar protein sequences and binding specificity (14). PA-IIL is mainly a 
fucose-binding lectin but does show activity against high-mannose epitopes, conversely RS-IIL 
is a primarily a mannose-binding lectin but does display activity against fucose-containing 
glycan epitopes (13). Crystal structures of both lectins with their appropriate monosaccharides 
are currently available (13, 14). The Imberty group produced three mutants of PA-IIL, one of 
which, PA-IIL S22A, switches the specificity from a fucose-binding to a mannose-binding lectin 
(14) (Figure 5.6A). RS-IIL WT contains an alanine at position 22, so we theorized that mutating 
the alanine back to serine, we could alter the specificity of RS-IIL to bind fucose-containing 
epitopes. Also, both proteins have a conserved aspartate residue critical to binding (PA-IIL D96 
and RS-IIL D95). Therefore, we generated PA-IIL S22A, PA-IIL D96A, RS-IIL A22S, and RS-
IIL D95A variants and assayed them against our glycoprotein array.  
 As expected, PA-IIL WT and RS-IIL WT bound very well to their respective 
glycoproteins (Figure 5.6). PA-IIL WT bound mostly fucosylated epitopes (Lewis and blood 
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group antigens), and the high-mannose containing RNase B. RS-IIL WT bound high-mannose 
containing glycoproteins and only mildly bound fucosylated antigens. When PA-IIL D96A was 
assayed against the panel of glycoproteins displayed significantly reduced activity against all of 
the positive signals. There was a reduction in binding for RNase B (100% reduced), fucose-BSA 
(95% reduced), 2‟-fucosyllactose (100% reduced), and the Lewis antigens (95 – 98% reduction). 
RS-IIL D95A did not show any binding activity against any of the glycoproteins tested, 
exhibiting >98% reduction in binding to all epitopes on the array (Figure 5.6B). 
   
 
Figure 5.6 Mutational analyses of PA-IIL and RS-IIL. A) Visualization of the crystal structure of  
  PA-IIL with bound fucose. Close-up of the interactions of D96, S22, and S23 with the  
  terminal fucose epitope. B) Heat map representation comparing wt PA-IIL and RS-IIL  
  against the D96/95 analogs. 
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 When profiling the other two mutants, we observed very interesting specificity profiles 
(Figure 5.7). As described previously, PA-IIL S22A reduced binding to fucose and increased 
activity for mannose monosaccharides (14). When probed against our array, PA-IIL S22A indeed 
displayed significantly reduced binding to fucosylated epitopes and yet maintained binding 
activity against RNase B and Mannose-BSA (Figure 5.7). In the case of RS-IIL A22S, we also 
observed a change of binding compared to the wild-type (Figure 5.7). Although we do observe a 
reduction in binding to the mannose- containing glycoproteins, we observe increased binding to 
some fucosylated epitopes (Le
x
, Le
a
, Sialyl LFP V, and 2‟-fucosyllactose). The RS-IIL A22S 
variant shows binding preference for fucose, which will be examined more in depth by our lab, 
although it does display reduced binding to the mannosylated ligands. We also performed ELISA 
assays to determine the specificity of the lectins (Figure 5.8). While probing activity against 
mannose-BSA and inhibiting with fucose and mannose monosaccharides, we further show that 
the specificities changed based on the inhibition. For PA-IIL WT, the inhibitions matched the 
expected outcome as fucose was a much better inhibitor than mannose (3.8 µM versus 61 µM, 
Figure 5.8A). When testing PA-IIL S22A, we had an observable IC50 of 61 µM for both of the 
monosaccharides (Figure 5.8B).  For RS-IIL WT, inhibitions again matched expected outcomes 
as mannose was a better inhibitor than fucose (1.5 µM versus 976 µM, Figure 5.8C). When 
testing RS-IIL A22S, we observed an IC50 of 1.5 mM when inhibited with mannose, but showed 
an IC50 of 0.39 mM when inhibited with fucose (Figure 5.8D). 
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Figure 5.7 Further mutational analyses of PA-IIL and RS-IIL. Heat map representation comparing  
  wt-PA-IIL and RS-IIL against the S22/A22 analogs. For PA-IIL, with the S22A mutant,  
  the specificity changes from solely a fucose-binding lectin to an equal binder of   
  mannose-containing epitopes. For RS-IIL, the A22S mutant reverses specificity from  
  mannose to fucose binding. 
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Figure 5.8 ELISA inhibition data for wt PA-IIL, wt RS-IIL, PA-IIL S22A, and RS-IIL A22S against 
  mannose-BSA. A) Inhibition of wt PA-IIL with fucose (open circles) and mannose  
  (closed circles). IC50 values were estimated from the inhibition curve. Fucose (3.8 µM) is  
  a better inhibitor of wt PA-IIL than mannose (61 µM).B) Inhibition of PA-IIL S22A with 
  fucose (open circles) and mannose (closed circles). IC50 values were estimated from the  
  inhibition curve. Fucose (61 µM) and mannose (61 µM) are very similar inhibitors of  
  glycan-binding. C) Inhibition of wt RS-IIL against fucose (open circles) and mannose  
  (closed circles). IC50 values were estimated from the inhibition curve. Mannose (1.5 µM)  
  is a better inhibitor of wt RS-IIL than fucose (976 µM). D) Inhibition of RS-IIL A22S  
  against fucose (open circles) and mannose (closed circles). IC50 values were estimated  
  from the inhibition curve. Fucose (0.39 mM) is a better inhibitor of RS-IIL A22S than  
  mannose (1.56 mM). ELISAs was performed in triplicate wells and error bars are  
  standard deviations from the mean signal. 
 
5.2.4 Lectin microarray analysis of lectin variants 
 Once we were confident with our lectin variants, we wanted to test how the recombinant 
lectins would bind if they were immobilized into a lectin microarray. In addition to the 
recombinant lectins and lectin variants which I oriented in situ, I also printed a set of 25 plant 
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lectins in our standard print buffer. I then hybridized the array with a dozen Cy3- or Cy5-labeled 
glycoproteins, all at 200 nM. We then plotted the data into a heat map, to aid in the visualization 
of activity (Figure 5.9). As expected, we observed common binding interactions. For the plant 
lectins, GS-I, HPA, SBA, and SNA bound to galactose epitopes, and DSA and WGA bound to 
GlcNAc- and GalNAc-containing glycans (Figure 5.9). More interestingly however, UEA-I 
bound not only the two epitopes with α1-2 fucose linkages, but it also bound to isoglobotriose 
(iGbO3, Galα1-3Galβ1-4Glc) with relatively high activity. This is odd considering UEA-I is not 
known to be anything but an α1-2 fucose-binding lectin, although one group has shown that 
binding to milk oligosaccharides is inhibited by Galα1-3 epitopes (25). I further analyzed this 
binding by inhibiting with fucose, and found that this was dependent of carbohydrate 
interactions. Looking at the recombinant lectins, specific lectin binding was also observed. For 
example, GafD bound to GlcNAc, PA-IL bound to the terminal Galα1-4 epitope and also 
GalNAc, PA-IIL bound fucose- and mannose-containing ligands, and RS-IIL bound to the high-
mannose containing glycoproteins OVA, RNase B, and some binding to fucosylated glycans. 
Unfortunately, at high concentrations of glycoprotein (200 nM) the lectin binding variants 
displayed activity as well. The variants GafD D88L, PA-IIL D96A, and RS-IIL D95A showed 
binding to their respective glycans, most likely due to the enhanced activity as a result of in situ 
orientation (Figure 5.9). Although GafD D88L displayed moderate binding in this format, the 
double mutant GafD D88L + T117A showed significantly reduced binding, arguing that it 
performs better as a negative control for GafD. Since the mutant showed activity at this 
concentration of glycoprotein, I also plotted the data with respect to 20 nM glycoprotein 
concentrations (Figure 5.10). As expected at this lower concentration, the binding mutants 
showed no activity for their respective glycoproteins (Figure 5.10). 
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Figure 5.9 Activities of immobilized lectins against 200 nM glycoproteins. Heat map representation  
  of lectin binding activity. Along with the recombinant lectins and variants, a set of 25  
  plant lectins were also printed. 
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Figure 5.10 Activities of immobilized lectins against 20 nM glycoproteins. Heat map representation  
  of lectin binding activity. Along with the recombinant lectins and variants, a set of 25  
  plant lectins were also printed.  
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5.2.5 Current efforts in lectin evolution 
 The directed evolution of proteins is a common practice in biotechnology to enhance 
enzyme activity, antibody binding, and specificity (26). Evolution is commonly performed by 
first manipulating the genomic DNA, by either error prone PCR (EP-PCR) or DNA shuffling, 
followed by selection and/or enrichment of a protein with a specific binding trait (27). Despite 
the need for greater diversity and enhanced specificity of lectins toward a particular glycan 
epitope, there has been very little work on the development of a technique for the evolution of 
lectins. One example by the Hirabayashi lab was an attempt to evolve Ricin B-chain lectin from 
a galactose-binding protein to a sialic acid-binding lectin using EP-PCR and in vitro protein 
synthesis and selection against a sialylated glycoprotein (28). Although the group was successful 
in obtaining a sialic acid-binding lectin, their method was lacking in complete selectivity because 
the lectin still bound to galactose-containing glycans.  
 
5.2.6     Phage display technology 
 One of the techniques used to evolve proteins is phage display which requires the 
expression and display of a given protein onto the surface of a viral particle (29). The most 
prominent carrier virion is the M13 phage, although other phage types are available for 
manipulation such as the λ- and T4-phage, all of which all E. coli specific phage (30).  The M13 
phage is covered by 5 major coat proteins, the predominant coat protein covering the hull of the 
phage comprises over a thousand copies is the P8 protein (Figure 5.11). Each end of the phage is 
comprised of a set of two proteins: P3 and P6 on one end and P7 and P9 at the other end (31, 32). 
Through the work of several groups, functional proteins have been produced on each protein 
type, yet the more predominantly used M13 coat proteins used in phage display  
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Figure 5.11 Protein expression on the surface of phage. The desired protein is cloned into a phagemid 
  containing a secretion signal, such as pelB, which is fused to an M13 coat protein. When  
  transformed into E. coli expressing the F‟ episome and treated with helper phage, you can 
  obtain whole phage particles with your fusion protein of interest. 
 
are P3 and P8 due to the membrane-bound localization of the protein prior to phage assembly 
(33, 34).  
 The first examples of phage-displayed polypeptides for the analysis of carbohydrate-
binding proteins and glycans were performed using galectin-3 (gal-3) as the displayed protein 
(35 - 37). In one of these studies, Moriki et al. created a library of digested gal-3 DNA and 
expressed the constructs on the surface of phage, then selected for and identified the smallest 
fragment needed to bind lactose, a target of gal-3 (35). In more recent examples, several groups 
have focused on polypeptide mimics of carbohydrate antigens to inhibit glycan recognition by 
lectins (38).  For example, the Thomsen-Friedenreich (TF)-antigen is a disaccharide unit (Galβ1-
3GalNAcα-Ser/Thr) thought to play a role in tumor cell metastasis (39). Since the TF-antigen is 
a known ligand for gal-3, the lectin plays a role in mediating cell adhesion and therefore, tumor 
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metastasis. Zou et al. demonstrate the selection for a peptide that inhibits gal-3 down to the lower 
nM range (37). In addition, due to the lack of antibodies to the TF-antigen, Heimburg-Molinaro 
et al. found a peptide that mimicked the glycan, then presented the ligand on a multivalent 
scaffold. When injected into mice, their TF-mimic induced the production of α-TF-antigen 
antibodies (39).  
 Given the previous work on lectin evolution, it became clear that using phage-display 
technology could provide a proper scaffold for the presentation of a lectin. Since there can be 
issues in expressing plant or eukaryotic proteins, an E. coli host seemed the best to produce 
endogenous recombinant lectins. In the last section of this chapter, I will discuss my efforts 
toward the directed evolution of GafD (Figure 5.12), a venture we undertook with the 
supervision and expertise of Professor Jonathan Lai at Albert Einstein College of Medicine. 
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Figure 5.12 Phage display technology for the directed evolution of GafD. GafD would   
  be cloned as a P3 fusion protein, which would then be fused to a phage particle. Creating  
  a library of GafD mutants would allow us to select and enrich a tighter binding „GafD‟ to  
  whatever target glycan we decide. Once a candidate is found, the new lectin can be  
  subcloned and purified as a free protein where further studies can be done. 
 
 
5.2.7 Progress toward the directed evolution of GafD  
 In the pursuit of exploring binding mutants for the lectins, we became interested in the 
ability to evolve the recombinant lectins toward specific antigens. Upon arriving to New York 
University, we were put into contact with Professor Jonathan Lai at Albert Einstein. The focus of 
the Lai lab is to develop tighter binding single chain variable fragments of antibodies (scFv) to a 
variety of targets using phage-display technology. Most notably, the group has indentified two 
inhibitors of the virus-membrane fusion events of HIV-1 and Ebola viruses (40, 41). Since the 
group has expertise in phage-display technology, we sought their help in evolving the GafD 
lectin. As mentioned before, GafD is a β-GlcNAc-binding adhesin, and we were interested in 
trying to evolve the lectin to specifically bind β-GalNAc, a C-4 epimer of its native target.   
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Figure 5.13 Activities of two different phage-displayed methods of GafD. A) Schematic of bivalent  
  displayed GafD. B) Comparison of activity from monovalent GafD (pDP3) and bivalent  
  GafD (pDP4) over several dilutions against 100 ng of β-GlcNAc-HSA. 
 
 I cloned GafD into two vectors they had available, a monovalent and bivalent display 
systems. The monovalent vector (pDP3) was a derivative of a vector developed by the Sullivan 
lab (42), which displays the protein as a fusion with the P3 coat protein. The bivalent vector 
(pDP4) was created by the Lai lab to enhance protein-ligand avidity for proteins with higher 
dissociation constants. The fusion protein is supposed to mimic an IgG structure, wherein two 
phage-displayed proteins would be tethered together via a hinge region with disulfide bridges 
followed by a GCN4, leucine zipper, domain (Figure 5.13A). Upon formation, two fusion 
proteins would come in contact and bind together creating an “IgG-like” structure.  When I 
tested the activity of the two phage-display systems, the bivalent phage greatly out-performed the 
monovalent phage due to the increased avidity of the bivalent system (Figure 5.13B). From this 
point forward, we used bivalent displayed GafD, however, there could be future use of the 
monvalent GafD which I will discuss later. 
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Figure 5.14 Activity of wt GafD against binding variants and a control KO7 helper phage. WT GafD  
  (closed circles) showed the highest activity toward the target, β-GlcNAc-HSA. The  
  mutants D88L (red circles), T117A (green circles), D88L + T117A (orange circles)  
  showed greatly reduced activity compared to the wt. To determine non-specific   
  interactions, we also probed the target with M13KO7 helper phage (blue circles). 
 
 
 To further explore whether GafD could be used in a phage-display system, I made several 
variants based on my work with the non-binding GafD variants I discovered earlier (Figure 5.3). 
To obtain mutant DNA, I performed a Kunkel mutagenesis from the corresponding ssDNA (43). 
When the activities were assayed against the same concentration of β-GlcNAc-HSA, wt GafD 
showed the highest overall activity compared to the three variants, D88L, T117A, and D88L + 
T117A (Figure 5.14). Helper phage KO7 was used as a second negative control, but the group 
has found several issues with using the helper phage as a control, so we believe the binding 
variants function as true negative controls. For further analysis, we compared wt GafD and the 
T117A variant against BSA, which will act as a negative control during our selections. When 
tested against BSA, both phage displayed lectins showed minimal binding to BSA, confirming 
that in a selection, we wouldn‟t enrich our GafD library against BSA (Figure 5.15A). 
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Figure 5.15 Activity of wt GafD against BSA and β-GlcNAc-HSA with inhibiting monosaccharide.  
  A) Activity of wt GafD and T117A variant against β-GlcNAc-HSA (closed circles) and  
  BSA (open circles). B) Inhibition of wt GafD with varying concentrations of N-  
  acetylglucosamine (GlcNAc). 
 
 
We also performed an inhibition experiment using varying amounts of N-acetylglucosamine 
(GlcNAc) and found a concentration dependent signal of phage actvitiy to our target glycan 
(Figure 5.15B). Since there is some binding of GafD T117A phage to the target protein, we 
needed to determine if we could enrich wt GafD over the variant phage during a selection. To 
test this, a made a 1:1000 mixture of wt GafD phage to GafD T117A phage and infected a 
culture of E. coli expressing the F‟ pilus. After going through five rounds of selection against β-
GlcNAc-HSA, we observed complete conversion of the clones present in the output of round 5 
from all variant GafD to all wt GafD, suggesting that a selection with varying activities for the 
target protein can work.  
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Figure 5.16 Detection of FLAG-tag on phage-displayed GafD. Mono- and bivalent phage ran on a 4 – 
  12% SDS-PAGE gel, transferred to a Western blot, and probed with 1:3000 α-FLAG- 
  HRP. Lanes: 1) pDP3, 2) KZ52 (a control monovalent sample), 3) pDP4 reduced, 4)  
  pDP4 non-reduced, 5) pLR16 (a control  bivalent sample) reduced, 6) pLR16 non- 
  reduced, and 7) FLAG peptide (1 µg). 
 
 
 Since we showed that phage-displayed GafD bound to GlcNAc-BSA, we wanted to 
determine if we could detect the P3-fusion protein via the FLAG tag, which is present in both the 
mono and bivalent constructs that can then serve as an activity handle in future experiments. 
Furthermore, if the bivalent phage were run on a gel under non-reducing conditions, we could 
see fully displayed bivalent protein. The P3 fusion protein has a molecular weight of about 25 
kDa and the GafD adhesin has a molecular weight of ~25 kDa. Reduced and non-reduced mono- 
and bivalent phage were ran on a 4 – 12% SDS-PAGE gel, transferred to a nitrocellulose 
membrane, and probed with horse-raddish peroxidase conjugated 1:3000 α-FLAG antibody (α-
FLAG-HRP), and then visualized using film (Figure 5.16). Unfortunately, for the pDP3, the 
monovalent phage, I could not see any detectable GafD-P3 fusion protein (Lane 1, Figure 5.16). 
On the other hand, I did observe this in pDP4 (Lane 3, Figure 5.16). I could not detect any higher 
order GafD-fusion proteins, meaning I could not detect fully organized bivalent GafD. This may 
be due to leakage from the sample next to it containing DTT, which can diffuse while preparing  
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Figure 5.17 Sequence of GafD expressed on the surface of phage. Underlined amino acids were  
  initially mutated into stop codons (TAA), but converted back to their original codon and  
  amino acids in red were randomized (NNS) to make the first GafD library. 
 
the sample (Lane 4, Figure 5.16). Taken together, this data suggests that we have displayed fully 
functioning GafD on the surface of phage.  
 Once we knew that GafD has the potential to perform well as a template for library 
function and selection, we analyzed the protein sequence and found which residues made contact 
with GlcNAc (16). Using Kunkel mutagenesis, we mutated the 11 amino acids chosen to the stop 
codon TAA. With this template, we can then construct our library. Ideally, when constructing 
your library all of your primers will anneal to your template DNA, however, this is rarely the 
case (43). By convention, people use a “stop codon template” where your selected amino acids 
are converted into stop codons, and then your library primers will anneal to this template. Then 
during rounds of selection, the phage with ssDNA that contain stop codons, a by-product of 
imperfect annealing conditions, will drop out early in the selection since they should not bind to 
the target protein. So after making the stop codon template, I then performed the Kunkel 
mutagenesis with the library primers. Of the 11 amino acids, we decided that we would 
randomize 6 of the amino acids which are close to the C4 position, to the degenerate „NNS‟ 
codon, which includes 32 different codons of the 20 amino acids, and no stop codons (aside from 
the amber (UAG) which is translated into glutamate in XL1 Blue cells). This randomization 
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gives us a theoretical diversity of 1.07 x 10
9
 unique codon sets. For the three primers, I obtained 
a primer incorporation of 42%, which is considered a decent yield. I used a standard annealing 
method for this Kunkel, but I later learned of an improved Kunkel mutagenesis annealing 
reaction method (see Materials and methods for both). Upon transformation in pre-treated SS320 
cells, a high phage-producing E. coli strain developed by the Sidhu lab (43), we obtained a 10
9
 
phage library size. 
 After I prepped my GafD library phage, I started panning selections against β-GlcNAc-
HSA, in the hopes of obtaining a tighter-binding GafD, and β-GalNAc-HSA, the desired target. I 
initially started out panning against 500 ng of target protein, but when I sequenced my outputs 
rounds, I observed no convergence of sequence homologies, and more importantly, the stop 
codon templates that were left over after the Kunkel mutagenesis still populated my output phage 
to a significant degree (>50% of 40 sequences). Thinking that I have too much target present for 
the weak binding proteins, I lowered the amount of target protein I used per well to 100 ng. I still 
went through 5 rounds of selection, yet I noticed something interesting with the selections 
against β-GalNAc-HSA. I screened all of the output phage and found that R3 gave a significantly 
higher amount of non-stop codon containing-sequences (~85% positive sequences), whereas R4 
and R5 contained higher amounts of stop codon sequences. It was at this point where my 
research with GafD ended, and passed on to another member of the lab. 
5.3 Conclusions 
 Using the recombinant lectins, we have shown that point mutations of each of the 
recombinant lectins can produce a binding mutant that does not bind the native antigen. In the 
case of GafD, we discovered that a double mutant provided the lowest overall signal from all 
glycans tested. For the PapG adhesins, we found that a mutation of a single amino acid that is 
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present in all alleles significantly reduces binding. For PA-IL, I made two mutants, yet one, PA-
IL N107A, displayed the lowest overall binding to each glycan epitope. In the case of the 
orthologous lectins PA-IIL and RS-IIL, we show that the same point mutant reduces all binding 
activity for their respective targets. We also showed that PA-IIL S22A, a mutant produced by the 
Imberty lab (14), shows expected lower fucose binding and maintaining mannose-binding. In 
contrast, mutating the same residue in RS-IIL back to serine (A22S) resulted in an inverse of 
binding activity, preferring fucose over mannose residues. With this single point mutant, we 
achieved the same evolution outcome as the Hirabayashi group presented (28), with far less 
complication. Although we cannot say for certain whether these lectin mutants retain overall 
protein fold, we believe that substituting the wild-type residues with alanine we could mainting 
the structure of the binding pocket. However, more work will need to be performed to analyze 
whether or not we maintin protein folding via circular dichroism analysis. 
 In the pursuit of developing novel binding lectins, we decided to pursue phage-display 
technology. We decided to modify GafD, the recombinant lectin with the simplest binding motif, 
in order to bind the β-GalNAc epitope. We enjoyed success in obtaining properly displayed and 
functional GafD, and created a library of GafD with 10
9
 diversity size. We had mild success at 
our selections, but there are several ways to improve the outcome of our selections. First, we can 
still tweak the conditions of the selection, such as increasing the amount of target protein coated 
in the wells to better attract properly folded and bound proteins. Or we can perform a negative 
selection by first incubating the input phage with BSA, then transferring the supernatant to the 
target protein. One interesting technique we would try is to incubate the library phage with 
immobilized α-GafD antibody, which should only pull out properly folded proteins, and would 
presumably drop out all of the stop codon-containing phage. Another creative method was 
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developed by the Lai lab to help decrease the amount of stop codon templates present in the later 
rounds of selection. Instead of the stop codon template, the group used a the rare arginine codon 
(AGA) which would, during expression, would slow down the production of the “truncated” 
proteins and allowing full-length proteins to be more favorably expressed (44). 
5.4 Materials and methods 
5.4.1 Cloning, expression, and purification of lectin variants 
 PapGI genomic DNA was isolated from Escherichia coli strain J96 (kind gift from Dr. 
Rodney A. Welch, University of Madison-Wisconsin) using the DNeasy blood and tissue kit 
(Qiagen, #69504). The carbohydrate binding domain of PapGI was PCR amplified with the 
appropriate LIC overhangs: Forward: 5‟ – GAC GAC GAC AAG ATG GCT GGA TGG CAC 
AAT GTC – 3‟; Reverse: 5‟ – GAG GAG AAG CCC GGT CAC CCA ACA TTA TCG AAT 
GA – 3‟. PCR reactions were performed with the Hot Start DNA Polymerase (New England 
Biolabs, #F120S) and reactions were tailored to product specifications. PCR products were 
treated and ligated into the pET-41 Ek/LIC kit (Novagen, #71017-3) according to the 
manufacturer‟s directions. Site-directed mutagenesis was performed using the QuikChange® 
Lighting Site-Directed Mutagenesis kit (Agilent, #210518-5). Primers (IDT, see Table 5.2) were 
designed according to product specifications.  DNA was then transformed into electrocompetent 
NovaBlue Gigasingles (Novagen, #71227), grown, and purified DNA was obtained using the 
Qiaprep Mini Kit (Qiagen, #27106), and sequenced. 
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Lectin Sense Anti-sense 
GafD D88L + T117A* 5‟ GGA AAT TAT GTA TCA GCG 
CAG GGA CTG TCT GTT C 3‟ 
5‟ G AAC AGA CAG TCC CTG 
CGC TGA TAC ATA ATT TCC 
3‟ 
PapGI W105A 5‟ CTT TGT TAA TGG TTA TGA 
AGC GGA TAC ATG GAC AAA 
TAA TGG 3‟ 
5‟ CCA TTA TTT GTC CAT 
GTA TCC GCT TCA TAA CCA 
TTA ACA AAG 3‟ 
PapGII W107A 5‟ CTC AAG GGG TAT AAG GCG 
GAT GAG CGG GCC TTT GAT 
GCA GGT 3‟ 
5‟ ACC TGC ATC AAA GGC 
CCG CTC ATC CGC CTT ATA 
CCC CTT GAG 3‟ 
PapGIII W107A 5‟ ACC AAG GGA TTT GCA GCG 
GAA GTC AAC TCA TCT GGA 3‟ 
5‟ TCC AGA TGA GTT GAC 
TTC CGC TGC AAA TCC CTT 
GGT 3‟ 
PA-IL N107A 5‟ GTG CCC GGA ACC TAT GGC 
GCT AAC TCC GGC TCG TTC 
AGT GTC 3‟ 
5‟ GAC ACT GAA CGA GCC 
GGA GTT AGC GCC ATA GGT 
TCC GGG CAC 3‟ 
PA-IIL S22A 5‟ GTC ACC GCC TTC GCC AAC 
GCG TCC GGA ACC CAG ACG 3‟ 
5‟ CGT CTG GGT TCC GGA 
CGC GTT GGC GAA GGC GGT 
GAC 3‟ 
PA-IIL D96A 5‟ GCC CTG GTC GGC TCT GAA 
GCC GGC ACC GAC AAC GAC 
TAC AAC 3‟ 
5‟ GTT GTA GTC GTT GTC 
GGT GCC GGC TTC AGA GCC 
GAC CAG GGC 3‟ 
RS-IIL A22S 5‟ GAC GGC ATT TGC AAA TTC 
AGC GAA CAC CCA GAC 3‟ 
5‟ GTC TGG GTG TTC GCT 
GAA TTT GCA AAT GCC GTC 
3‟ 
RS-IIL D95A 5‟ GCG ATG GTG GGC TCG GAA 
GCC GGC ACC GAC AAC GAC 3‟ 
5‟ GTC GTT GTC GGT GCC 
GGC TTC CGA GCC CAC CAT 
CGC 3‟ 
Table 5.2:  Mutagenic primers for recombinant lectins. 
    * Mutagenesis was performed on GafD D88L DNA. 
 
 
 Purified DNA was transformed into electrocompetent BL21(DE3) cells, and grown on 
LB-Agar supplemented with kanamycin (30 µg/mL). Colonies were picked for overnight growth 
in Terrfic Broth (TB, 1.2% tryptone, 2.4% yeast extract, 0.4% glycerol), and were then 
inoculated into 1 L of TB supplemented with kanamycin (30 µg/mL). Cultures were grown to an 
OD600 0.7 – 1.0, then induced with 1% lactose and grown for 3 hr at 37°C, shaking at 250 rpm. 
Cells were pelleted (3000 x g, 15 min) and resuspended in 40 mL of lysis buffer (phosphate 
buffered saline (PBS, 10 mM sodium phosphate and 15 mM sodium chloride) + 0.2% Triton-
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X10) with protease inhibitor mix. Lysozyme (~1 mg/mL) was added and mixed on ice for 30 
min. DNase I (New England Biolabs #M0303, ~5 units/mL of lysate) was added and mixed for 
10 min on ice. Mixture was then centrifuged at 30,000 x g for 30 min. The supernatant was then 
loaded onto a 1 mL GSH-sepharose column (GE Healthcare, #17-0756-01), washed with 10 mL 
of PBS, and eluted with 10 mM GSH in 50 mM Tris, pH 8.0, and collecting 1 mL fractions. 
Purification was analyzed by SDS-PAGE, and fractions containing sample were pooled and 
dialyzed against PBS. Aliquots were prepared and snap frozen in liquid N2 and stored at -80°C 
until needed. 
5.4.2 Glycoprotein microarray protocol 
 Lyophilized neoglycoproteins (for full name, abbreviations, and suppliers see Table 5.1) 
were suspended in PBS, and then diluted to 0.5 mg/mL in our glycoprotein print buffer (PBS 
with 0.005% Tween-20 and 2.5% glycerol) and loaded into a 384-well microplate (Whatman, 
Piscataway, NJ), and loaded into the SpotBot2 Personal Microarrayer (ArrayIt, Sunnyvale, CA). 
Printing programs were created with the MMF Spocle Program. Samples were printed with 
triplicate spots onto Nexterion H slides (Schott North America, Elmsford, NY) with an SMP3 
pin (ArrayIt, #SMP3). During the print, the slide chamber maintained humidity at ~50% 
throughout the print process. After printing, the slides were allowed to warm to room 
temperature for 2 hr, while maintaining humidity at ~50%. After 2 hr, the slides were then placed 
in a coplin jar and blocked with 50 mM ethanolamine in 50 mM sodium borate buffer (pH 8.5) 
for 1 hr, at room temperature with mild shaking. After one hour, the slides were washed with 
PBS with 0.005% Tween (0.005% PBS-T, 3 x 3 min) and once with PBS. The slides were dried 
using a slide spinner (Labnet Intl., Edison, NJ), and then fastened in a 24-well hybridization 
chamber (ArrayIt). The GST-tagged lectins were dissolved in 0.005% PBS-T with 1% BSA, and 
138 
 
were incubated for 1 hr, at roomperature with mild shaking. After 1 hr, the slides were washed 
with 0.005% PBS-T (5 x 3 min), once with PBS, and then incubated with α-GST rabbit Alexa 
fluor 488 (10 µg/mL, Invitrogen, #A11131) in 0.005% PBS-T with 1% BSA. The slides were 
incubated for 1 hr at room temperature with mild shaking. After 1 hr, samples were aspirated and 
washed with 0.005% PBS-T (5 x 3 min) and once with PBS. The slides were dried as before and 
loaded into the Genepix 4100A slide scanner (Molecular Devices, Union City, CA). Data was 
extracted with GenePixPro 5.0 (Molecular Devices) and analyzed and graphed using Microsoft 
Office Excel 2007. 
5.4.3 Lectin mutant ELISA protocol 
 ELISAs were performed as previously described (15). Briefly, 100 µL of Mannose-BSA 
(Dextra UK) was dissolved in PBS (5 ng/µL) and added to 96-well microtiter plates (Grenier 
Bio-one, #655061, Monroe, NC).  Following incubation (overnight at 4°C), the plates were 
washed five times with 0.05% PBST (PBS and 0.05% Tween 20). Wells were then blocked with 
PBS containing 5% BSA for 1 h at RT and again washed five times with PBST. For the 
inhibition, lectins were diluted (10 ng/µL) in 0.05% PBST containing 1% BSA, 1 mM CaCl2, 1 
mM MgCl2, and varying concentrations of the appropriate monosaccharide, and incubated for 30 
min. After 30 min, 50 µL of sample were applied to the wells and incubated for another 30 min.  
In all experiments, wells containing buffer alone were used to measure the background (noise) of 
the plate. After 30 min, wells were washed five times with PBST and lectin binding was detected 
with anti-His6-horseradish peroxidase-conjugated antibody (50 µL, 1 : 625 in 0.05% PBST, 1 h, 
RT, Novus Biologicals No. NB600-393, Littleton, CO). Wells were then washed 5 times with 
PBST and HRP activity was detected using o-phenylenediamine dihydrochloride (OPD Pierce 
No. 34 005, Rockford, IL). In brief, OPD solution (100 mL, 0.4 mg/mL in 0.1 M 
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phosphate/citrate, pH 5.0 containing 0.004% H2O2) was added to each well. After 30 min, the 
enzymatic reaction was stopped by the addition of 50 mL of 2.5 M H2SO4. The absorbance at 
492 nm was read using a Synergy HT microplate reader (BIO-TEK, Winooski, VT). A reference 
wavelength of 620 nm was subtracted from these values to account for non-specific absorbance. 
For data analysis, the lectin binding activity was defined as the signal to noise (S/N): absorbance 
of samples divided by the average background absorbance values. To determine inhibition of the 
monosaccharides, percent of control (% control) was calculated: (the absorbance of the sample in 
the presence of inhibitor/absorbance of uninhibited sample)/100. Microsoft Excel 2007 software 
was used for statistical analysis, curve fitting, and to generate graphs and tables. 
5.4.4 Lectin microarray protocol 
 Plant and recombinant lectins (Appendix A Table 3) were diluted in PBS and 
supplemented with 0.5 mg/mL and loaded into a 384-well microplate (Whatman, Piscataway, 
NJ), and loaded into the SpotBot2 Personal Microarrayer (ArrayIt, Sunnyvale, CA). Printing 
programs were created with the MMF Spocle Program. Samples were printed with triplicate 
spots onto Nexterion H slides (Schott North America, Elmsford, NY) with an SMP3 pin 
(ArrayIt, #SMP3). During the print, the slide chamber maintained humidity at ~50% throughout 
the print process. After printing, the slides were allowed to warm to room temperature for 2 hr, 
while maintaining humidity at ~50%. After 2 hr, the slides were then placed in a coplin jar and 
blocked with 50 mM ethanolamine in 50 mM sodium borate buffer (pH 8.5) for 1 hr, at room 
temperature with mild shaking. After one hour, the slides were washed with PBS with 0.05% 
Tween (0.05% PBS-T, 3 x 3 min) and once with PBS. The slides were dried using a slide spinner 
(Labnet Intl., Edison, NJ), and then fastened in a 24-well hybridization chamber (ArrayIt). 
Labeled samples were dissolved in 0.005% PBS-T, loaded onto the arrays and incubated for 2 hr 
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with mild shaking. After 2 hr, the slides were washed with 0.005% PBS-T (5 x 3 min), once with 
PBS, then dried as before and loaded into the Genepix 4100A slide scanner (Molecular Devices, 
Union City, CA). Data was extracted with GenePixPro 5.0 (Molecular Devices) and analyzed 
and graphed using Microsoft Office Excel 2007. 
5.4.5 Cloning and Kunkel mutagenesis of GafD for phage display 
 GafD (see Appendix B for gene) was cloned into the mono- and bi-valent phage display 
vectors and denoted as pDP3 and pDP4, respectively. For pDP3, I used the following primers 
with HindIII (5‟) and SalI (3‟) restriction sites: Forward: 5‟ GAC GAC AAG CTT GTT TCA 
TTT ATT GGC AGT ACG GAG 3‟; Reverse: 5‟ GAA GCC GTC GAC CTG TGT CAT TCA 
GCG TAA ATG GAT TCA GGC 3‟. For pDP4, I used the following primers with HindIII (5‟) 
and SacI (3‟) restriction sites: Forward: 5‟ GAC GAC AAG CTT GTT TCA TTT ATT GGC 
AGT ACG GAG 3‟; Reverse: 5‟ GAA GCC GAG CTC CTG TGT CAT TCA GCG TAA ATG 
GAT TCA GGC 3‟. 
 For Kunkel mutagenesis, I first had to prepare deoxyuridine single-stranded DNA 
(dUssDNA). I transformed pDP4 DNA into electrocompetent CJ236 cells, and plated on LB 
Agar plates supplemented with chloramphenicol (CAM, 30 µg/mL) and carbenicillin (CARB, 
100 µg/mL), and grown overnight at 37°C. The next day, a single colony was picked and grown 
in 20 mL of 2xYT (in a 250 mL baffle flask) for 1 hr at 37°C. After 1 hr, CARB and CAM was 
added and incubated for an additional 1 hr. Then 8 µL of M13KO7 (10
12
 concentration) was 
added, along with 20 µL of uridine (2.5 mg/mL stock) and grown for 1 hr. After 1 hr, kanamycin 
(KAN, 50 µg/mL) was added and the cultures were grown overnight (~15 hr). After the 
overnight growth, the culture was transferred to 500 mL 2xYT, supplemented with CARB, 
CAM, 200 uL of M13KO7, and 50 µL of uridine, then incubated for 1 hr. After 1 hr, KAN was 
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added, then an additional 50 µL of uridine was added and the cultures were incubated overnight 
at 37°C (~15 hr). After the overnight incubation, the cultures were pelleted at 7000 rpm for 20 
min. The supernatant was transferred to clean centrifuge tubes and then a 5x PEG/NaCl solution 
was added to make a 1x concentration (4% wt/vol PEG8000, 3% wt/vol NaCl), and incubated 
one ice for 1 hr. After 1 hr, the solutions were spun at 10,000 rpm for 30 min at 4°C (Note: For 
these large scale spins, use the 450 mL centrifuge tubes and rotor JA-10). Phage pellets are 
translucent and were resuspended in PBS. pDP4 dUssDNA was purified following the M13 spin 
column protocol (Qiagen, #27704).  
 After quantifying the dUssDNA, Kunkel reactions were ran with 10 µg of total pDP4 
dUssDNA. The ratio of mutagenic primer to dUssDNA used was 12:1, and were mixed into a 
250 µL reaction solution with the following additives: 25 µL T7 polymerase buffer (New 
England Biolabs, #M0274), 25 µL T4 DNA ligase buffer (New England Biolabs, #M0202), and 
added ddi H2O up to 250 µL total volume. The reaction mixtures were then subjected to a “PCR 
reaction”: 95 °C for 2 min, 42 °C for 3 min, and 25 °C for 5 min. A different cycle optimized 
later in the Lai lab found that the following cycle resulted in better primer annealing: 90 °C for 5 
min, 75 °C for 45 sec, 70 °C for 1 min, 65°C for 1 min, 60 °C for 1 min, 55 °C for 1 min, 52 °C 
for 3 min, 45°C for 30 sec, 35 °C for 30 sec, 25 °C for 45 sec, and 22 °C for 1.5 min. After the 
cycle, 10 µL of 25 mM dNTPs (New England Biolabs, #N0447), 3 µL of T7 polymerase, and 2 
µL of T4 DNA ligase. The mixtures were incubated at room temperature overnight (~12 hr). The 
reactions were then purified using the PCR purification kit (Qiagen, #28104) and transformed 
into XL1 Blue cells. For isolating mutant DNA, single colonies were picked, grown overnight, 
and mini-prepped. For sequencing libraries, whole LB-agar plants were sent for sequencing and 
analyzed using BioEdit.  
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 For the stop-codon template, the 5‟ phosphorylated primers were designed as follows: 
Primer 1: 5‟ ACT AAT ACG CCA GAC TTA TTA ATT CTG ATA TCC AAT 3‟; Primer 2: 5‟ 
GTT TCC ACT CAT CGC GGT ACC TTA GGA ATA ATT TTA TTA CCC CAT CCA TAT 
AAG 3‟; Primer 3: 5‟ TCT TAC GTG AAC AGA CAG TTA TTA TTA TTA TAC ATA ATT 
TCC CAC GCA TTA TCC GGA TTA GAC ATT CTC CCA TGA 3‟. For the D88L mutant: 5‟ 
CCT GGA ATA ATT CGT GAG CCC CAT CCA TAT AAG 3‟. For the T117A mutant: 5‟ G 
AAC AGA CAG TCC CTG CGC TGA TAC ATA ATT TCC 3‟. For the double mutant, both 
primers were used together since they did not overlap. For the GafD library: Primer 1: 5‟ ACT 
AAT ACG CCA GAC ATT SNN ATT CTG ATA TCC AAT 3‟; Primer 2: 5‟ GTT TCC ACT 
CAT CGC GGT ACC CCT GGA ATA ATT SNN SNN CCC CAT CCA TAT AAG 3‟; Primer 
3: 5‟ TCT TAC GTG AAC AGA CAG TCC/SNN SNN CGT TGA TAC ATA ATT TCC CAC 
GCA SNN TCC GGA SNN GAC ATT CTC CCA TGA 3‟. The codons changed to stop codons 
were either changed to degenerate codons (NNS) or repaired to their original codon. Although I 
did not have time to perform alanine scanning mutagenesis, I still ordered the following primers: 
Primer 1: 5‟ AC TAA TAC GCC AGA CGK YTG CGK YTK SAT ATC CAA TGT TGT A 3‟; 
Primer 2: 5‟ GT TTC CAC TCA TCG CGG TAC CAS SGG AAT AGK YAG YAK CCC CCA 
TCC ATA TAA G 3‟; Primer 3: 5‟ TC TTA CGT GAA CAG ACA GAS CTK SAG YGG MAR 
CAK MAT TTC CCA CGC ACS MTC CGG AAR MGA CAT TCT CCC ATG A 3‟. 
5.4.6 Creation of GafD library phage 
 Although I generated enough DNA to finally make a library (~200 µg), I have been 
informed that one can use ~20 µg of library DNA. First, streak a loop of SS320 cells on LB-agar 
plates supplemented with tetracycline (TET, 5 µg/mL), and incubate overnight at 37 °C. 
Inoculate 25 mL of 2xYT containing TET with a single SS320 colony and grow for ~4 hr, until 
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OD600 reaches 0.8. Near the end of the growth, make 10-fold serial dilutions of M13KO7 in PBS 
(have at least 200 uL to use later). When culture reaches OD600 of 0.8, mix 500 µL of SS320 
culture and 200 µL of M13KO7 solution into 4 mL of top agar. Then pour the mix on top of pre-
warmed, thin, LB-agar TET plates and incubate overnight at 37 °C. Pick a single plaque from the 
overnight plates, and transfer to 1 mL of 2xYT containing KAN and TET, and incubate for 8 hr 
at 37 °C. Then, transfer the culture to 20 mL starter culture 2xYT with KAN (in a 250 mL 
baffled flask) and shake overnight at 37 °C. Then, transfer 5 - 10 mL of the overnight culture to 4 
x 500 mL Superbroth supplemented with TET and KAN, and grow until OD600 reaches 0.8 
(usually ~4 - 5 hr).  
 The next steps should be performed on ice and in a cold room: Once the cells reach the 
optimal density, chill the flasks on ice for 5 min with occasional swirling. After 5 min, spin the 
cells down in 6-500 mL pre-chilled centrifuge tubes (each containing a stir bar) at 5,500 x g, for 
10 min at 4 °C. Carefully pour off supernatant, then resuspend pellets in 1 L of 1 mM HEPES 
buffer (pre-chilled) and combine tubes to 4-500 mL centrifuge tubes. Spin cells down at 5,500 x 
g, for 10 min, at 4 °C. Carefully pour off supernatant again, then resuspend pellets in 1 L of 1 
mM HEPES buffer, and spin down cells again at 5,500 g, for 10 min, at 4 °C. Carefully pour off 
supernatant, then resuspend pellets in 800 mL of 10% glycerol (pre-chilled), and spin down at 
5,500 x g for 10 min at 4 °C. Carefully pour off supernatant again, and resuspend a single pellet 
in ~150 mL of 10% glycerol. Then transfer suspension to another pellet and resuspend, and 
repeat until left with one centrifuge tube containing all resuspended pellets. Pellet the cells again, 
and very careful in pouring off the supernatant, then resuspend the pellet in 2 mL of 10% 
glycerol (if too thick, add an additional 1 mL). Aliquot in 350 uL amounts and flash freeze and 
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store at -80 °C.  The Lai lab mentions that one can store these aliquots for a couple of days and 
have not seen any deleterious effects. 
 I then transformed 1 µg of my library into 350 µL of the prepped SS320 cells and 
recovered in 5 mL of 2xYT. After recovering for 45 min, I performed serial dilutions of the 
recovery, staring with 5 µL with 1:10 dilutions, and plated the dilutions onto LB-agar plates with 
CARB and TET. Incubate overnight at 37 °C and count colonies the next day. I found that 2 
colonies had grown on my 10
-6
 plate for my library, and performing the back-calculations, the 
transformation efficiency of the SS320 cells that I prepped was 10
9
, suitably competent cells 
from which to make a library. I then transformed 10 aliquots of the prepared SS320 cells with 1 
µg of library DNA each. I recovered with 1 mL of SOC, and then washed each cuvette with an 
additional 1 mL of SOC, and I transferred all recovered samples to 30 mL of SOC in a 250 mL 
baffle flask. After are aliquots were pooled, the culture was recovered for 45 min at 37 °C. I then 
titered the recovery by taking 10 µL of the culture and mixed it with 90 µL of 2YT, then 1:10 
dilutions downward. I then plated on LB-agar plates to obtain colonies for sequencing. After 
recovery, the 50 mL culture was split into 2x500 mL 2xYT cultures in 2 L flasks with CARB 
and KAN, and grown for ~20 hr at 30 °C. The recovery titer formed 3 colonies at the 10
-5
 
dilution, from the back calculations, we have a library the size of 1.5 x 10
9
. The recovered cells 
grew well and then I pelleted the cells as usual, and  resuspened the supernatant with 5x 
PEG/NaCl, and incubated on ice for 1 hr. Flasks were then pelleted at 10,000 rpm, 30 min, 4 °C, 
then dried as usual, resuspended each pellet in 2 mL of PBS. The library phage was then put into 
1 mL aliquots, which can be stored at -80 °C indefinitely with 10% glycerol.  
 
 
145 
 
5.4.7 ELISA protocol for phage 
 β-GlcNAc-BSA (Iso sep) was dissolved into 50 mM sodium borate (pH 8.5, 5 ng/µL) and 
100 µL of this solution was added to each well and incubated for 1 hr. After 1 hr, the wells were 
blocked with 5% BSA in PBS and incubated for an additional 1 hr. The wells were then washed 
3x with 0.05 % PBST. Prior to addition of the phage, the samples were diluted into 3% BSA in 
0.05% PBST and 100 µL was added to each well and incubated for 1 hr. After 1 hr, the wells 
were washed 5x with 0.05% PBST, followed by the addition of 100 µL of α-M13-HRP (1:2500 
in 1% BSA in 0.05% PBS), and the samples were incubated for 1 hr. The wells were then 
washed 5x with 0.05% PBST, followed by the addition of 200 µL of TMB solution (Sigma 
Aldrich, #T0565). After 5 min, the reaction was quenched with 100 µL of 0.5 M H2SO4. The 
plate was then read at 450 nm, and Microsoft Excel 2007 software was used for statistical 
analysis, curve fitting, and to generate graphs and tables. 
5.4.8 Phage selection protocol 
 At the beginning of the day, inoculate 10 mL of 2xYT, containing TET, with a single 
colony of XL1 Blue cells, and grow in a 250mL baffled flask at 37 °C until OD600 reaches 0.6 – 
0.8. For round 1, coat 8 – 10 wells with target protein in 50 mM sodium bicarbonate (pH 8.5, 100 
µL total volume per well), and incubate at room temperature for 1 hr. As a control, incubate a 
single well with 1 µg of BSA to act as a negative control, which will be used to assay library 
enrichment. After 1 hr, decant the wells and block with 150 µL of 3% BSA in PBS for 1 hr. Then 
wash wells 3x with 0.05% PBST. After purifying your library phage (R0), mix the phage (100 
µL) with 3% BSA in 0.05% PBST (30 µL), and add mixture (100 µL) to each well, and incubate 
1 hr. After 1 hr, wash the wells 5x with 0.05% PBST, and after thorough drying, add 100 µL of 
elution buffer (100 mM glycine, pH 2.0) to each well and incubate for 5 min. After 5 min, pool 
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elutions into a 1.5 mL tube and add 30 µL of neutralizing buffer (2 M Tris, pH 7.5) per well. Do 
not mix the negative control well. Once XL1 blue culture has reached an optimal OD600, infect 
the cells by mixing 5 mL of XL1 blue cells with half of your output phage and incubate for 30 
min. After 30 min, add 10 µL of M13KO7 helper phage (10
12
) and incubate further. Then pour 
culture into a 250 mL baffle flask containing 25 mL of 2xYT supplememted with CARB and 
KAN. Repeat selections out to round 5, reducing the number of target wells each round.  
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Appendix A: Lectin microarray print lists  
 
 
Print number Lectin [Lectin] µM [Lectin] µg/mL Monosaccharide 
in print buffer 
1 GafD 20 1000 GlcNAc 
2 GafD 10 500 GlcNAc 
3 GafD 5 250 GlcNAc 
4 GafD 2.5 125 GlcNAc 
5 GafD 1.2 62 GlcNAc 
6 GafD 0.6 31 GlcNAc 
7 GafD 0.3 16 GlcNAc 
8 PA-IL 24 1000 Galactose 
9 PA-IL 12 500 Galactose 
10 PA-IL 6 250 Galactose 
11 PA-IL 3 125 Galactose 
12 PA-IL 1.5 62 Galactose 
13 PA-IL 0.8 31 Galactose 
14 PA-IL 0.4 16 Galactose 
15 PA-IIL 24 1000 Fucose 
16 PA-IIL 12 500 Fucose 
17 PA-IIL 6 250 Fucose 
18 PA-IIL 3 125 Fucose 
19 PA-IIL 1.5 62 Fucose 
20 PA-IIL 0.8 31 Fucose 
21 PA-IIL 0.4 16 Fucose 
22 PapGII 20 1000 Galactose 
23 PapGII 10 500 Galactose 
24 PapGII 5 250 Galactose 
25 PapGII 2.5 125 Galactose 
26 PapGII 1.2 62 Galactose 
27 PapGII 0.6 31 Galactose 
28 PapGII 0.3 16 Galactose 
29 PapGIII 20 1000 Galactose 
30 PapGIII 10 500 Galactose 
31 PapGIII 5 250 Galactose 
32 PapGIII 2.5 125 Galactose 
33 PapGIII 1.2 62 Galactose 
34 PapGIII 0.6 31 Galactose 
35 PapGIII 0.3 16 Galactose 
36 RS-IIL 24 1000 Mannose 
37 RS-IIL 12 500 Mannose 
38 RS-IIL 6 250 Mannose 
39 RS-IIL 3 125 Mannose 
40 RS-IIL 1.5 62 Mannose 
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41 RS-IIL 0.8 31 Mannose 
42 RS-IIL 0.4 16 Mannose 
43 GafD-m 20 1000 GlcNAc 
44 GafD-m 10 500 GlcNAc 
45 GafD-m 5 250 GlcNAc 
46 GafD-m 2.5 125 GlcNAc 
47 GafD-m 1.2 62 GlcNAc 
48 GafD-m 0.6 31 GlcNAc 
49 GafD-m 0.3 16 GlcNAc 
50 AAA 14 1000 Fucose 
51 Jacalin, AIA 10 500 Galactose 
52 BPA 3 500 Galactose 
53 ConA 10 500 Mannose 
54 DBA 4 500 Galactose 
55 DSA 6 500 Lactose 
56 ECA 19 1000 Galactose 
57 GNA 10 500 Mannose 
58 GS-I 4 500 Galactose 
59 GS-II 4 500 GlcNAc 
60 HPA 6 500 Galactose 
61 LcH 20 1000 Mannose 
62 Lotus 9 500 Fucose 
63 MAA 4 500 Lactose 
64 PAA N/A 500 GlcNAc 
65 PNA 5 500 Galactose 
66 SBA 4 500 Galactose 
67 SNA 3 500 Lactose 
68 STA 5 500 GlcNAc 
69 UEA-I 8 500 Fucose 
70 WGA 28 1000 GlcNAc 
Table 1 : Three spots were printed for each lectin/concentration and 15 spots/5 lectins were printed 
  per row.  Lectins 1 – 70 were printed on the top half of each array, and samples 1 – 49  
  were printed again on the modified, bottom half of the array.  
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Number Row Lectin [Lectin] µM [Lectin] 
µg/mL 
Monosaccharide 
1 1 AAA 14 1000 Fucose 
2 1 AIA, Jacalin 10 500 Galactose 
3 1 BPA 3 500 Galactose 
4 1 ConA 10 500 Mannose 
5 1 DBA 4 500 Galactose 
6 2 DSA 6 500 Lactose 
7 2 ECA 19 500 Galactose 
8 2 GNA 10 500 Mannose 
9 2 GS-I 4 500 Galactose 
10 2 GS-II 4 500 GlcNAc 
11 3 HPA 6 500 Galactose 
12 3 LcH 20 1000 Mannose 
13 3 Lotus 9 500 Fucose 
14 3 MAA 4 500 Lactose 
15 3 PAA N/A 500 GlcNAc 
16 4 PNA 5 500 Galactose 
17 4 PHA-E 4 500 Lactose 
18 4 PHA-L 5 500 Galactose 
19 4 SBA 4 500 Galactose 
20 4 SNA 3 500 Lactose 
21 5 STA 5 500 GlcNAc 
22 5 TJA-I 8 500 Lactose 
23 5 TJA-II 8 500 Lactose 
24 5 UEA-I 8 500 Fucose 
25 5 WGA 28 1000 GlcNAc 
26 6 GafD 20 1000 GlcNAc 
27 6 GafD 10 500 GlcNAc 
28 6 GafD 5 250 GlcNAc 
29 6 GafD 2.5 125 GlcNAc 
30 6 GafD 1.25 62.5 GlcNAc 
31 7 PA-IL 23 1000 Galactose 
32 7 PA-IL 11 500 Galactose 
33 7 PA-IL 6 250 Galactose 
34 7 PA-IL 3 125 Galactose 
35 7 PA-IL 1.4 62.5 Galactose 
36 8 PA-IIL 23 1000 Fucose 
37 8 PA-IIL 11 500 Fucose 
38 8 PA-IIL 6 250 Fucose 
39 8 PA-IIL 3 125 Fucose 
40 8 PA-IIL 1.4 62.5 Fucose 
41 9 PapGII 19 1000 Galactose 
42 9 PapGII 9 500 Galactose 
43 9 PapGII 4.5 250 Galactose 
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44 9 PapGII 2.3 125 Galactose 
45 9 PapGII 1.2 62.5 Galactose 
46 10 PapGIII 19 1000 Galactose 
47 10 PapGIII 9 500 Galactose 
48 10 PapGIII 5 250 Galactose 
49 10 PapGIII 2.5 125 Galactose 
50 10 PapGIII 1.2 62.5 Galactose 
51 11 RS-IIL 23 1000 Mannose 
52 11 RS-IIL 11 500 Mannose 
53 11 RS-IIL 6 250 Mannose 
54 11 RS-IIL 3 125 Mannose 
55 11 RS-IIL 1.4 62.5 Mannose 
Table 2:  Print list for lectin array shown in Figure 4. Three spots were printed for each   
  lectin/concentration and 15 spots/5 lectins were printed per row. Bolded samples were  
  printed in GSH-B (100 mM GSH, 50 mM sodium borate buffer, pH 8.5 with 0.5 mg/mL  
  BSA). All others printed in PB (10 mM sodium phosphate, 15 mM sodium chloride, pH  
  = 7.4 with 0.5 mg/mL BSA) 
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Number Lectin [Lectin] µM [Lectin] µg/mL Monosaccharide 
1 AAA 14 500 Fucose 
2 AIA, Jacalin 10 500 Galactose 
3 BPA 3 500 Galactose 
4 ConA 10 500 Mannose 
5 DBA 4 500 Galactose 
6 DSA 6 500 Lactose 
7 ECA 19 500 Galactose 
8 GNA 10 500 Mannose 
9 GS-I 4 500 Galactose 
10 GS-II 4 500 GlcNAc 
11 HPA 6 500 Galactose 
12 LcH 20 500 Mannose 
13 Lotus 9 500 Fucose 
14 MAA 4 500 Lactose 
15 PAA N/A 500 GlcNAc 
16 PNA 5 500 Galactose 
17 PHA-E 4 500 Lactose 
18 PHA-L 5 500 Galactose 
19 SBA 4 500 Galactose 
20 SNA 3 500 Lactose 
21 STA 5 500 GlcNAc 
22 TJA-I 8 500 Lactose 
23 TJA-II 8 500 Lactose 
24 UEA-I 8 500 Fucose 
25 WGA 28 1000 GlcNAc 
26 GafD 10 500 GlcNAc 
27 GafD D88L 10 500 GlcNAc 
28 GafD D88L + T117A 10 500 GlcNAc 
29 PA-IL 11 500 Galactose 
30 PA-IL N107A 11 500 Galactose 
31 PA-IIL 11 500 Fucose 
32 PA-IIL S22A 11 500 Fucose 
33 PA-IIL D96A 11 500 Fucose 
34 PapGI 9 500 Galactose 
35 PapGI W105A 9 500 Galactose 
36 PapGII 9 500 Galactose 
37 PapGII W107A 9 500 Galactose 
38 RS-IIL 11 500 Mannose 
39 RS-IIL A22S 11 500 Mannose 
40 RS-IIL D97A 11 500 Mannose 
Table 4:  Print list for lectin mutant array. Three spots were printed for each    
  lectin/concentration and 15 spots/5 lectins were printed per row. Bolded samples were  
  printed in GSH-B. All others printed in PB 
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Appendix B: Genes of synthesized SpG and PpL 
 
 
SpG Gene Synthesized by Genewiz©: 
ATGGAGAAAGAGAAAAAAGTCAAATATTTCCTGCGCAAAAGCGCCTTTGGTCTGGC
ATCAGTTTCAGCAGCATTCCTGGTTGGTAGCACCGTGTTCGCCGTGGATTCACCGAT
TGAGGATACGCCGATCATTCGTAATGGTGGGGAGCTGACAAATCTGCTGGGTAACA
GCGAAACAACACTGGCTCTGCGTAACGAAGAATCAGCAACCGCCGACCTGACAGCG
GCAGCCGTAGCCGATACAGTAGCAGCGGCAGCGGCCGAAAATGCCGGAGCAGCCG
CCTGGGAAGCAGCGGCAGCGGCAGACGCTCTGGCTAAAGCGAAAGCCGACGCCCTG
AAAGAATTCAACAAATATGGCGTGAGCGACTATTATAAAAACCTGATCAATAACGC
TAAAACCGTCGAAGGTGTGAAAGATCTGCAGGCACAGGTGGTAGAAAGTGCCAAAA
AAGCCCGTATTAGTGAAGCGACCGATGGACTGAGTGATTTTCTGAAATCCCAGACAC
CGGCTGAGGACACTGTTAAAAGCATCGAGCTGGCAGAAGCAAAAGTTCTGGCAAAC
CGTGAACTGGACAAATATGGGGTGTCGGACTATCACAAAAACCTGATCAACAATGC
CAAAACGGTTGAGGGGGTTAAAGACCTGCAAGCCCAAGTTGTAGAGAGTGCCAAAA
AAGCCCGTATTAGTGAGGCAACGGACGGCCTGAGTGACTTCCTGAAATCTCAAACA
CCTGCCGAGGATACCGTGAAATCCATTGAACTGGCGGAGGCCAAAGTGCTGGCTAA
CCGTGAGCTGGACAAATATGGTGTAAGCGATTATTATAAAAACCTGATCAATAATGC
CAAAACGGTGGAAGGCGTGAAAGCACTGATCGATGAGATCCTGGCGGCACTGCCTA
AAACAGACACGTATAAACTGATCCTGAACGGCAAAACGCTGAAAGGTGAAACAACC
ACCGAAGCCGTTGACGCCGCCACCGCTGAAAAAGTGTTCAAACAGTATGCCAACGA
TAACGGTGTGGATGGAGAGTGGACCTATGATGACGCCACGAAAACGTTTACAGTGA
CCGAGAAACCGGAAGTGATTGATGCTAGCGAACTGACACCAGCCGTTACCACATAT
AAACTGGTGATTAACGGGAAAACCCTGAAAGGTGAGACTACGACAAAAGCAGTAG
ACGCCGAAACAGCTGAGAAAGCATTCAAACAATATGCTAACGATAATGGGGTGGAC
GGAGTTTGGACGTATGACGACGCCACCAAAACATTCACCGTGACGGAAATGGTTAC
CGAGGTTCCGGGTGACGCTCCTACAGAACCGGAAAAACCAGAAGCGAGCATCCCAC
TGGTTCCTCTGACTCCAGCAACCCCAATTGCCAAAGATGACGCTAAAAAAGATGAC
ACGAAAAAAGAAGATGCTAAAAAACCGGAGGCGAAAAAAGAGGACGCCAAAAAA
GCAGAAACACTGCCGACAACAGGTGAAGGCTCAAATCCGTTCTTTACCGCCGCTGCT
CTGGCTGTTATGGCAGGAGCAGGAGCACTGGCAGTAGCCTCTAAACGTAAAGAGGA
TTGA 
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PpL gene synthesized by Genewiz ©: 
ATGAAAAAAACGGCGATTGCTATTGCTGTGGCTCTGGCAGGATTTGCTACTGTTGCT
CAAGCGGCTGTCGAAAACAAAGAGGAAACCCCGGAAACACCTGAAACCGATTCGG
AAGAAGAAGTGACGATCAAAGCGAACCTGATTTTTGCCAATGGCAGCACCCAAACA
GCGGAATTCAAAGGCACCTTCGAGAAAGCGACCTCTGAAGCATATGCCTATGCCGA
TACGCTGAAAAAAGACAACGGCGAGTATACCGTGGATGTGGCGGATAAAGGTTATA
CCCTGAACATCAAATTTGCCGGTAAAGAGAAAACTCCTGAGGAGCCGAAAGAGGAG
GTTACCATTAAAGCCAATCTGATCTATGCCGACGGAAAAACCCAGACGGCGGAGTT
CAAAGGCACATTCGAAGAAGCAACTGCCGAAGCTTATCGTTATGCTGATGCCCTGA
AAAAAGACAATGGCGAGTATACGGTGGACGTTGCCGACAAAGGCTATACGCTGAAC
ATCAAATTCGCTGGTAAAGAGAAAACCCCAGAAGAACCAAAAGAGGAGGTTACGAT
CAAAGCCAACCTGATCTATGCCGATGGGAAAACACAAACAGCTGAGTTCAAAGGGA
CGTTTGAGGAGGCTACTGCTGAGGCCTATCGCTATGCCGACCTGCTGGCTAAAGAAA
ACGGGAAATATACAGTCGATGTGGCCGACAAAGGTTATACGCTGAACATCAAATTC
GCCGGTAAAGAAAAAACACCGGAGGAGCCTAAAGAAGAAGTCACCATCAAAGCCA
ACCTGATTTATGCCGACGGAAAAACACAAACTGCCGAGTTCAAAGGAACGTTTGCC
GAAGCGACGGCGGAAGCATATCGCTATGCCGATCTGCTGGCCAAAGAGAACGGAAA
ATATACGGCCGACCTGGAAGATGGAGGTTATACAATCAACATTCGTTTCGCCGGTAA
AAAAGTGGACGAGAAACCGGAAGAACCGATGGACACCTATAAACTGATTCTGAACG
GAAAAACGCTGAAAGGCGAGACAACAACCGAAGCCGTGGACGCTGCTACTGCTGA
AAAAGTGTTCAAACAATATGCCAACGACAACGGTGTGGATGGAGAATGGACCTATG
ACGATGCCACCAAAACATTCACAGTGACCGAGAAACCAGAAGTCATTGACGCCTCG
GAACTGACTCCGGCGGTTACAACATATAAACTGGTCATTAACGGAAAAACCCTGAA
AGGCGAGACTACCACAAAAGCGGTAGACGCTGAAACAGCGGAGAAAGCATTCAAA
CAATATGCCAATGATAATGGCGTTGACGGCGTTTGGACATATGACGACGCTACGAA
AACCTTCACGGTGACGGAAATGTAA 
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